U.S. patent application number 14/707472 was filed with the patent office on 2015-09-24 for methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid.
The applicant listed for this patent is BHI Limited Partnership. Invention is credited to Abderrahim Bouzide, Stephane Ciblat, Richard Frenette, Xianqi Kong, Nigel Levens, Johanne Renaud.
Application Number | 20150266814 14/707472 |
Document ID | / |
Family ID | 43585812 |
Filed Date | 2015-09-24 |
United States Patent
Application |
20150266814 |
Kind Code |
A1 |
Kong; Xianqi ; et
al. |
September 24, 2015 |
METHODS, COMPOUNDS, AND COMPOSITIONS FOR DELIVERING
1,3-PROPANEDISULFONIC ACID
Abstract
The invention relates to methods, compounds, and compositions
for delivering 1,3-propanedisulfonic acid (1,3PDS) in a subject,
preferably a human subject. The invention encompasses compounds
that will yield or generate 1,3PDS, either in vitro or in vivo. The
invention also relates to sulfonate ester prodrugs of 1,3PDS as
well as Gemini dimmers and oligomers of 1,3PDS for the prevention
or treatment of associated diseases and conditions.
Inventors: |
Kong; Xianqi;
(Dollard-des-Ormeaux, CA) ; Levens; Nigel;
(Beaconsfield, CA) ; Bouzide; Abderrahim; (Laval,
CA) ; Ciblat; Stephane; (Montreal, CA) ;
Frenette; Richard; (Laval, CA) ; Renaud; Johanne;
(Laval, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
BHI Limited Partnership |
Laval |
|
CA |
|
|
Family ID: |
43585812 |
Appl. No.: |
14/707472 |
Filed: |
May 8, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13389606 |
Apr 20, 2012 |
9051248 |
|
|
PCT/CA2010/001229 |
Aug 6, 2010 |
|
|
|
14707472 |
|
|
|
|
61232597 |
Aug 10, 2009 |
|
|
|
Current U.S.
Class: |
514/108 ;
514/335; 514/435; 514/470; 514/517; 546/261; 549/19; 549/305;
558/45; 558/47 |
Current CPC
Class: |
A61K 31/255 20130101;
C07F 9/4006 20130101; C07C 309/65 20130101; A61P 3/06 20180101;
C07C 309/05 20130101; C07D 307/77 20130101; C07D 213/65 20130101;
C07D 307/58 20130101; C07D 327/00 20130101; A61P 1/18 20180101;
C07F 9/4043 20130101; A61P 5/50 20180101; A61P 3/00 20180101; A61K
31/351 20130101; C07C 2601/04 20170501; C07C 311/51 20130101; C07D
307/00 20130101; A61P 3/10 20180101; C07C 2601/14 20170501; C07D
319/06 20130101; C07D 327/10 20130101; A61P 13/12 20180101; C07D
213/64 20130101; C07F 9/091 20130101; C07D 231/12 20130101; A61K
31/365 20130101; A61K 31/366 20130101; C07C 311/06 20130101; C07D
307/33 20130101; C07D 309/22 20130101; A61P 3/04 20180101 |
International
Class: |
C07C 309/65 20060101
C07C309/65; C07D 213/64 20060101 C07D213/64; C07F 9/40 20060101
C07F009/40; C07D 327/00 20060101 C07D327/00; C07D 307/00 20060101
C07D307/00 |
Claims
1. A compound of Formula I: ##STR00140## wherein, R.sup.1 is
selected from OR.sup.3, --NHC(O)R.sup.5, --NHC(NH)NHR.sup.5,
--NH(C.sub.5-C.sub.10heteroaryl) or a nitrogen atom part of a mono
or bicyclic heteroaryl having from 5 to 10 ring members; R.sup.2 is
selected from OR.sup.4, --NHC(O)R.sup.5, --NHC(NH)NHR.sup.5,
--NH(C.sub.5-C.sub.10heteroaryl) or a nitrogen atom part of a mono
or bicyclic heteroaryl having from 5 to 10 ring members, or R.sup.1
is a covalent bond and R.sup.2 is selected from O, NH,
NC(O)R.sup.5, NC(NH)NHR.sup.5, and N(C.sub.5-C.sub.10heteroaryl)
when R.sup.1 and R.sup.2 are taken together with their adjacent
atoms to form a heterocycle; R.sup.3 is selected from hydrogen and
a substituted or unsubstituted group selected from
C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12alkynyl, C.sub.3-C.sub.15cycloalkyl,
C.sub.3-C.sub.15heterocycloalkyl, C.sub.6-C.sub.15aryl, and
C.sub.5-C.sub.15heteroaryl; R.sup.4 is a substituted or
unsubstituted group selected from C.sub.1-C.sub.12alkyl,
C.sub.2-C.sub.12alkenyl, C.sub.2-C.sub.12alkynyl,
C.sub.3-C.sub.15cycloalkyl, C.sub.3-C.sub.15heterocycloalkyl,
C.sub.6-C.sub.15aryl, and C.sub.5-C.sub.15heteroaryl; and R.sup.5
is selected from hydrogen and a substituted or unsubstituted group
selected from C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12alkynyl, C.sub.3-C.sub.15cycloalkyl,
C.sub.3-C.sub.15heterocycloalkyl, C.sub.6-C.sub.15aryl, and
C.sub.5-C.sub.15heteroaryl; or a pharmaceutically acceptable salt
or solvate thereof.
2. The compound of claim 1, wherein said compound is a compound of
Formula II: ##STR00141## wherein, R.sup.3 is selected from hydrogen
and a substituted or unsubstituted group selected from
C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12alkynyl, C.sub.3-C.sub.15cycloalkyl,
C.sub.3-C.sub.15heterocycloalkyl, C.sub.6-C.sub.15aryl, and
C.sub.5-C.sub.15heteroaryl; and R.sup.4 is a substituted or
unsubstituted group selected from C.sub.1-C.sub.12alkyl,
C.sub.2-C.sub.12alkenyl, C.sub.2-C.sub.12alkynyl,
C.sub.3-C.sub.15cycloalkyl, C.sub.3-C.sub.15heterocycloalkyl,
C.sub.6-C.sub.15aryl, and C.sub.5-C.sub.15heteroaryl; wherein at
least one of R.sup.3 and R.sup.4 is a substituted branched
C.sub.3-C.sub.8alkyl, a substituted or unsubstituted
C.sub.6-C.sub.15aryl or C.sub.5-C.sub.15heteroaryl group, or a
group of Formula B: ##STR00142## wherein, R.sup.7 and R.sup.8 are
each independently a substituted or unsubstituted croup selected
from C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl,
C.sub.2-C.sub.6alkynyl, C.sub.3-C.sub.6cycloalkyl,
C.sub.3-C.sub.6heterocycloalkyl, C.sub.6-C.sub.10aryl,
C.sub.5-C.sub.10heteroaryl, C(O)OH, C(O)OC.sub.1-C.sub.6alkyl,
NH.sub.2, NHC(O)OC.sub.1-C.sub.6alkyl; and R.sup.22 is a hydrogen
atom or a group selected from C.sub.1-C.sub.6alkyl, C(O)OH, or
C(O)OC.sub.1-C.sub.6alkyl; and R.sup.6 is a croup of formula C:
##STR00143## wherein R.sup.9 is absent; X is selected from the
group consisting of OH, NO.sub.2, CN, SH, C(O)OH, C(O)OR.sup.12,
OC(O)OR.sup.12, SC(O)OR.sup.12, P(O)(OH).sub.2,
P(O)(OR.sup.12).sub.2, P(O)(OR.sup.12)(OH), OC(O)R.sup.13,
OC(O)NHR.sup.13, SC(O)R.sup.13, C(O)R.sup.14, and NHR.sup.15; n is
0; R.sup.12 is a substituted or unsubstituted group selected from
C.sub.1-C.sub.6alkyl, C.sub.3-C.sub.6cycloalkyl,
C.sub.3-C.sub.6heterocycloalkyl, C.sub.6aryl,
C.sub.5-C.sub.6heteroaryl, benzyl, CH.sub.2R.sup.16, and
CH(C.sub.1-C.sub.6alkyl)R.sup.16; R.sup.13 is a substituted or
unsubstituted group selected from C.sub.1-C.sub.6alkyl,
C.sub.3-C.sub.6cycloalkyl, C.sub.3-C.sub.6heterocycloalkyl,
C.sub.6aryl, C.sub.5-C.sub.6heteroaryl, and benzyl; R.sup.14 is the
residue of a natural or unnatural N-coupled amino acid having an
protected or unprotected carboxyl end; R.sup.15 is the residue of a
natural or unnatural C-coupled amino acid having an protected or
unprotected amino end; and R.sup.16 is selected from the group
consisting of OC(O)C.sub.1-C.sub.6alkyl and
OC(O)OC.sub.1-C.sub.6alkyl; or a pharmaceutically acceptable salt
or solvate thereof.
3. The compound of claim 2, wherein R.sup.3 is a substituted or
unsubstituted group selected from C.sub.1-C.sub.12alkyl,
C.sub.2-C.sub.12alkenyl, C.sub.2-C.sub.12alkynyl,
C.sub.3-C.sub.15cycloalkyl, C.sub.3-C.sub.15heterocycloalkyl,
C.sub.6-C.sub.15aryl, and C.sub.5-C.sub.15heteroaryl.
4. The compound of claim 2, wherein said compound is a compound of
Formula II-A ##STR00144## wherein, R.sup.4 is a substituted
branched C.sub.3-C.sub.8alkyl, or a substituted or unsubstituted
C.sub.6-C.sub.15aryl or C.sub.5-C.sub.15heteroaryl; or a
pharmaceutically acceptable salt or solvate thereof.
5-10. (canceled)
11. The compound of claim 2, wherein at least one of R.sup.3 and
R.sup.4 is a group of Formula D: ##STR00145## wherein, R.sup.17 in
each occurrence is each independently a hydrogen atom or a
substituted or unsubstituted group selected from
C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl,
C.sub.2-C.sub.6alkynyl, C.sub.3-C.sub.6cycloalkyl,
C.sub.3-C.sub.6heterocycloalkyl, C.sub.6-C.sub.10aryl,
C.sub.5-C.sub.10heteroaryl, an electron-withdrawing group or a
substituent selected from the group consisting of amino, amido,
hydroxyl, alkoxy, acyloxy, alkoxycabonyloxy, and the like; and m is
an integer from 1 to 5.
12-13. (canceled)
14. The compound of claim 2, wherein said compound is selected
from: ##STR00146## ##STR00147## ##STR00148## or a pharmaceutically
acceptable salt or solvate thereof.
15. (canceled)
16. The compound of 1, wherein said compound is selected from:
##STR00149## or a pharmaceutically acceptable salt or solvate
thereof.
17-23. (canceled)
24. The compound of claim 1, wherein said compound is a compound of
Formula IV: ##STR00150## wherein, R.sup.18 is selected from
OR.sup.3, NH.sub.2, --NHC(O)R.sup.5, --NHC(NH)NHR.sup.5,
--NH(C.sub.5-C.sub.10heteroaryl), --NR.sup.20R.sup.21, R.sup.14,
and --NHR.sup.15; R.sup.19 is selected from NH.sub.2,
--NHC(O)R.sup.5, --NHC(NH)NHR.sup.5,
--NH(C.sub.5-C.sub.10heteroaryl), --NR.sup.20R.sup.21, R.sup.14,
and --NHR.sup.15; R.sup.3, R.sup.5, R.sup.14, and R.sup.15 are as
defined in any one of the preceding claims; and R.sup.20 and
R.sup.21 are taken together with their adjacent nitrogen atom to
form a mono or bicyclic heteroaryl having from 5 to 10 ring
members; or a pharmaceutically acceptable salt or solvate
thereof.
25. The compound of claim 24, wherein: R.sup.18 is selected from
OR.sup.3, --NHC(O)R.sup.5, --NHC(NH)NHR.sup.5,
--NH(C.sub.5-C.sub.10heteroaryl) and --NR.sup.20R.sup.21; R.sup.19
is selected from --NHC(O)R.sup.5, --NHC(NH)NHR.sup.5,
--NH(C.sub.5-C.sub.10heteroaryl) and --NR.sup.20R.sup.21; R.sup.3
and R.sup.5 are as defined in any one of the preceding claims; and
R.sup.20 and R.sup.21 are taken together with their adjacent
nitrogen atom to form a mono or bicyclic heteroaryl having from 5
to 10 ring members; or a pharmaceutically acceptable salt or
solvate thereof.
26. The compound of claim 24, wherein said compound is selected
from: ##STR00151## ##STR00152## or a pharmaceutically acceptable
salt or solvate thereof.
27-28. (canceled)
29. A pharmaceutical composition comprising a compound according to
claim 1 together with a pharmaceutically acceptable carrier.
30-42. (canceled)
43. A method for treating AA amyloidosis or diabetic naphropathy,
comprising the step of administering to a subject in need thereof,
a therapeutically effective amount of a compound of claim 1 such
that said AA amyloidosis or diabetic naphropathy is treated.
44. A method for treating a renal disorder, comprising the step of
administering to a subject in need thereof, a therapeutically
effective amount of a compound of claim 1, such that said renal
disorder is treated.
45. The method of claim 43, wherein diabetic nephropathy is
treated.
46. A method for the treatment of metabolic syndrome,
hyperglycemia, or diabetes mellitus, comprising the step of
administering to a subject in need thereof, a therapeutically
effective amount of a compound of claim 1, such that said metabolic
syndrome, hyperglycemia, or diabetes mellitus is treated.
47-48. (canceled)
49. The method of claim 46, wherein said diabetes mellitus is type
1 diabetes.
50. The method of claim 46, wherein said diabetes mellitus is type
2 diabetes.
51. The method of claim 50, wherein said diabetes mellitus is type
2 diabetes with features of metabolic syndrome.
52. A method for increasing insulin levels circulating in blood in
response to food, decreasing resistance to insulin and/or
increasing insulin sensitivity in selected tissues, increasing
insulin secretion by pancreatic cells, increasing beta-cells and/or
islets of Langerhans neogenesis and/or regeneration of islets of
Langerhans or preventing their destruction by apoptosis, preventing
apoptosis in beta-cells, and stabilizing, restoring, and/or
improving beta-cells size, growth and/or function, or delaying the
requirement for treating a diabetic patient with exogenous insulin,
comprising administering a therapeutically effective amount of a
compound of claim 1 to a subject in need thereof.
53. (canceled)
54. The method of claim 43, wherein AA amyloidosis is treated.
55-62. (canceled)
Description
FIELD OF THE INVENTION
[0001] The invention relates to methods, compounds and compositions
for delivering 1,3-propanedisulfonic acid (1,3PDS) in a subject,
preferably a human subject. The invention encompasses compounds
that will yield or generate 1,3PDS, either in vitro or in vivo.
Preferred compounds include sulfonate ester prodrugs of 1,3PDS for
use, including but not limited to, the prevention and treatment of
metabolic, renal and pancreatic diseases and disorders, including
AA amyloidosis, diabetic nephropathy, diabetes and metabolic
syndrome.
BACKGROUND OF THE INVENTION
[0002] 1,3-Propanedisulfonic acid (1,3PDS, eprodisate, Kiacta.TM.)
is an investigational new drug for the treatment of AA amyloidosis
(or secondary (AA) amyloidosis), which is a manifestation of a
number of diseases that provoke a sustained acute phase response.
Such diseases include chronic inflammatory disorders, chronic local
or systemic microbial infections, and malignant neoplasms. The most
common form of AA amyloidosis is seen as the result of
long-standing inflammatory conditions. For example, patients with
Rheumatoid Arthritis or Familial Mediterranean Fever (a genetic
disease) can develop AA amyloidosis.
[0003] 1,3PDS has also exhibited potential activity for the
treatment of renal disorders such as diabetic nephropathy and
reduction of triglyceride serum levels, such as for the treatment
of dyslipidemia and vascular or cardiovascular diseases (patent
application published on Oct. 11, 2007 as US 2007/0238788 and PCT
application published as WO 2007/125385, incorporated herein by
reference in their entirety). It has also been found to exhibit
beneficial properties in vivo against features of metabolic
syndrome and diabetes, such as insulin and glucose levels as well
as for preserving pancreatic islets of Langherans (patent
application published on Oct. 23, 2008 as US 2008/0262088 and PCT
application published as WO 2008/078176, incorporated herein by
reference in their entirety).
[0004] Generally, when used as a therapeutic, expected dosage of
1,3PDS to be used may range from about 800 mg to about 3200 mg per
day, separated in multiple doses throughout the day.
SUMMARY OF THE INVENTION
[0005] The invention includes methods, compounds and compositions
for delivering in a subject, preferably a human subject,
1,3-propanedisulfonic acid, or salts thereof. 1,3-Propanedisulfonic
acid (referred to herein as 1,3PDS) has the following
structure:
##STR00001##
[0006] According to one aspect, the present invention relates to
compounds or compositions that will yield or generate 1,3PDS after
being administered to a subject. In one embodiment, the compound
that will yield 1,3PDS is a sulfonate ester prodrug of 1,3PDS. In
another embodiment, the compound that will yield 1,3PDS is a
neopentyl sulfonate ester or a neopentyl-derived sulfonate ester of
1,3PDS. In another embodiment, the compound that will yield 1,3PDS
is a mono-sulfonate ester prodrug of 1,3PDS. In another embodiment,
the compound is a disulfonate ester prodrug of 1,3PDS. In another
embodiment, the compound that will yield or generate 1,3PDS is an
oligomer or gemini dimer of 1,3PDS which comprises at least one
sulfonate ester of 1,3PDS. In another embodiment, the compound that
will yield or generate 1,3PDS is an oligomer or gemini dimer of
1,3PDS which comprises a neopentyl or neopentyl-derived sulfonate
ester of 1,3PDS. In certain embodiments, the sulfonate ester
prodrugs of 1,3PDS that are capable of yielding or generating,
either in vitro or in vivo 1,3PDS have one of the general or
specific formulae or structures disclosed herein.
[0007] More particularly, the invention relates to compounds of any
one of Formulae I, II, II-A, III and III-A, IV and V, as well as
any embodiments and examples described in section II of the
description, such as Formulae (B) to (F) and embodiments thereof,
as well as their pharmaceutically acceptable salts and solvates.
The invention also encompasses the compounds exemplified herein,
for example, Compounds A1-A73, Compounds B1-B87, Compounds C1-C3,
Compounds D1-D8, Compounds G1-G4, Compounds N1-N18, and Compound
P1, as well as their pharmaceutically acceptable salt and solvates
where applicable.
[0008] The invention also further relates to a method or process
for preparing the compounds of the invention. The invention, for
example, relates to a method for the preparation of a compound of
Formula II-A as herein described, comprising the steps of: a)
preparing a disulfonyl chloride of the formula:
ClO.sub.2S--(CH.sub.2).sub.3--SO.sub.2Cl; b) reacting the
disulfonyl chloride of step (a) with a compound of the formula
PGOH, wherein PG is a protecting group to produce a monosulfonyl
chloride of the formula: PGO.sub.3S--(CH.sub.2).sub.3--SO.sub.2Cl;
c) reacting the monosulfonyl chloride of step (b) with an alcohol
of the formula R.sup.4OH, wherein R.sup.4 is as herein described to
produce a monoprotected compound of the formula:
PGO.sub.3S--(CH.sub.2).sub.3--SO.sub.3OR.sup.4; and d) cleaving the
protecting group from the monoprotected compound of step c) to
produce a compound of Formula II-A. In one embodiment, step (a)
comprises reacting a the disodium salt of 1,3PDS with phosphorus
pentachloride. In one embodiment, the PGOH compound of step (b) is
phenol and step (d) comprises reacting the monoprotected compound
with a source of palladium and a source of hydrogen gas, for
example palladium hydroxide (Pd(OH).sub.2), an acid and hydrogen
gas, for example palladium hydroxide, acetic acid and hydrogen gas.
In another embodiment, steps (b) and (c) further comprise addition
of a base, for example an organic base, for example pyridine.
[0009] The present invention also relates to pharmaceutical
compositions comprising a compound of the present invention,
optionally together with a pharmaceutically acceptable carrier.
[0010] The invention also relates to the use of the compounds of
the invention for the treatment of pancreatic and/or renal and/or
metabolic and/or vascular diseases and disorders. The invention
further relates to the use of the compounds of the invention in the
treatment of amyloid A amyloidosis (AA amyloidosis). The invention
further relates to the use of the compounds of the invention in the
treatment or prevention of renal impairement in patients with AA
amyloidosis. The invention also relates to the use of the compounds
of the invention in the treatment of renal disorders, such as
diabetic nephropathy. The invention further relates to the use of
the compounds of the invention in delaying the onset or the need
for dialysis in renally impaired patients, e.g. in patients with AA
amyloidosis or diabetic nephropathy. The invention further relates
to the use of the compounds of the invention in the treatment of
dyslipidemia, hyperlipidemia, and for reducing serum triglyceride
levels. The invention further relates to the use of the compounds
of the invention in the treatment of metabolic syndrome and/or
diabetes.
[0011] In another aspect, the invention relates to the use of the
compounds of the invention for increasing insulin levels
circulating in blood in response to food, decreasing resistance to
insulin and/or increasing insulin sensitivity in selected tissues
(e.g. fat, muscle and liver), increasing insulin secretion by
pancreatic cells, increasing beta-cells and/or islets of Langerhans
neogenesis and/or regeneration of islets of Langerhans or
preventing their destruction by apoptosis, preventing apoptosis in
beta-cells, and stabilizing, restoring, and/or improving pancreatic
function, and more particularly stabilizing, restoring, and/or
improving beta-cells size, growth and/or function.
[0012] In another aspect, this invention relates to a method for
the prevention or treatment of hyperglycemia, a disease directly
related to an undesirably high glycemia or undesirably low
circulating levels of insulin and/or low insulin secretion by
pancreatic cells and/or restoring its target organ sensitivity to
its action on glucose disposal, to a method of reducing serum
glucose levels, preferably the disease is diabetes, e.g. type 1
and/or type 2. The invention further includes a method for
stabilizing renal function or delaying progression of a renal
disorder.
[0013] The invention also provides methods for the treatment or
prevention of the aforementioned diseases comprising administration
of a therapeutically effective amount of a compound of the
invention or a composition comprising the same, to a subject,
preferably a human subject in need thereof.
[0014] The present invention further relates to a method for
increasing the therapeutic effectiveness of 1,3PDS comprising
administering to a subject, preferably a human subject, an
effective amount of a prodrug of the present invention.
[0015] The present invention also provides processes for converting
compounds of the invention to 1,3PDS. The conversion and/or
generation of 1,3PDS involve contacting any of the compounds of the
invention with, for example, blood, plasma, organs and/or cells.
The conversion can occur in vitro or in vivo. The conversion may
also occur in the presence of enzymes capable of cleaving the
prodrug bonds, including sulfonate ester bonds and amide bonds,
such as peptidases, or other enzymes appropriate for other
structures herein, including those found in the blood, plasma
and/or organs.
[0016] In certain embodiments, a pharmaceutical composition,
formulation, or dosage form of the present invention is capable of
maintaining a therapeutically effective concentration of 1,3PDS in
the plasma or blood of a patient for a time period of at least
about 1 hour, for at least 2 hours, for at least 3 hours, 4 hours,
for at least about 8 hours, for a period of at least about 12
hours, at least about 16 hours, at least about 20 hours, and in
certain embodiments for at least about 24 hours after the
pharmaceutical composition, formulation, or dosage form comprising
a corresponding compound according to the invention and a
pharmaceutically acceptable vehicle is orally administered to the
patient. In certain embodiments, a pharmaceutical composition,
formulation, or dosage form of the present invention is capable of
improving the T.sub.max of 1,3PDS by at least 2 fold, or by at
least 3, 4, 5, 6, 7, 8, 9 or 10 fold or more. In certain
embodiments, a pharmaceutical composition, formulation, or dosage
form of the present invention is capable of improving the
bioavailability (% F) of 1,3PDS by at least 1.2 fold, or by at
least 1.5, 1.8, 2, 2.5, 3, 4, 5, 6 fold or more. In certain
embodiments, a pharmaceutical composition, formulation, or dosage
form of the present invention is capable of improving the AUC of
1,3PDS by at least 1.2 fold, or by at least 1.5, 1.8, 2, 2.5, 3, 4,
5, 6 fold or more.
[0017] Additional objects, advantages and features of the present
invention will become more apparent upon reading of the following
non-restrictive description of preferred embodiments which are
exemplary and should not be interpreted as limiting the scope of
the invention.
DETAILED DESCRIPTION
I. Definitions
[0018] All technical and scientific terms used herein have the same
meaning as commonly understood by one ordinary skilled in the art
to which the invention pertains. For convenience, the meaning of
certain terms and phrases used herein are provided below.
[0019] To the extent the definitions of terms in the publications,
patents, and patent applications incorporated herein by reference
are contrary to the definitions set forth in this specification,
the definitions in this specification control. The section headings
used herein are for organizational purposes only, and are not to be
construed as limiting the subject matter disclosed.
[0020] It should be noted that, the singular forms "a", "an", and
"the" include plural referents unless the content clearly dictates
otherwise. Thus, for example, reference to a composition containing
"a compound" includes a mixture of two or more compounds. It should
also be noted that the term "or" is generally employed in its sense
including "and/or" unless the content clearly dictates
otherwise.
[0021] Abbreviations may also be used throughout the application,
unless otherwise noted, such abbreviations are intended to have the
meaning generally understood by the field. Examples of such
abbreviations include Me (methyl), Et (ethyl), Pr (propyl), i-Pr
(isopropyl), Bu (butyl), t-Bu (tert-butyl), i-Bu (iso-butyl), s-Bu
(sec-butyl), c-Bu (cyclobutyl), Ph (phenyl), Bn (benzyl), Bz
(benzoyl), CBz or Cbz or Z (carbobenzyloxy), Boc or BOC
(tert-butoxycarbonyl), and Su or Suc (succinimide). For greater
certainty, other examples of abbreviations include 1,3PDS
(1,3-propanedisulfonic acid), MeOH (methanol), EtOH (ethanol),
Et.sub.2O (diethyl ether), CH.sub.2Cl.sub.2 (dichloromethane),
CH.sub.2I.sub.2 (diiodomethane), CH.sub.3CN or MeCN (acetonitrile),
H.sub.2O (water), THF (tetrahydrofuran), DMF
(N,N-dimethylformamide), HCl (hydrochloric acid), and DBU
(1,8-biazabicyclo[5.4.0]undec-7-ene).
[0022] The chemical structures herein are drawn according to the
conventional standards known in the art. Thus, where an atom, such
as a carbon atom, as drawn appears to have an unsatisfied valency,
then that valency is assumed to be satisfied by a hydrogen atom
even though that hydrogen atom is not necessarily explicitly drawn.
Hydrogen atoms should be inferred to be part of the compound.
[0023] The symbol "--" in general represents a bond between two
atoms in the chain. Thus
CH.sub.3--O--CH.sub.2--CH(R.sub.i)--CH.sub.3 represents a
2-substituted-1-methoxypropane compound. In addition, the symbol
"--" represents the point of attachment of the substituent to a
compound. Thus for example --(C.sub.1-C.sub.6)alkylaryl indicates
an arylalkyl group, such as benzyl, attached to the compound
through the alkyl moiety. Further, when partial structures of the
compounds are illustrated, brackets or equivalents indicate the
point of attachment of the partial structure to the rest of the
molecule.
[0024] Where multiple substituents are indicated as being attached
to a structure, it is to be understood that the substituents can be
the same or different. Thus for example "R.sub.m optionally
substituted with 1, 2 or 3 R.sub.q groups" indicates that R.sub.m
is substituted with 1, 2, or 3 R.sub.q groups where the R.sub.q
groups can be the same or different.
[0025] As used herein, the terms "compounds of the present
invention", "prodrugs of the present invention" and equivalent
expressions refer to compounds mentioned herein as being useful for
at least one purpose of the invention, e.g., those encompassed by
structural Formulae such as (I), (II), (II-A), (III), (III-A), (IV)
and (V) optionally with reference to any of the applicable
embodiments of Formulae (B) to (F), and includes specific compounds
mentioned herein such as, for example, Compounds A1-A73, B1-B87,
C1-C3, D1-D8, G1-G4, N1-N18, and P1, as well as their
pharmaceutically acceptable salts and solvates when applicable.
Reference to specific salts in the examples is made by the addition
of the counterion in brackets (e.g. Compound B51(2TFA) is
understood as the bis-trifluoroacetic acid salt of Compound D51).
Embodiments herein may exclude one or more of the compounds of the
invention. Compounds may be identified either by their chemical
structure and/or chemical name. When the chemical structure and
chemical name conflict, the chemical structure is determinative of
the identity of the compound.
[0026] The term compounds of the invention, unless otherwise noted,
also encompass all possible enantiomers and stereoisomers of the
illustrated compounds including the stereoisomerically pure form
(e.g., geometrically pure, enantiomerically pure, or
diastereomerically pure) and enantiomeric and stereoisomeric
mixtures if applicable. Enantiomeric and stereoisomeric mixtures
can be resolved into their component enantiomers or stereoisomers
using separation techniques or chiral synthesis techniques well
known to the skilled artisan, e.g., chiral chromatography (such as
chiral HPLC), immunoassay techniques, or the use of covalently
(such as Mosher's esters) and non-covalently (such as chiral salts)
bound chiral reagents to respectively form a diastereomeric mixture
which can be separated by conventional methods, such as
chromatography, distillation, crystallization or sublimation, the
chiral salt or ester is then exchanged or cleaved by conventional
means, to recover the desired isomers. The compounds may also exist
in several tautomeric forms including the enol form, the keto form,
and mixtures thereof. Accordingly, the term also encompass all
possible tautomeric forms of the illustrated compounds. The term
also include isotopically labeled compounds where one or more atoms
have an atomic mass different from the atomic mass most abundantly
found in nature. Examples of isotopes that may be incorporated into
the compounds of the present invention include, but are not limited
to, .sup.2H (D), .sup.3H (T), .sup.11C, .sup.13C, .sup.14C,
.sup.15N, .sup.18O, .sup.17O, any one of the isotopes of sulfur,
etc. Compounds may exist in unsolvated forms as well as solvated
forms, including hydrated forms. Certain compounds may exist in
multiple crystalline or amorphous forms. In general, all physical
forms are equivalent for the uses contemplated herein and are
intended to be within the scope of the present invention, and are
intended to be included by the term "compounds of the invention"
and equivalents.
[0027] The term "prodrug" and equivalent expressions refer to
agents which can be converted in vitro or in vivo directly or
indirectly to an active form (see, e.g., R. B. Silverman, 1992,
"The Organic Chemistry of Drug Design and Drug Action," Academic
Press, Chap. 8; Bundgaard, Hans; Editor. Neth. (1985), "Design of
Prodrugs". 360 pp. Elsevier, Amsterdam; Stella, V.; Borchardt, R.;
Hageman, M.; Oliyai, R.; Maag, H.; Tilley, J. (Eds.) (2007),
"Prodrugs: Challenges and Rewards, XVIII, 1470 p. Springer).
Prodrugs can be used to alter the biodistribution (e.g., to allow
agents which would not typically enter the reactive site of the
protease) or the pharmacokinetics for a particular agent. A wide
variety of groups have been used to modify compounds to form
prodrugs, for example, esters, ethers, phosphates, etc. When the
prodrug is administered to a subject, the group is cleaved,
enzymatically or non-enzymatically, reductively, oxidatively, or
hydrolytically, or otherwise to reveal the active form. Prodrugs
are frequently, although not necessarily, pharmacologically
inactive until converted to the parent drug.
[0028] The term "oligomer" or "gemini dimer" and equivalent
expressions refer to a synthetic compound comprising at least two
moieties of the same agent or drug coupled together. For background
on gemini dimers, see: Hammell D C, Hamad M, Vaddi H K, Crooks P A,
Stinchcomb A L, A duplex "Gemini" prodrug of naltrexone for
transdermal delivery, J Control Release, 2004, 97(2):283-90. In
preferred embodiment, the gemini dimers of the invention are made
of two linked 1,3PDS molecules that may be converted in vitro or in
vivo directly or indirectly to release at least one, preferably
two, pharmaceutically active 1,3PDS molecules.
[0029] The term "ester" refers to compounds that can be represented
by the formula RCOOR (carboxylic ester) or the formula RSO.sub.3R'
(sulfonate ester), where the group R can be, for example 1,3PDS or
the 3-sulfopropane part thereof, and the group R' is another
organic group. These compounds are usually respectively formed by
the reaction between a carboxylic or a sulfonic acid and an alcohol
usually with the elimination of water, or by the reaction of an
activated form of the carboxylic or sulfonic acid with an alcohol.
The term "sulfonate ester" refers to an esterified sulfonic acid,
and which are represented, for example, by the compounds of
Formulae II and II-A.
[0030] The term "amino acid" generally refers to an organic
compound comprising both a carboxylic acid group and an amine
group. The term "amino acid" includes both "natural" and
"unnatural" or "non-natural" amino acids. Additionally, the term
amino acid includes O-alkylated or N-alkylated amino acids, as well
as amino acids having nitrogen or oxygen-containing side chains
(such as Lys, Orn, or Ser) in which the nitrogen or oxygen atom has
been acylated or alkylated. Amino acids may be pure L or D isomers
or mixtures of L and D isomers, including racemic mixtures. Amino
acid may be .alpha.-, or .beta.-, or .gamma.-, or .delta.-, or
.omega.-amino acid.
[0031] The term "natural amino acid" and equivalent expressions
refer to L-amino acids commonly found in naturally occurring
proteins. Examples of natural amino acids include, without
limitation, alanine (Ala), cystein (Cys), aspartic acid (Asp),
glutamic acid (Glu), phenylalanine (Phe), glycine (Gly), histidine
(His), isoleucine (Ile), lysine (Lys), leucine (Leu), methionine
(Met), asparagine (Asp), proline (Pro), glutamine (Gln), arginine
(Arg), serine (Ser), threonine (Thr), valine (Val), tryptophan
(Trp), tyrosine (Tyr), .beta.-alanine (.beta.-ALA), and
.gamma.-aminobutyric acid (GABA).
[0032] The term "unnatural amino acid" refers to any derivative of
a natural amino acid including D forms, and .alpha.- and
.beta.-amino acid derivatives. The terms "unnatural amino acid" and
"non-natural amino acid" are used interchangeably herein and are
meant to include the same moieties. It is noted that certain amino
acids, e.g., hydroxyproline, that are classified as a non-natural
amino acid herein, may be found in nature within a certain organism
or a particular protein. Amino acids with many different protecting
groups appropriate for immediate use in the solid phase synthesis
of peptides are commercially available. In addition to the twenty
most common naturally occurring amino acids, the following examples
of non-natural amino acids and amino acid derivatives may be used
according to the invention (common abbreviations in parentheses):
2-aminoadipic acid (Aad), 3-aminoadipic acid (.beta.-Aad),
2-aminobutyric acid (2-Abu), .alpha.,.beta.-dehydro-2-aminobutyric
acid (8-AU), 1-aminocyclopropane-1-carboxylic acid (ACPC),
aminoisobutyric acid (Aib), 3-aminoisobutyric acid (.beta.-Aib),
2-amino-thiazoline-4-carboxylic acid, 5-aminovaleric acid (5-Ava),
6-aminohexanoic acid (6-Ahx), 2-aminoheptanoic acid (Ahe),
8-aminooctanoic acid (8-Aoc), 11-aminoundecanoic acid (11-Aun),
12-aminododecanoic acid (12-Ado), 2-aminobenzoic acid (2-Abz),
3-aminobenzoic acid (3-Abz), 4-aminobenzoic acid (4-Abz),
4-amino-3-hydroxy-6-methylheptanoic acid (Statine, Sta),
aminooxyacetic acid (Aoa), 2-aminotetraline-2-carboxylic acid
(ATC), 4-amino-5-cyclohexyl-3-hydroxypentanoic acid (ACHPA),
para-aminophenylalanine (4-NH.sub.2-Phe), 2-aminopimelic acid
(Apm), biphenylalanine (Bip), para-bromophenylalanine (4-Br-Phe),
ortho-chlorophenylalanine (2-Cl-Phe), meta-chlorophenylalanine
(3-Cl-Phe), para-chlorophenylalanine (4-Cl-Phe),
meta-chlorotyrosine (3-Cl-Tyr), para-benzoylphenylalanine (Bpa),
tert-butylglycine (TLG), cyclohexylalanine (Cha), cyclohexylglycine
(Chg), desmosine (Des), 2,2-diaminopimelic acid (Dpm),
2,3-diaminopropionic acid (Dpr), 2,4-diaminobutyric acid (Dbu),
3,4-dichlorophenylalanine (3,4-C1.sub.2-Phe),
3,4-diflurorphenylalanine (3,4-F.sub.2-Phe), 3,5-diiodotyrosine
(3,5-I.sub.2-Tyr), N-ethylglycine (EtGly), N-ethylasparagine
(EtAsn), ortho-fluorophenylalanine (2-F-Phe),
meta-fluorophenylalanine (3-F-Phe), para-fluorophenylalanine
(4-F-Phe), meta-fluorotyrosine (3-F-Tyr), homoserine (Hse),
homophenylalanine (Hfe), homotyrosine (Htyr), hydroxylysine (Hyl),
allo-hydroxylysine (aHyl), 5-hydroxytryptophan (5-OH-Trp), 3- or
4-hydroxyproline (3- or 4-Hyp), para-iodophenylalanine (4-I-Phe),
3-iodotyrosine (3-I-Tyr), indoline-2-carboxylic acid (Idc),
isodesmosine (Ide), allo-isoleucine (a-Ile), isonipecotic acid
(Inp), N-methylisoleucine (MeIle), N-methyllysine (MeLys),
meta-methyltyrosine (3-Me-Tyr), N-methylvaline (MeVal),
1-naphthylalanine (1-NaI), 2-naphthylalanine (2-NaI),
para-nitrophenylalanine (4-NO.sub.2-Phe), 3-nitrotyrosine
(3-NO.sub.2-Tyr), norleucine (Nle), norvaline (Nva), ornithine
(Orn), ortho-phosphotyrosine (H.sub.2PO.sub.3-Tyr),
octahydroindole-2-carboxylic acid (Oic), penicillamine (Pen),
pentafluorophenylalanine (F.sub.5-Phe), phenylglycine (Phg),
pipecolic acid (Pip), propargylglycine (Pra), pyroglutamic acid
(PGLU), sarcosine (Sar), tetrahydroisoquinoline-3-carboxylic acid
(Tic), thienylalanine, and thiazolidine-4-carboxylic acid
(thioproline, Th).
[0033] The term "aliphatic group" includes organic moieties
characterized by straight or branched-chains, typically having
between 1 and 16 carbon atoms, or having between 1 to 12, 1 to 8, 1
to 5 or 1 to 3 carbon atoms. Aliphatic groups include acyclic alkyl
groups, alkenyl groups, and alkynyl groups.
[0034] As used herein, the term "acyclic" refers to an organic
moiety without ring system.
[0035] As used herein, the term "alkyl" refers to saturated
hydrocarbons having from one to sixteen carbon atoms, including
linear or branched alkyl groups. Examples of alkyl groups include,
without limitation, methyl, ethyl, propyl, butyl, pentyl, hexyl,
heptyl, octyl, nonyl, decyl, isopropyl, tert-butyl, sec-butyl,
isobutyl, and the like. The term "C.sub.1-C.sub.nalkyl" refers to
an alkyl group having from 1 to the indicated "n" number of carbon
atoms.
[0036] As used herein, the term "alkenyl" refers to unsaturated
hydrocarbons having from two to sixteen carbon atoms, including
linear or branched alkenyl groups, and comprising between one and
six carbon-carbon double bonds. Examples of alkenyl groups include,
without limitation, vinyl, allyl, 1-propen-2-yl, 1-buten-3-yl,
1-buten-4-yl, 2-buten-4-yl, 1-penten-5-yl, 1,3-pentadien-5-yl, and
the like. The term alkenyl includes both unsubstituted alkenyl
groups and substituted alkenyl groups. The term
"C.sub.2-C.sub.nalkenyl" refers to an alkenyl group having from 2
to the indicated "n" number of carbon atoms.
[0037] As used herein, the term "alkynyl" refers to unsaturated
hydrocarbons having from two to twelve carbon atoms, including
linear or branched alkynyl groups, and comprising between one to
six carbon-carbon triple bond. Examples of alkynyl groups include,
without limitation, ethynyl, 1-propyn-3-yl, 1-butyn-4-yl,
2-butyn-4-yl, 1-pentyn-5-yl, 1,3-pentadiyn-5-yl, and the like. The
term alkynyl includes both unsubstituted alkynyl groups and
substituted alkynyl groups. The term "C.sub.2-C.sub.nalkynyl"
refers to an alkynyl group having from 2 to the indicated "n"
number of carbon atoms.
[0038] Unless the number of carbons is otherwise specified, "lower"
as in "lower aliphatic," "lower alkyl," "lower alkenyl," and "lower
alkylnyl", as used herein means that the moiety has at least one
(two for alkenyl and alkynyl) and equal or less than 6 carbon
atoms.
[0039] The terms "cycloalkyl", "alicyclic", "carbocyclic" and
equivalent expressions refer to a group comprising a saturated or
partially unsaturated (non aromatic) carbocyclic ring in a
monocyclic or polycyclic ring system, including spiro (sharing one
atom) or fused (sharing at least one bond) carbocyclic ring
systems, having from three to fifteen ring members. Examples of
cycloalkyl groups include, without limitation, cyclopropyl,
cyclobutyl, cyclopentyl, cyclopenten-1-yl, cyclopenten-2-yl,
cyclopenten-3-yl, cyclohexyl, cyclohexen-1-yl, cyclohexen-2-yl,
cyclohexen-3-yl, cycloheptyl, bicyclo[4,3,0]nonanyl, norbornyl, and
the like. The term cycloalkyl includes both unsubstituted
cycloalkyl groups and substituted cycloalkyl groups. The term
"C.sub.3-C.sub.ncycloalkyl" refers to a cycloalkyl group having
from 3 to the indicated "n" number of carbon atoms in the ring
structure. Unless the number of carbons is otherwise specified,
"lower cycloalkyl" groups as herein used, have at least 3 and equal
or less than 8 carbon atoms in their ring structure.
[0040] The term "heterocycloalkyl" and equivalent expressions refer
to a group comprising a saturated or partially unsaturated (non
aromatic) carbocyclic ring in a monocyclic or polycyclic ring
system, including spiro (sharing one atom) or fused (sharing at
least one bond) carbocyclic ring systems, having from three to
fifteen ring members, where one or more (up to six) ring members
are substituted or unsubstituted heteroatoms (e.g. N, O, S, P) or
groups containing such heteroatoms (e.g. NH, NR.sub.x (R.sub.x is
alkyl, acyl, aryl, heteroaryl or cycloalkyl), PO.sub.2, SO,
SO.sub.2, and the like). Heterocycloalkyl groups may be C-attached
or heteroatom-attached (e.g. via a nitrogen atom) where such is
possible. Examples of heterocycloalkyl groups include, without
limitation, pyrrolidino, tetrahydrofuranyl, tetrahydrodithienyl,
tetrahydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino,
thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl,
thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl,
diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl,
3-pyrrolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl,
pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl,
dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl,
imidazolidinyl, 3-azabicyclo[3,1,0]hexanyl,
3-azabicyclo[4,1,0]heptanyl, quinolizinyl, and sugars, and the
like. The term heterocycloalkyl includes both unsubstituted
heterocycloalkyl groups and substituted heterocycloalkyl groups.
The term "C.sub.3-C.sub.nheterocycloalkyl" refers to a
heterocycloalkyl group having from 3 to the indicated "n" number of
atoms (carbon or heteroatom or group) in the ring structure,
including at least one hetero group or atom as defined above.
Unless the number of carbons is otherwise specified, "lower
heterocycloalkyl" groups as herein used, have at least 3 and equal
or less than 8 ring members in their ring structure.
[0041] The terms "aryl" and "aryl ring" refer to aromatic groups
having 4n+2 .pi.(pi) electrons, wherein n is an integer from 1 to
3, in a conjugated monocyclic or polycyclic system (fused or not)
and having six to fourteen ring atoms. A polycyclic ring system
includes at least one aromatic ring. Aryl may be directly attached,
or connected via a C.sub.1-C.sub.3alkyl group (also referred to as
arylalkyl or aralkyl). Examples of aryl groups include, without
limitation, phenyl, benzyl, phenetyl, 1-phenylethyl, tolyl,
naphthyl, biphenyl, terphenyl, indenyl, benzocyclooctenyl,
benzocycloheptenyl, azulenyl, acenaphthylenyl, fluorenyl,
phenanthernyl, anthracenyl, and the like. The term aryl includes
both unsubstituted aryl groups and substituted aryl groups. The
term "C.sub.6-C.sub.naryl" refers to an aryl group having from 6 to
the indicated "n" number of carbons in the ring structure.
[0042] The terms "heteroaryl" and "heteroaryl ring" refer to
aromatic groups having 4n+2 .pi.(pi) electrons, wherein n is an
integer from 1 to 3, in a conjugated monocyclic or polycyclic
system (fused or not) and having five to fourteen ring members,
including one to six substituted or unsubstituted heteroatoms (e.g.
N, O, S) or groups containing such heteroatoms (e.g. NH, NR.sub.x
(R.sub.x is alkyl, acyl, aryl, heteroaryl or cycloalkyl), SO, and
the like). A polycyclic ring system includes at least one
heteroaromatic ring. Heteroaryls may be directly attached, or
connected via a C.sub.1-C.sub.3alkyl group (also referred to as
heteroarylalkyl or heteroaralkyl). Heteroaryl groups may be
C-attached or heteroatom-attached (e.g. via a nitrogen atom), where
such is possible. Examples of heteroaryl groups include, without
limitation, pyridyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl,
tetrazolyl, furyl, thienyl; isooxazolyl, thiazolyl, oxazolyl,
isothiazolyl, pyrrollyl, quinolinyl, isoquinolinyl, indolyl,
3H-indolyl, indolinyl, isoindolyl, chromenyl, isochromenyl,
benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl,
phthalazinyl, pyridazinyl, pyrazinyl, triazinyl, isoindolyl,
pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl,
benzofurazanyl, benzothiophenyl, benzothienyl, benzothiazolyl,
benzoxazolyl, quinazolinyl, quinolizinyl, quinolonyl,
isoquinolonyl, quinoxalinyl, naphthyridinyl, furopyridinyl,
carbazolyl, phenanthridinyl, acridinyl, perimidinyl,
phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxazinyl,
dibenzofurnayl, and the like. The term heteroaryl includes both
unsubstituted heteroaryl groups and substituted heteroaryl groups.
The term "C.sub.5-C.sub.nheteroaryl refers to an heteroaryl group
having from 5 to the indicated "n" number of atoms (carbon or
heteroatom or group) in the ring structure, including at least one
hetero group or atom as defined above.
[0043] The terms "heterocycle" or "heterocyclic" or "heterocyclyl"
include heterocycloalkyl and heteroaryl groups. Examples of
heterocycles include, without limitation, acridinyl, azocinyl,
benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl,
benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl,
benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl,
4.alpha.H-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl,
decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl,
dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl,
imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl,
indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl,
isochromanyl, isoindazolyl, isoindolinyl, isoindolyl,
isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl,
morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl,
1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl,
1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl,
pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl,
phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl,
piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl,
pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl,
pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole,
pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl,
pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl,
quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl,
tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl,
tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl,
1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl,
thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl,
thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl,
1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, xanthenyl, and
the like. The term heterocycle includes both unsubstituted
heterocyclic groups and substituted heterocyclic groups.
[0044] The term "amine" or "amino," as used herein, refers to an
unsubstituted or substituted moiety of the formula
--NR.sup.aR.sup.b, in which R.sup.a and R.sup.b are each
independently hydrogen, alkyl, aryl, or heterocyclyl, or R.sup.a
and R.sup.b, taken together with the nitrogen atom to which they
are attached, form a heterocyclic ring. The term "aminocarbonyl"
includes compounds or moieties which contain a nitrogen atom bound
to the carbon of a carbonyl or a thiocarbonyl group. The term
acylamino refers to an amino group directly attached to an acyl
group as defined herein.
[0045] The term "nitro" means --NO.sub.2; the terms "halo" and
"halogen" refer to bromine, chlorine, fluorine or iodine
substituents; the term "thiol", "thio", or "mercapto" means SH; and
the term "hydroxyl" or "hydroxy" means --OH. The term "alkylthio"
refers to an alkyl group, having a sulfhydryl group attached
thereto. Suitable alkylthio groups include groups having 1 to about
12 carbon atoms, preferably from 1 to about 6 carbon atoms. The
term "alkylcarboxyl" as used herein means an alkyl group having a
carboxyl group attached thereto.
[0046] The term "alkoxy" or "lower alkoxy" as used herein means an
alkyl group having an oxygen atom attached thereto. Representative
alkoxy groups include groups having 1 to about 6 carbon atoms,
e.g., methoxy, ethoxy, propoxy, tert-butoxy and the like. Examples
of alkoxy groups include methoxy, ethoxy, isopropyloxy, propoxy,
butoxy, pentoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy,
chloromethoxy, dichloromethoxy, trichloromethoxy groups and the
like. The term alkoxy includes both unsubstituted or substituted
alkoxy groups, etc., as well as halogenated alkyloxy groups.
[0047] The term "carbonyl" or "carboxy" includes compounds and
moieties which contain a carbon connected with a double bond to an
oxygen atom. Examples of moieties which contain a carbonyl include
aldehydes, ketones, carboxylic acids, amides, esters, anhydrides,
etc.
[0048] The term "acyl" refers to a carbonyl group that is attached
through its carbon atom to a hydrogen (i.e., formyl), an aliphatic
group (C.sub.1-C.sub.nalkyl, C.sub.1-C.sub.nalkenyl,
C.sub.1-C.sub.nalkynyl, wherein n is an integer from 2 to 10; e.g.
acetyl, a cycloalkyl group (e.g. C.sub.3-C.sub.8cycloalkyl), a
heterocyclic group (e.g. C.sub.3-C.sub.8heterocycloalkyl and
C.sub.5-C.sub.6heteroaryl), an aromatic group (e.g. C.sub.6aryl,
e.g., benzoyl), and the like. Acyl groups may be unsubstituted or
substituted acyl groups (e.g. salicyloyl).
[0049] It will be understood that "substitution" or "substituted
with" includes the implicit proviso that such substitution is in
accordance with the permitted valence of the substituted atom and
the substituent, and that the substitution results in a stable
compound, e.g., which does not spontaneously undergo transformation
such as by rearrangement, cyclization, elimination, etc. As used
herein, the term "substituted" is meant to include all permissible
substituents of organic compounds. In a broad aspect, the
permissible substituents include acyclic and cyclic, branched and
unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic
substituents of organic compounds. The permissible substituents can
be one or more. The term "substituted", when in association with
any of the foregoing groups refers to a group substituted at one or
more position with substituents such as acyl, amino (including
simple amino, mono and dialkylamino, mono and diarylamino, and
alkylarylamino), acylamino (including carbamoyl, and ureido),
alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy,
alkoxycarbonyl, carboxy, carboxylate, aminocarbonyl, mono and
dialkylaminocarbonyl, cyano, azido, halogen, hydroxyl, nitro,
trifluoromethyl, thio, alkylthio, arylthio, alkylthiocarbonyl,
thiocarboxylate, lower alkyl, lower alkenyl, lower alkynyl,
cycloalkyl, heterocycloalkyl, aryl, heteroaryl, lower alkoxy,
aryloxy, aryloxycarbonyloxy, benzyloxy, benzyl, sulfinyl,
alkylsulfinyl, sulfonyl, sulfate, sulfonate, sulfonamide,
phosphate, phosphonato, phosphinato, oxo, guanidine, imino, formyl
and the like. Any of the above substituents can be further
substituted if permissible, e.g. if the group contains an alkyl
group, an aryl group, or other.
[0050] The term "solvate" refers to a physical association of a
compound of this invention with one or more solvent molecules,
whether organic or inorganic. This physical association includes
hydrogen bonding. In certain instances, the solvate will be capable
of isolation, for example when one or more solvent molecules are
incorporated in the crystal lattice of the crystalline solid.
"Solvate" encompasses both solution-phase and isolable solvates.
Exemplary solvates include hydrates, hemihydrates, ethanolates,
hemiethanolates, n-propanolates, iso-propanolates, 1-butanolates,
2-butanolate, and solvates of other physiologically acceptable
solvents, such as the Clas 3 solvents described in the
International Conference on Harmonization (ICH), Guide for
Industry, Q3C Impurities: Residual Solvents (1997). The compounds
of the invention include each solvate and mixtures thereof.
[0051] A "pharmaceutically acceptable salt" of a compound and
equivalent expressions, means a salt of a compound that is
pharmaceutically acceptable. Desirable are salts of a compound that
retain or improve the biological effectiveness and properties of
the free acids and bases of the parent compound as defined herein
or that takes advantage of an intrinsically basic, acidic or
charged functionality on the molecule and that is not biologically
or otherwise undesirable. Example of pharmaceutically acceptable
salts are also described, for example, in Berge et al.,
"Pharmaceutical Salts", J. Pharm. Sci. 66, 1-19 (1977). Such salts
include:
[0052] (1) acid addition salts, formed on a basic or positively
charged functionality, by the addition of inorganic acids such as
hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric
acid, sulfamic acid, nitric acid, phosphoric acid, carbonate
forming agents, and the like; or formed with organic acids such as
acetic acid, propionic acid, lactic acid, oxalic, glycolic acid,
pivalic acid, t-butylacetic acid, .beta.-hydroxybutyric acid,
valeric acid, hexanoic acid, cyclopentanepropionic acid, pyruvic
acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric
acid, tartaric acid, citric acid, benzoic acid,
3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid,
methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic
acid, 2-hydroxyethanesulfonic acid, cyclohexylaminosulfonic acid,
benzenesulfonic acid, sulfanilic acid, 4-chlorobenzenesulfonic
acid, 2-napthalenesulfonic acid, 4-toluenesulfonic acid,
camphorsulfonic acid, 3-phenyl propionic acid, lauryl sulphonic
acid, lauryl sulfuric acid, oleic acid, palmitic acid, stearic
acid, lauric acid, embonic (pamoic) acid, palmoic acid, pantothenic
acid, lactobionic acid, alginic acid, galactaric acid, galacturonic
acid, gluconic acid, glucoheptonic acid, glutamic acid, naphthoic
acid, hydroxynapthoic acid, salicylic acid, ascorbic acid, stearic
acid, muconic acid, and the like;
[0053] (2) base addition salts, formed when an acidic proton
present in the parent compound either is replaced by a metal ion,
including, an alkali metal ion (e.g. lithium, sodium, potassium),
an alkaline earth ion (e.g. magnesium, calcium, barium), or other
metal ions such as aluminum, zinc, iron, vanadium and the like; or
coordinates with an organic base such as ammonia, ethylamine,
diethylamine, ethylenediamine, N,N'-dibenzylethylenediamine,
ethanolamine, diethanolamine, triethanolamine, tromethamine,
N-methylglucamine, piperazine, chloroprocain, procain, choline,
lysine and the like.
[0054] Pharmaceutically acceptable salts may be synthesized from
the parent agent that contains a basic or acidic moiety, by
conventional chemical methods. Generally, such salts are prepared
by reacting the free acid or base forms of these agents with a
stoichiometric amount of the appropriate base or acid in water or
in an organic solvent, or in a mixture of the two. Salts may be
prepared in situ, during the final isolation or purification of the
agent or by separately reacting a purified compound of the
invention in its free acid or base form with the desired
corresponding base or acid, and isolating the salt thus formed. The
term "pharmaceutically acceptable salts" also include zwitterionic
compounds containing a cationic group covalently bonded to an
anionic group, as they are "internal salts".
[0055] All acid, salt, base, and other ionic and non-ionic forms of
the compounds described are included as compounds of the invention.
For example, if a compound is shown as an acid herein, the salt
forms of the compound are also included. Likewise, if a compound is
shown as a salt, the acid and/or basic forms are also included.
[0056] "AUC" is the area under a curve representing the
concentration of a compound in a biological sample of a subject as
a function of time following administration of the compound to the
subject. Examples of biological samples include biological fluids
such as plasma and blood, or organ homogenates such as brain or
liver homogenates. The AUC can be determined by measuring the
concentration of a compound in a biological sample such as the
plasma, blood or brain homogenate using methods such as liquid
chromatography-tandem mass spectrometry (LC/MS/MS), at various time
intervals, and calculating the area under the
concentration-versus-time curve. Suitable methods for calculating
the AUC from a drug concentration-versus-time curve are well known
in the art. As relevant to the disclosure here, an AUC for 1,3PDS
can be determined by measuring the concentration of 1,3PDS in the
plasma, blood or brain homogenate of a subject following oral
administration of a compound of the invention to the subject.
Unless noted otherwise herein; AUC means AUC.sub.0-.infin..
[0057] "Bioavailability" refers to the rate and amount of a drug
that reaches the systemic circulation of a subject following
administration of the drug or prodrug thereof to the patient and
can be determined by evaluating, for example, the plasma or blood
concentration-versus-time profile for the drug. Parameters useful
in characterizing a plasma or blood concentration-versus-time curve
include the area under the curve (AUC), the time to peak
concentration (T.sub.max), and the maximum drug concentration
(C.sub.max). Bioavailability is often expressed as F(%) referring
to the ratio in percentage of the AUC of the compound for a
specific mode of administration (e.g. orally) over AUC of the
compound after an IV administration. "C.sub.max" is the maximum
concentration of a drug in the biological sample of a subject
following administration of a dose of the drug or prodrug to the
subject. "T.sub.max" is the time to the maximum concentration
(C.sub.max) of a drug in the biological sample of a subject
following administration of a dose of the drug or prodrug to the
subject.
[0058] "Bioequivalence" refers to equivalence of the rate and
extent of absorption of a drug after administration of equal doses
of the drug or prodrug to a patient. As used herein, two plasma or
blood concentration profiles are bioequivalent if the 90%
confidence interval for the ratio of the mean response of the two
profiles is within the limits of 0.8 and 1.25. The mean response
includes at least one of the characteristic parameters of a profile
such as C.sub.max, T.sub.max, and AUC.
[0059] As used herein the term "effective amount" refers to the
amount or dose of the compound, upon single or multiple dose
administration to the patient, which provides the desired effect in
the patient under diagnosis or treatment. An effective amount can
be readily determined by the attending diagnostician, as one
skilled in the art, by the use of known techniques and by observing
results obtained under analogous circumstances. In determining the
effective amount or dose of compound administered, a number of
factors are considered by the attending diagnostician, including,
but not limited to: the size, age, and general health of the
subject; the specific disease involved; the degree of or
involvement or the severity of the disease; the response of the
individual subject; the particular compound administered; the mode
of administration; the bioavailability characteristics of the
preparation administered; the dose regimen selected; the use of
concomitant medication; and other relevant circumstances.
[0060] As used herein the term "therapeutic bio-distribution of
1,3PDS" refers to one or more pharmacokinetic parameters of 1,3PDS
which affect 1,3PDS therapeutic activity. Examples of such
pharmacokinetic (PK) parameters include but are not limited to:
bioavailability of 1,3PDS, AUC of 1,3PDS, C.sub.max of 1,3PDS,
T.sub.max of 1,3PDS, bio-absorption of 1,3PDS, bio-distribution of
1,3PDS etc.
[0061] As used herein the terms "increased (or like terms, e.g.,
increasing, increase in, etc.) therapeutic effectiveness of 1,3PDS"
and "enhanced (or like terms, e.g., enhancing, enhancement, etc.)
therapeutic effectiveness of 1,3PDS" refer to an increased
effectiveness of 1,3PDS as measured, e.g., by one or more
parameters listed under "therapeutic bio-distribution of 1,3PDS"
above, e.g., by 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%,
95%, 99%, 125%, etc., or even more, e.g., 2, or 4 fold, or even
more when administered to a subject, e.g., animal or human, which
increase is with respect to the same equivalent molar dose of
1,3PDS administered orally in water solution.
[0062] The term "reduction of side effects of 1,3PDS" refers to
decreasing the amount of or severity of one or more side effects of
1,3PDS by, e.g., 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%,
95%, 99%, or 99.9%, or even 100%, which decrease is with respect to
the amount of or severity of a side effect of 1,3PDS that is
exhibited when the same equivalent molar dose of free or disodium
salt of 1,3PDS is administered orally.
[0063] The term "reduction of effective dosage of 1,3PDS" refers to
decreasing the molar amount of 1,3PDS in the prodrug necessary to
be administered to achieve the same or equivalent result as
achieved by administering free 1,3PDS (e.g. to achieve equivalent
parameters such as one of AUC, C.sub.max, T.sub.max, % F, an the
like). The decrease is for example administration of 5%, 10%, 20%,
30%, 40%, 50%, 60%, 70%, or 80%, of the dose of 1,3PDS (molar
equivalent) in order to achieve the same or equivalent blood levels
as compared to administration of free 1,3PDS, or to reach
equivalent efficacy.
[0064] More generally, the terms lessening etc., increasing etc.,
refer in context herein to the percentage changes, e.g., by 5%,
10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 125%, etc.,
or even more, e.g., 2, or 4 fold, or even more.
[0065] When referring to "1,3PDS" being produced (e.g., released
from a formulation or prodrug), all forms of 1,3PDS are included,
e.g., solvates thereof, ionically dissociated forms thereof,
charged forms thereof, etc.
[0066] "Pharmaceutically acceptable" and equivalent expressions
refer to salts, drugs, medicaments, inert ingredients, carrier,
vehicle, fillers, etc., which the term describes, suitable for use
in contact with the tissues of humans and lower animals without
undue toxicity, incompatibility, instability, irritation, allergic
response, and the like, commensurate with a reasonable benefit/risk
ratio. It preferably refers to a compound or composition that is
approved or approvable by a regulatory agency of the Federal or
state government or listed in the U.S. Pharmacopoeia or other
generally recognized pharmacopoeia for use in animals and more
particularly in humans.
[0067] "Pharmaceutical composition" refers to at least one compound
and at least one pharmaceutically acceptable vehicle, with which
the compound is administered to a subject.
[0068] "Pharmaceutically acceptable vehicle" and equivalent
expressions refer to a diluent, adjuvant, excipient, or carrier
with which a compound is administered.
[0069] Reference will now be made in detail to certain embodiments
of compounds and methods. The disclosed embodiments are not
intended to be limiting of the invention.
II. Compounds of the Invention
[0070] The present invention relates to methods, compounds and
compositions for delivering in a subject, preferably a human
subject, 1,3-propanedisulfonic acid, or salts thereof, also
referred herein as 1,3PDS. The invention encompasses compounds that
will yield or generate 1,3PDS, either in vitro or in vivo.
[0071] Accordingly, the invention relates to compounds of Formula
I:
##STR00002##
wherein,
[0072] R.sup.1 is selected from OR.sup.3, --NHC(O)R.sup.5,
--NHC(NH)NHR.sup.5, and --NH(C.sub.5-C.sub.10heteroaryl);
[0073] R.sup.2 is selected from OR.sup.4, --NHC(O)R.sup.5,
--NHC(NH)NHR.sup.5, and --NH(C.sub.5-C.sub.10heteroaryl), or
R.sup.1 is a covalent bond and R.sup.2 is selected from O,
OC.sub.1-C.sub.3alkylO, NH, NC(O)R.sup.5, NC(NH)NHR.sup.5, and
N(C.sub.5-C.sub.10heteroaryl) when R.sup.1 and R.sup.2 are taken
together with their adjacent atoms to form a heterocycle;
[0074] R.sup.3 is selected from hydrogen and a substituted or
unsubstituted group selected from C.sub.1-C.sub.12alkyl,
C.sub.2-C.sub.12alkenyl, C.sub.2-C.sub.12alkynyl,
C.sub.3-C.sub.15cycloalkyl, C.sub.3-C.sub.15heterocycloalkyl,
C.sub.6-C.sub.15aryl, and C.sub.5-C.sub.15heteroaryl;
[0075] R.sup.4 is a substituted or unsubstituted group selected
from C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12alkynyl, C.sub.3-C.sub.15cycloalkyl,
C.sub.3-C.sub.15heterocycloalkyl, C.sub.6-C.sub.15aryl, and
C.sub.5-C.sub.15heteroaryl; and
[0076] R.sup.5 is selected from hydrogen and a substituted or
unsubstituted group selected from C.sub.1-C.sub.12alkyl,
C.sub.2-C.sub.12alkenyl, C.sub.2-C.sub.12alkynyl,
C.sub.3-C.sub.15cycloalkyl, C.sub.3-C.sub.15heterocycloalkyl,
C.sub.6-C.sub.15aryl, and C.sub.5-C.sub.15heteroaryl;
or a pharmaceutically acceptable salt or solvate thereof.
[0077] The invention pertains to both salt forms and free acid/base
forms of the compounds of the invention. For example, the invention
pertains not only to the particular salt forms of compounds shown
herein as salts, but also the invention includes other
pharmaceutically acceptable salts, and the acid and/or base form of
the compound. The invention also pertains to salt forms of
compounds shown herein as free acids or bases.
[0078] To avoid any confusion, in this section the exemplary
compounds of the invention are all shown in their free (i.e. free
acid or base) form. Reference to specific salts in the examples is
made by the addition of the counterion in brackets. For example,
Compound A29(Na) or Compound A29(sodium salt) is the sodium salt of
Compound A29, and Compound B51(2TFA) is understood as the
bis(trifluoroacetic acid) salt of Compound B51.
[0079] The sulfonate ester moiety, any other pharmacokinetic
modulating moiety of the prodrugs, their precursors, as well as
combinations thereof, may be cleaved prior to absorption by the
gastrointestinal tract (e.g., within the stomach or intestinal
lumen) and/or after absorption by the gastrointestinal tract (e.g.,
in intestinal tissue, blood, liver, or other suitable tissue of a
mammal). In certain embodiments, 1,3PDS remains covalently attached
to the pharmacokinetic modulating moiety during transit across the
intestinal mucosal barrier. In certain embodiments, pharmacokinetic
modulating moieties according to the invention are essentially not
metabolized to the corresponding 1,3PDS within cells of the
intestine or liver (e.g. enterocytes, hepatocytes), but generates
the parent 1,3PDS molecule once within the systemic circulation.
These prodrugs may be absorbed into the systemic circulation either
by active transport, passive diffusion, or by a combination of both
active and passive processes.
[0080] The pharmacokinetic modulating moiety of certain of the
compounds according to the invention may be cleaved either
chemically and/or enzymatically. One or more enzymes present in the
stomach, intestinal lumen, intestinal tissue, blood, liver, or any
other suitable tissue or organ of a mammal may enzymatically cleave
release 1,3PDS. The pharmacokinetic moiety may also be cleaved
indirectly by the cleavage of a moiety located, for example, 5 to 7
atoms away from the sulfonate ester, the cleavage of said moiety
triggering internal cyclization, or other internal reaction, to
liberate the desired free drug. The cleavable moiety will generally
comprise a bond which is known to be so cleavable such as but not
limited to, a peptide, amide, ester, sulfide, disulfide,
carboxamate, urea, --N--O--, etc. bond, and others as demonstrated
for example in the structures disclosed herein, all of which are in
general applicable as linkages in compounds in general. Actual
cleavability of the linker can be assessed in vitro and/or in vivo
by using hydrolytic-, enzymatic- (e.g. peptidase, esterase) or
metabolic-based tests and assays well known in the art.
International PCT application WO 91/14434, WO 96/18609, published
applications US 2005/0096317, and US 2006/0046967, and Yan L. et
al, (2004), J. Med. Chem., 47, 1031-43, are all incorporated herein
by reference in their entirety since they describe a variety of
linkers that may be useful according to the present invention.
[0081] Although theory of operation is discussed herein, for
specific compound structures, including all generic structural
formulas and specific names and formulas of compounds, the
invention is not limited by any such theories unless specifically
stated otherwise. Thus, all uses of all novel compounds are
encompassed by the invention, irrespective of mechanism or theory
of operation.
[0082] A. The Sulfonate Ester Prodrugs:
[0083] The invention also relates to a compound of the Formula
II:
##STR00003##
wherein,
[0084] R.sup.3 is selected from hydrogen and a substituted or
unsubstituted group selected from C.sub.1-C.sub.12alkyl,
C.sub.2-C.sub.12alkenyl, C.sub.2-C.sub.12alkynyl,
C.sub.3-C.sub.15cycloalkyl, C.sub.3-C.sub.15heterocycloalkyl,
C.sub.6-C.sub.15aryl, and C.sub.5-C.sub.15heteroaryl; and
[0085] R.sup.4 is a substituted or unsubstituted group selected
from C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12alkynyl, C.sub.3-C.sub.15cycloalkyl,
C.sub.3-C.sub.15heterocycloalkyl, C.sub.6-C.sub.15aryl, and
C.sub.5-C.sub.15heteroaryl; or a pharmaceutically acceptable salt
or solvate thereof.
[0086] The invention also relates to compounds of Formula II,
wherein at least one of R.sup.3 or R.sup.4 is a pharmacokinetic
modulating moiety. Examples of suitable pharmacokinetic modulating
moieties include sulfonate esters, neopentyl sulfonate esters, aryl
sulfonate ester, and nitro-substituted aryl sulfonate esters.
[0087] In another aspect, the invention relates to Formula II-A, as
well as salts and solvates thereof:
##STR00004##
wherein,
[0088] R.sup.4 is a substituted or unsubstituted group selected
from C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12alkynyl, C.sub.3-C.sub.15cycloalkyl,
C.sub.3-C.sub.15heterocycloalkyl, C.sub.6-C.sub.15aryl, and
C.sub.5-C.sub.15heteroaryl; or a pharmaceutically acceptable salt
or solvate thereof.
[0089] The invention also relates to compounds of Formula II or
II-A, wherein R.sup.3 and/or R.sup.4 are each independently
selected from the group consisting of: (i) a substituted or
unsubstituted group selected from C.sub.1-C.sub.12alkyl,
C.sub.2-C.sub.12alkenyl, C.sub.2-C.sub.12alkynyl,
C.sub.3-C.sub.15cycloalkyl, C.sub.3-C.sub.15heterocycloalkyl,
C.sub.6-C.sub.15aryl, and C.sub.5-C.sub.15heteroaryl; (ii) a
substituted or unsubstituted group selected from
C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.6-C.sub.15aryl, and C.sub.5-C.sub.15heteroaryl; (iii) a
substituted or unsubstituted group selected from
C.sub.3-C.sub.8alkyl, C.sub.6-C.sub.10aryl, and
C.sub.5-C.sub.10heteroaryl; (iv) a substituted or unsubstituted
C.sub.1-C.sub.12alkyl group; (v) a substituted C.sub.3-C.sub.8alkyl
group; (vi) a branched C.sub.3-C.sub.8alkyl group; (vii) a
substituted branched C.sub.3-C.sub.8alkyl group; (viii) a
substituted or unsubstituted neopentyl group; (ix) a substituted
neopentyl group; or (x) a group of Formula B:
##STR00005##
wherein,
[0090] R.sup.6, R.sup.7 and R.sup.8 are each independently a
substituted or unsubstituted group selected from
C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl,
C.sub.2-C.sub.6alkynyl, C.sub.3-C.sub.6cycloalkyl,
C.sub.3-C.sub.6heterocycloalkyl, C.sub.6-C.sub.10aryl,
C.sub.5-C.sub.10heteroaryl, C(O)OH, C(O)OC.sub.1-C.sub.6alkyl,
NH.sub.2, NHC(O)OC.sub.1-C.sub.6alkyl, or R.sup.7 and R.sup.8 are
taken together with their adjacent carbon atom to form a group
selected from C.sub.3-C.sub.8cycloalkyl, and
C.sub.3-C.sub.8heterocycloalkyl, or R.sup.6, R.sup.7 and R.sup.8
are taken together with their adjacent carbon atom to form a
C.sub.4-C.sub.10cycloalkyl or C.sub.4-C.sub.10heterocycloalkyl
fused ring group, or a C.sub.6-C.sub.10aryl, and
C.sub.6-C.sub.10heteroaryl; and
[0091] R.sup.22 is a hydrogen atom or a group selected from
C.sub.1-C.sub.6alkyl, C(O)OH, or C(O)OC.sub.1-C.sub.6alkyl.
[0092] According to one aspect, at least one of R.sup.3 and/or
R.sup.4 in Formula II or II-A is the group of Formula B, wherein
R.sup.22 is C.sub.2-C.sub.6alkyl, wherein R.sup.22 is a
C.sub.3-C.sub.5alkyl, or wherein R.sup.22 is a
C.sub.3-C.sub.4alkyl. According to another aspect, at least one of
R.sup.3 and/or R.sup.4 in Formula II or II-A is a group of Formula
Formula B' defined as follows:
##STR00006##
wherein, [0093] R.sup.6, R.sup.7 and R.sup.8 are as previously
defined.
[0094] More particularly, the invention relates to compounds of
Formula II or II-A, wherein R.sup.3 and/or R.sup.4 are each
independently a group of Formula B or B', wherein R.sup.6 is
--CH.sub.2CH.sub.2Nu or --CH.sub.2Nu, wherein Nu is a nucleophilic
group, which is a functional group having a reactive pair of
electrons and having the ability of forming a chemical bond by
donating electrons. For example, the nucleophilic group is selected
from the group consisting of carboxylates, sulfonates, substituted
or unsubstituted amines, alcohols (hydroxyl), thiols, sulfides,
hydroxylamines, and imines. In another embodiment, the nucleophilic
group is selected from the group consisting of substituted or
unsubstituted amines, and alcohols (hydroxyl), preferably an
unsubstituted amine (NH.sub.2). The invention also further relates
to compounds of Formula II or II-A, wherein R.sup.4 is a group of
Formula B or B', wherein R.sup.6 is --CH.sub.2CH.sub.2NH.sub.2, and
R.sup.7 and R.sup.8 are each independently a substituted or
unsubstituted group selected from C.sub.1-C.sub.6alkyl,
C.sub.2-C.sub.6alkenyl, C.sub.2-C.sub.6alkynyl,
C.sub.3-C.sub.6cycloalkyl, C.sub.3-C.sub.6heterocycloalkyl,
C.sub.6-C.sub.10aryl, and C.sub.5-C.sub.10heteroaryl, or R.sup.7
and R.sup.8 are taken together with their adjacent carbon atom to
form a group selected from C.sub.3-C.sub.8cycloalkyl and
C.sub.3-C.sub.8heterocycloalkyl. Also, R.sup.4 may be a group of
Formula B or B' wherein R.sup.6 is
--CH.sub.2CH.sub.2NH(aa).sub.1-3, wherein aa is independently in
each occurence, the residue of a C-coupled amino acid, and R.sup.7
and R.sup.8 are each independently a substituted or unsubstituted
group selected from C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl,
C.sub.2-C.sub.6alkynyl, C.sub.3-C.sub.6cycloalkyl,
C.sub.3-C.sub.6heterocycloalkyl, C.sub.6-C.sub.10aryl, and
C.sub.5-C.sub.10heteroaryl, or R.sup.7 and R.sup.8 are taken
together with their adjacent carbon atom to form a group selected
from C.sub.3-C.sub.8cycloalkyl and C.sub.3-C.sub.8heterocycloalkyl.
In a further aspect, R.sup.4 is a group of Formula B or B' wherein
R.sup.6 is --CH.sub.2CH.sub.2NH.sub.2, and R.sup.7 and R.sup.8 are
each independently a C.sub.1-C.sub.6alkyl, or R.sup.7 and R.sup.8
are taken together with their adjacent carbon atom to form a
C.sub.3-C.sub.8cycloalkyl, preferably R.sup.7 and R.sup.8 are each
a methyl group. In yet another aspect, R.sup.4 is a group of
Formula B or B' wherein R.sup.6 is --CH.sub.2CH.sub.2NH(aa),
wherein aa is the residue of a C-coupled amino acid, and R.sup.7
and R.sup.8 are each independently a C.sub.1-C.sub.6alkyl, or
R.sup.7 and R.sup.8 are taken together with their adjacent carbon
atom to form a C.sub.3-C.sub.8cycloalkyl, preferably R.sup.7 and
R.sup.8 are each a methyl group. In a further aspect, R.sup.7 and
R.sup.8 are taken together with their adjacent carbon atom to form
a C.sub.3-C.sub.8heterocycloalkyl, or R.sup.7 and R.sup.8 are taken
together with their adjacent carbon atom to form a lactone (e.g. a
furanone). In yet a further aspect, R.sup.6 is a methyl group and
R.sup.7 and R.sup.8 are taken together with their adjacent carbon
atom to form a C.sub.3-C.sub.8heterocycloalkyl, or R.sup.7 and
R.sup.8 are taken together with their adjacent carbon atom to form
a lactone (e.g. a furanone).
[0095] The invention also relates to compounds of Formula II or
II-A, wherein R.sup.3 and/or R.sup.4 are each independently a group
of Formula B or B', wherein R.sup.6 is a group of Formula C:
##STR00007##
wherein,
[0096] R.sup.9 is, separately in each occurrence, selected from
hydrogen, hydroxyl, halogen, cyano, trifluoromethyl, nitro, and a
substituted or unsubstituted group selected from
C.sub.1-C.sub.6alkyl, C.sub.3-C.sub.6cycloalkyl,
C.sub.3-C.sub.6heterocycloalkyl, C.sub.6aryl,
C.sub.5-C.sub.6heteroaryl, C(O)OH, C(O)OR.sup.11, OR.sup.11,
OC(O)R.sup.11, OC(O)OR.sup.11, NHC(O)R.sup.11, NH.sub.2,
NHR.sup.11, and N(R.sup.11).sub.2;
[0097] X is selected from the group consisting of OH, NH.sub.2,
NO.sub.2, CN, SH, C(O)OH, C(O)OR.sup.12, OC(O)OR.sup.12,
NHC(O)OR.sup.12, SC(O)OR.sup.12, P(O)(OH).sub.2,
P(O)(OR.sup.12).sub.2, P(O)(OR.sup.12)(OH), OC(O)R.sup.13,
OC(O)NHR.sup.13, SC(O)R.sup.13, C(O)R.sup.14, and NHR.sup.15;
[0098] n is an integer selected from 0, 1, 2 and 3;
[0099] R.sup.11 is a substituted or unsubstituted group selected
from C.sub.1-C.sub.6alkyl, C.sub.3-C.sub.6cycloalkyl,
C.sub.3-C.sub.6heterocycloalkyl, C.sub.6aryl,
C.sub.5-C.sub.6heteroaryl and benzyl;
[0100] R.sup.12 is a substituted or unsubstituted group selected
from C.sub.1-C.sub.6alkyl, C.sub.3-C.sub.6cycloalkyl,
C.sub.3-C.sub.6heterocycloalkyl, C.sub.6aryl,
C.sub.5-C.sub.6heteroaryl, benzyl, CH.sub.2R.sup.16, and
CH(C.sub.1-C.sub.6alkyl)R.sup.16;
[0101] R.sup.13 is a substituted or unsubstituted group selected
from C.sub.1-C.sub.6alkyl, C.sub.3-C.sub.6cycloalkyl,
C.sub.3-C.sub.6heterocycloalkyl, C.sub.6aryl,
C.sub.5-C.sub.6heteroaryl, and benzyl;
[0102] R.sup.14 is the residue of a natural or unnatural N-coupled
amino acid having an protected or unprotected carboxyl end;
[0103] R.sup.15 is the residue of a natural or unnatural C-coupled
amino acid having an protected or unprotected amino end; and
[0104] R.sup.16 is selected from the group consisting of
OC(O)C.sub.1-C.sub.6alkyl and OC(O)OC.sub.1-C.sub.6alkyl.
[0105] The invention also relates to compounds of Formula II or
II-A, wherein R.sup.3 and/or R.sup.4 are each independently a group
of Formula B or B', wherein R.sup.6 is a group of Formula C,
wherein R.sup.9 is selected from hydrogen, hydroxyl,
C.sub.1-C.sub.6alkyl, OR.sup.11, OC(O)R.sup.11, and OC(O)OR.sup.11,
and all other groups are as previously defined. In one example,
R.sup.9 is selected from hydrogen, hydroxyl, C.sub.1-C.sub.6alkyl,
OR.sup.11, OC(O)R.sup.11, and OC(O)OR.sup.11. In another example,
R.sup.9 is selected from hydrogen, hydroxyl, C.sub.1-C.sub.6alkyl,
OR.sup.11, OC(O)R.sup.11, and OC(O)OR.sup.11. In another example,
R.sup.9 is selected from hydroxyl, OR.sup.11, OC(O)R.sup.11, and
OC(O)OR.sup.11. According to a further example, R.sup.9 is hydroxyl
and all other groups are as previously defined. In yet another
example, R.sup.9 is selected from C(O)OH and C(O)OR.sup.11.
[0106] Another example of compounds of the invention are compounds
of Formula II or II-A, wherein at least one of R.sup.3 and R.sup.4
is a group of Formula B or B', wherein R.sup.6 is a group of
Formula C, wherein X is selected from OH, NH.sub.2, and SH. In
another example, X is selected from C(O)OH, C(O)OR.sup.12, and
C(O)R.sup.14. In another example, X is selected from
OC(O)OR.sup.12, OC(O)R.sup.13, and OC(O)NHR.sup.13. In another
example, X is selected from SC(O)R.sup.13 and, SC(O)OR.sup.12. In
another example, X is selected from NHC(O)OR.sup.12 and NHR.sup.15.
In another example, X is selected from OH, OC(O)OR.sup.12,
OC(O)R.sup.13, and OC(O)NHR.sup.13. In a further example, X is
selected from SH, SC(O)R.sup.13 and, SC(O)OR.sup.12. In yet another
example, X is selected from NH.sub.2, NHC(O)OR.sup.12 and
NHR.sup.15.
[0107] The invention also relates to compounds of Formula II or
II-A, wherein R.sup.3 and/or R.sup.4 are each independently a group
of Formula B or B', wherein R.sup.6 is a group of Formula C,
wherein X is C(O)OR.sup.12 and all other groups are as previously
defined. As an example, X is C(O)OR.sup.12, and R.sup.12 is
selected from C.sub.1-C.sub.6alkyl, C.sub.6aryl, benzyl,
CH.sub.2R.sup.16, and CH(C.sub.1-C.sub.6alkyl)R.sup.16. As another
example, X is C(O)OR.sup.12, and R.sup.12 is selected from
C.sub.1-C.sub.6alkyl, CH.sub.2R.sup.16, and
CH(C.sub.1-C.sub.6alkyl)R.sup.16 and all other groups are as
previously defined. According to another example, X is
C(O)OR.sup.12, R.sup.9 is selected from hydrogen, hydroxyl,
C.sub.1-C.sub.6alkyl, OR.sup.11, OC(O)R.sup.11, and OC(O)OR.sup.11,
and all other groups are as previously defined. In a further
example, X is C(O)OR.sup.12, R.sup.9 is selected from hydrogen,
hydroxyl, C.sub.1-C.sub.6alkyl, OR.sup.11, OC(O)R.sup.11, and
OC(O)OR.sup.11, and R.sup.12 is selected from C.sub.1-C.sub.6alkyl,
C.sub.6aryl, benzyl, CH.sub.2R.sup.16, and
CH(C.sub.1-C.sub.6alkyl)R.sup.16. In yet another example, X is
C(O)OR.sup.12, R.sup.9 is selected from hydrogen, hydroxyl,
C.sub.1-C.sub.6alkyl, OR.sup.11, OC(O)R.sup.11, and OC(O)OR.sup.11,
and R.sup.12 is selected from C.sub.1-C.sub.6alkyl,
CH.sub.2R.sup.16, and CH(C.sub.1-C.sub.6alkyl)R.sup.16. In one
aspect, when X is C(O)OR.sup.12, then n is an integer selected from
1 or 2, preferably n is 1.
[0108] The invention also relates to compounds of Formula II or
II-A, wherein R.sup.3 and/or R.sup.4 are each independently a group
of Formula B or B', wherein R.sup.6 is a group of Formula C and
wherein X is NHC(O)OR.sup.12 and all other groups are as previously
defined. As an example, X is NHC(O)OR.sup.12, and R.sup.12 is
selected from C.sub.1-C.sub.6alkyl, C.sub.6aryl, benzyl,
CH.sub.2R.sup.16, and CH(C.sub.1-C.sub.6alkyl)R.sup.16. In another
example, X is NHC(O)OR.sup.12, and R.sup.12 is selected from
C.sub.1-C.sub.6alkyl, CH.sub.2R.sup.16, and
CH(C.sub.1-C.sub.6alkyl)R.sup.16. According to another example, X
is NHC(O)OR.sup.12, and R.sup.9 is selected from hydrogen,
hydroxyl, C.sub.1-C.sub.6alkyl, OR.sup.11, OC(O)R.sup.11, and
OC(O)OR.sup.11, and all other groups are as previously defined. In
another example, X is NHC(O)OR.sup.12, R.sup.9 is selected from
hydrogen, hydroxyl, C.sub.1-C.sub.6alkyl, OR.sup.11, OC(O)R.sup.11,
and OC(O)OR.sup.11, and R.sup.12 is selected from
C.sub.1-C.sub.6alkyl, C.sub.6aryl, benzyl, CH.sub.2R.sup.16, and
CH(C.sub.1-C.sub.6alkyl)R.sup.16. In a further example, X is
NHC(O)OR.sup.12, R.sup.9 is selected from hydrogen, hydroxyl,
C.sub.1-C.sub.6alkyl, OR.sup.11, OC(O)R.sup.11, and OC(O)OR.sup.11,
and R.sup.12 is selected from C.sub.1-C.sub.6alkyl,
CH.sub.2R.sup.16, and CH(C.sub.1-C.sub.6alkyl)R.sup.16. The
invention also relates to compounds of Formula II or II-A, wherein
R.sup.3 and/or R.sup.4 are each independently a group of Formula B
or B', wherein R.sup.6 is a group of Formula C and wherein n is 2,
X is NHC(O)OR.sup.12, and all other groups are as previously
defined. As an example, n is 2, X is NHC(O)OR.sup.12, and R.sup.12
is selected from C.sub.1-C.sub.6alkyl, C.sub.6aryl, benzyl,
CH.sub.2R.sup.16, and CH(C.sub.1-C.sub.6alkyl)R.sup.16. In another
example, n is 2, X is NHC(O)OR.sup.12, and R.sup.12 is selected
from C.sub.1-C.sub.6alkyl, CH.sub.2R.sup.16, and
CH(C.sub.1-C.sub.6alkyl)R.sup.16. In another example, n is 2, X is
NHC(O)OR.sup.12, R.sup.12 is selected from C.sub.1-C.sub.6alkyl,
CH.sub.2R.sup.16, and CH(C.sub.1-C.sub.6alkyl)R.sup.16 and R.sup.9
in at least one occurrence, is selected from hydroxyl,
C.sub.1-C.sub.6alkyl, OR.sup.11, OC(O)R.sup.11, and OC(O)OR.sup.11.
In a further example, n is 2, X is NHC(O)OR.sup.12, R.sup.12 is
selected from C.sub.1-C.sub.6alkyl, CH.sub.2R.sup.16, and
CH(C.sub.1-C.sub.6alkyl)R.sup.16 and R.sup.9 in at least one
occurrence, is selected from C(O)OH and C(O)OR.sup.11. In one
aspect, when X is NHC(O)OR.sup.12, then n is an integer selected
from 1 or 2, preferably n is 2.
[0109] The invention also relates to compounds of Formula II or
II-A, wherein R.sup.3 and/or R.sup.4 are each independently a group
of Formula B or B', wherein R.sup.6 is a group of Formula C and
wherein X is OC(O)R.sup.13 and all other groups are as previously
defined. For example, X is OC(O)R.sup.13, and R.sup.13 is selected
from C.sub.1-C.sub.6alkyl, C.sub.6aryl, and benzyl. In another
example, X is OC(O)R.sup.13, and R.sup.13 is C.sub.1-C.sub.6alkyl.
In another example, X is OC(O)R.sup.13, and R.sup.13 is
C.sub.6aryl. According to another example, X is OC(O)R.sup.13, and
R.sup.9 is selected from hydrogen, hydroxyl, C.sub.1-C.sub.6alkyl,
OR.sup.11, OC(O)R.sup.11, and OC(O)OR.sup.11. In another example, X
is OC(O)R.sup.13, R.sup.9 is selected from hydrogen, hydroxyl,
C.sub.1-C.sub.6alkyl, OR.sup.11, OC(O)R.sup.11, and OC(O)OR.sup.11,
and R.sup.13 is selected from C.sub.1-C.sub.6alkyl, C.sub.6aryl,
and benzyl. In another example, X is OC(O)R.sup.13, R.sup.9 is
selected from hydrogen, hydroxyl, C.sub.1-C.sub.6alkyl, OR.sup.11,
OC(O)R.sup.11, and OC(O)OR.sup.11, and R.sup.13 is
C.sub.1-C.sub.6alkyl. In yet another aspect, X is OC(O)R.sup.13,
R.sup.9 is selected from hydrogen, hydroxyl, C.sub.1-C.sub.6alkyl,
OR.sup.11, OC(O)R.sup.11, and OC(O)OR.sup.11, and R.sup.13 is
C.sub.6aryl, and all other groups are as previously defined. The
invention also relates to compounds of Formula II or II-A, wherein
R.sup.3 and/or R.sup.4 are each independently a group of Formula B
or B', wherein R.sup.6 is a group of Formula C and wherein n is 2,
X is OC(O)R.sup.13, and all other groups are as previously defined.
As an example, n is 2, X is OC(O)R.sup.13, and R.sup.9 in at least
one occurrence, is selected from hydroxyl, C.sub.1-C.sub.6alkyl,
OR.sup.11, OC(O)R.sup.11, and OC(O)OR.sup.11. In a further example,
n is 2, X is OC(O)R.sup.13, and R.sup.9 in at least one occurrence,
is selected from C(O)OH and C(O)OR.sup.11. In one aspect, when X is
OC(O)R.sup.13, then n is an integer selected from 1 or 2,
preferably n is 2.
[0110] The invention also relates to compounds of Formula II or
II-A, wherein R.sup.3 and/or R.sup.4 are each independently a group
of Formula B or B', wherein R.sup.6 is a group of Formula C and
wherein X is SH, SC(O)R.sup.13 or SC(O)OR.sup.12 and all other
groups are as previously defined. In one aspect, when X is SH,
SC(O)R.sup.13 or SC(O)OR.sup.12, then n is an integer selected from
1 or 2, preferably n is 2. In another example, n is 2, X is SH,
SC(O)R.sup.13 or SC(O)OR.sup.12, and all other groups are as
previously defined. As another example, n is 2, X is SH,
SC(O)R.sup.13 or SC(O)OR.sup.12, and R.sup.9 in at least one
occurrence, is selected from hydroxyl, C.sub.1-C.sub.6alkyl,
OR.sup.11, OC(O)R.sup.11, and OC(O)OR.sup.11. In a further example,
n is 2, X is SH, SC(O)R.sup.13 or SC(O)OR.sup.12, and R.sup.9 in at
least one occurrence, is selected from C(O)OH and
C(O)OR.sup.11.
[0111] The invention also relates to compounds of Formula II or
II-A, wherein R.sup.3 and/or R.sup.4 are each independently a group
of Formula B or B', wherein R.sup.6 is a group of Formula C and
wherein X is NHR.sup.15 and all other groups are as previously
defined. For example, X is NHR.sup.15, and R.sup.15 is the residue
of a natural C-coupled amino acid. In another example, X is
NHR.sup.15, and R.sup.15 is the residue of a natural C-coupled
hydrophobic amino acid, such as an aliphatic hydrophobic amino acid
(e.g. alanine, isoleucine, leucine, valine and the like), an
aromatic hydrophobic amino acid (e.g. phenylalanine, tryptophan,
tyrosine and the like) or a polar hydrophobic amino acid (e.g.
cystein, methionine and the like). In another example, X is
NHR.sup.15, and R.sup.15 is the residue of a natural C-coupled
hydrophilic amino acid (e.g. arginine, lysine, asparagine,
histidine, proline, aspartic acid, glutamic acid and the like). In
another example, X is NHR.sup.15, and R.sup.15 is the residue of a
natural C-coupled neutral polar amino acid (e.g. asparagine,
cystein, glutamine, methionine, serine, threonine and the like). In
another example, X is NHR.sup.15, and R.sup.15 is the residue of a
natural C-coupled acidic amino acid (e.g. aspartic acid, glutamic
acid and the like). In yet another example, X is NHR.sup.15, and
R.sup.15 is the residue of a natural C-coupled basic amino acid
(e.g. arginine, histidine, lysine and the like). According to
another example, X is NHR.sup.15, and R.sup.9 is selected from
hydrogen, hydroxyl, C.sub.1-C.sub.6alkyl, OR.sup.11, OC(O)R.sup.11,
and OC(O)OR.sup.11. In another example, X is NHR.sup.15, R.sup.9 is
selected from hydrogen, hydroxyl, C.sub.1-C.sub.6alkyl, OR.sup.11,
OC(O)R.sup.11, and OC(O)OR.sup.11, and R.sup.15 is the residue of a
natural C-coupled amino acid. In a further example, X is
NHR.sup.15, R.sup.9 is selected from hydrogen, hydroxyl,
C.sub.1-C.sub.6alkyl, OR.sup.11, OC(O)R.sup.11, and OC(O)OR.sup.11,
and R.sup.15 is the residue of a natural C-coupled lipophilic amino
acid. In yet another example, X is NHR.sup.15, R.sup.9 is selected
from hydrogen, hydroxyl, C.sub.1-C.sub.6alkyl, OR.sup.11,
OC(O)R.sup.11, and OC(O)OR.sup.11, and R.sup.15 is the residue of a
natural C-coupled hydrophilic amino acid. The invention also
relates to compounds of Formula II or II-A, wherein R.sup.3 and/or
R.sup.4 are each independently a group of Formula B, wherein
R.sup.6 is a group of Formula C and wherein n is 2, X is
NHR.sup.15, and all other groups are as previously defined. As an
example, n is 2, X is NHR.sup.15, and R.sup.9 in at least one
occurrence, is selected from hydroxyl, C.sub.1-C.sub.6alkyl,
OR.sup.11, OC(O)R.sup.11, and OC(O)OR.sup.11. In a further example,
n is 2, X is NHR.sup.15, and R.sup.9 in at least one occurrence, is
selected from C(O)OH and C(O)OR.sup.11. In one aspect, when X is
NHR.sup.15, then n is an integer selected from 1 or 2, preferably n
is 2.
[0112] Furthermore, the compounds of the invention are encompassed
by Formula II or II-A, wherein R.sup.3 and/or R.sup.4 are each
independently a group of Formula B or B' and wherein R.sup.6 is a
group of Formula C, and all other groups are as previously defined.
In one example, R.sup.6 is a group of Formula C, and R.sup.7 and
R.sup.8 are each independently a substituted or unsubstituted group
selected from C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl,
C.sub.2-C.sub.6alkynyl, C.sub.3-C.sub.6cycloalkyl,
C.sub.3-C.sub.6heterocycloalkyl, C.sub.6-C.sub.10aryl, and
C.sub.5-C.sub.10heteroaryl, or R.sup.7 and R.sup.8 are taken
together with their adjacent carbon atom to form a group selected
from C.sub.3-C.sub.8cycloalkyl and C.sub.3-C.sub.8heterocycloalkyl.
In another example, R.sup.6 is a group of Formula C, and R.sup.7
and R.sup.8 are each independently a C.sub.1-C.sub.6alkyl, or
R.sup.7 and R.sup.8 are taken together with their adjacent carbon
atom to form a C.sub.3-C.sub.8cycloalkyl, preferably R.sup.7 and
R.sup.8 are each a methyl group.
[0113] The invention also relates to compounds of Formula II or
II-A, wherein R.sup.3 and/or R.sup.4 are each independently a
substituted or unsubstituted C.sub.6-C.sub.10aryl or
C.sub.5-C.sub.10heteroaryl. For example, R.sup.3 and/or R.sup.4 are
each independently a substituted C.sub.6-C.sub.10aryl or
C.sub.5-C.sub.10heteroaryl. In another example, R.sup.3 and/or
R.sup.4 are each independently a substituted or unsubstituted
C.sub.6aryl or C.sub.5-C.sub.6heteroaryl. In a further example,
R.sup.3 and/or R.sup.4 are each independently a group of Formula
D:
##STR00008##
wherein,
[0114] R.sup.17 in each occurrence is each independently a hydrogen
atom or a substituted or unsubstituted group selected from
C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl,
C.sub.2-C.sub.6alkynyl, C.sub.3-C.sub.6cycloalkyl,
C.sub.3-C.sub.6heterocycloalkyl, C.sub.6-C.sub.10aryl,
C.sub.5-C.sub.10heteroaryl, an electron-withdrawing group or a
substituent selected from the group consisting of amino, amido,
hydroxyl, alkoxy, acyloxy, alkoxycabonyloxy, and the like; and
[0115] m is an integer from 1 to 5.
[0116] For example, in Formula II or II-A, where R.sup.3 and/or
R.sup.4 are each independently a group of Formula D, then R.sup.17
is, in at least one occurrence, an electron-withdrawing group,
which is a group having the ability to attract valence electrons
from neighboring atoms. In another embodiment, R.sup.17 is an
electron-withdrawing group selected from nitro, acyl (ketone),
carboxylate (acid), alkoxycarbonyl (ester), alkylaminocarbonyl
(amide), formyl (aldehyde), sulfonyl, trifluoromethyl, halogeno
(chloro, fluoro, iodo and bromo), and cyano groups. In another
example, R.sup.17 is selected from nitro, acyl (ketone),
carboxylate, trifluoromethyl, and halogeno groups (chloro, fluoro,
iodo and bromo). In another example, m is an integer selected from
1 to 3, preferably 1 or 2, preferably 1.
[0117] The following structures are examples of monosulfonate ester
prodrugs of the invention and are illustrative of the invention
only and they should not be construed as further limiting:
##STR00009## ##STR00010## ##STR00011## ##STR00012## ##STR00013##
##STR00014## ##STR00015## ##STR00016##
or a pharmaceutically acceptable salt or solvate of any one of
Compounds A1 to A73.
[0118] The following structures are examples of disulfonate ester
prodrugs of the invention and are illustrative of the invention
only and they should not be construed as further limiting:
##STR00017## ##STR00018## ##STR00019## ##STR00020## ##STR00021##
##STR00022## ##STR00023## ##STR00024##
or a pharmaceutically acceptable salt or solvate of any one of
Compounds B1-B87.
[0119] In another example, the compound is a compound of Formula I,
wherein R.sup.1 is a covalent bond, and R.sup.2 is an oxygen atom,
then R.sup.1 and R.sup.2 taken together with their adjacent atoms
form the 6-membered heterocyclic ring Compound C1.
##STR00025##
[0120] In yet another example, the compound is a compound of
Formula I, wherein R.sup.1 is a covalent bond, and R.sup.2 is a
substituted or unsubstituted OC.sub.1-C.sub.3alkylO group, and
R.sup.1 and R.sup.2 taken together with their adjacent atoms form
an 8 to 10-membered heterocyclic ring. In one embodiment, the
compound is Compound C2.
##STR00026##
[0121] In another embodiment, the compound is Compound C3
##STR00027##
[0122] The invention also further relates to a compound of Formula
II, wherein at least one of R.sup.3 or R.sup.4 is a group of
Formula E:
##STR00028##
wherein,
[0123] R.sup.z is a substituted or unsubstituted group selected
from C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12alkynyl, C.sub.3-C.sub.15cycloalkyl,
C.sub.3-C.sub.15heterocycloalkyl, C.sub.6-C.sub.15aryl,
C.sub.5-C.sub.15heteroaryl, OC.sub.1-C.sub.12alkyl,
OC.sub.2-C.sub.12alkenyl, OC.sub.2-C.sub.12alkynyl,
OC.sub.3-C.sub.15cycloalkyl, OC.sub.3--OC.sub.15heterocycloalkyl,
OC.sub.6-C.sub.15aryl, and OC.sub.5-C.sub.15heteroaryl.
[0124] According to one aspect, the compound of the invention is a
compound of Formula II, and one of R.sup.3 or R.sup.4 is a group of
Formula E. In an embodiment of this aspect, R.sup.4 is Formula E,
wherein R.sup.z is a group selected from OC.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6alkyl, C.sub.3-C.sub.7cycloalkyl, or C.sub.6aryl,
and R.sup.3 is H. In another embodiment, R.sup.4 is Formula E,
wherein R.sup.z is a group selected from OC.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6alkyl, C.sub.3-C.sub.7cycloalkyl, or C.sub.6aryl,
and R.sup.3 is a group of Formula B. In another embodiment, R.sup.4
is Formula E, wherein R.sup.z is a group selected from
OC.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6alkyl,
C.sub.3-C.sub.7cycloalkyl, or C.sub.6aryl, and R.sup.3 is a group
of Formula B, wherein R.sup.6 is a group of Formula C. In another
embodiment, R.sup.4 is Formula E, wherein R.sup.z is a group
selected from OC.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6alkyl,
C.sub.3-C.sub.7cycloalkyl, or C.sub.6aryl, and R.sup.3 is a group
of Formula B, wherein R.sup.6 is a group of Formula C, and wherein
X is C(O)OR.sup.12. In another embodiment, R.sup.4 is Formula E,
wherein R.sup.z is a C.sub.1-C.sub.6alkyl, and R.sup.3 is H. In
another embodiment, R.sup.4 is Formula E, wherein R.sup.z is a
C.sub.1-C.sub.6alkyl, and R.sup.3 is a group of Formula B. In
another embodiment, R.sup.4 is Formula E, wherein R.sup.z is a
C.sub.1-C.sub.6alkyl, and R.sup.3 is a group of Formula B, wherein
R.sup.6 is a group of Formula C. In another embodiment, R.sup.4 is
Formula E, wherein R.sup.z is a C.sub.1-C.sub.6alkyl, and R.sup.3
is a group of Formula B, wherein R.sup.6 is a group of Formula C,
and wherein X is C(O)OR.sup.12. In another embodiment, R.sup.4 is
Formula E, wherein R.sup.z is a C.sub.2-C.sub.5alkyl, and R.sup.3
is H. In another embodiment, R.sup.4 is Formula E, wherein R.sup.z
is a C.sub.2-C.sub.5alkyl, and R.sup.3 is a group of Formula B. In
another embodiment, R.sup.4 is Formula E, wherein R.sup.z is a
C.sub.2-C.sub.5alkyl, and R.sup.3 is a group of Formula B, wherein
R.sup.6 is a group of Formula C. In another embodiment, R.sup.4 is
Formula E, wherein R.sup.z is a C.sub.2-C.sub.5alkyl, and R.sup.3
is a group of Formula B, wherein R.sup.6 is a group of Formula C,
and wherein X is C(O)OR.sup.12. In another embodiment, R.sup.4 is
Formula E, wherein R.sup.z is a C.sub.3-C.sub.7cycloalkyl, and
R.sup.3 is H. In another embodiment, R.sup.4 is Formula E, wherein
R.sup.z is a C.sub.3-C.sub.7cycloalkyl, and R.sup.3 is a group of
Formula B. In another embodiment, R.sup.4 is Formula E, wherein
R.sup.z is a C.sub.3-C.sub.7cycloalkyl, and R.sup.3 is a group of
Formula B, wherein R.sup.6 is a group of Formula C. In another
embodiment, R.sup.4 is Formula E, wherein R.sup.z is a
C.sub.3-C.sub.7cycloalkyl, and R.sup.3 is a group of Formula B,
wherein R.sup.6 is a group of Formula C, and wherein X is
C(O)OR.sup.12. In another embodiment, R.sup.4 is Formula E, wherein
R.sup.z is a C.sub.5-C.sub.6cycloalkyl, and R.sup.3 is H. In
another embodiment, R.sup.4 is Formula E, wherein R.sup.z is a
C.sub.5-C.sub.6cycloalkyl, and R.sup.3 is a group of Formula B. In
another embodiment, R.sup.4 is Formula E, wherein R.sup.z is a
C.sub.5-C.sub.6cycloalkyl, and R.sup.3 is a group of Formula B,
wherein R.sup.6 is a group of Formula C. In another embodiment,
R.sup.4 is Formula E, wherein R.sup.z is a
C.sub.5-C.sub.6cycloalkyl, and R.sup.3 is a group of Formula B,
wherein R.sup.6 is a group of Formula C, and wherein X is
C(O)OR.sup.12. In another embodiment, R.sup.4 is Formula E, wherein
R.sup.z is a C.sub.6aryl, and R.sup.3 is H. In further another
embodiment, R.sup.4 is Formula E, wherein R.sup.z is a C.sub.6aryl,
and R.sup.3 is a group of Formula B. In yet another embodiment,
R.sup.4 is Formula E, wherein R.sup.z is a C.sub.6aryl, and R.sup.3
is a group of Formula B, wherein R.sup.6 is a group of Formula C.
In a further embodiment, R.sup.4 is Formula E, wherein R.sup.z is a
C.sub.6aryl, and R.sup.3 is a group of Formula B, wherein R.sup.6
is a group of Formula C, and wherein X is C(O)OR.sup.12.
[0125] In another aspect, the compound of the invention is a
compound of Formula II, and R.sup.3 and R.sup.4 are each
independently a group of Formula E. In one embodiment of this
aspect, R.sup.z in each of R.sup.3 and R.sup.4 is independently a
group selected from C.sub.1-C.sub.6alkyl,
C.sub.3-C.sub.7cycloalkyl, or C.sub.6aryl. In another embodiment,
R.sup.z in the group R.sup.3 is a group selected from
OC.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6alkyl,
C.sub.3-C.sub.7cycloalkyl, or C.sub.6aryl, and R.sup.z in the group
R.sup.4 is C.sub.1-C.sub.6alkyl. In another embodiment, R.sup.z in
the group R.sup.3 is a group selected from OC.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6alkyl, C.sub.3-C.sub.7cycloalkyl, or C.sub.6aryl,
and Fe in the group R.sup.4 is C.sub.2-C.sub.5alkyl. In another
embodiment, R.sup.z in the group R.sup.3 is a group selected from
OC.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6alkyl,
C.sub.3-C.sub.7cycloalkyl, or C.sub.6aryl, and R.sup.z in the group
R.sup.4 is C.sub.3-C.sub.7cycloalkyl. In another embodiment,
R.sup.z in the group R.sup.3 is a group selected from
OC.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6alkyl,
C.sub.3-C.sub.7cycloalkyl, or C.sub.6aryl, and R.sup.z in the group
R.sup.4 is C.sub.5-C.sub.6cycloalkyl. In another embodiment,
R.sup.z in the group R.sup.3 is a group selected from
OC.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6alkyl,
C.sub.3-C.sub.7cycloalkyl, or C.sub.6aryl, and R.sup.z in the group
R.sup.4 is C.sub.6aryl. In another embodiment, R.sup.z in the group
R.sup.3 is C.sub.1-C.sub.6alkyl, and R.sup.z in the group R.sup.4
is a group selected from OC.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6alkyl, C.sub.3-C.sub.7cycloalkyl, or C.sub.6aryl. In
another embodiment, R.sup.z in each of R.sup.3 and R.sup.4 is
independently a C.sub.1-C.sub.6alkyl group. In another embodiment,
R.sup.z in the group R.sup.3 is C.sub.1-C.sub.6alkyl, and R.sup.z
in the group R.sup.4 is C.sub.2-C.sub.5alkyl. In another
embodiment, R.sup.z in the group R.sup.3 is C.sub.1-C.sub.6alkyl,
and R.sup.z in the group R.sup.4 is C.sub.3-C.sub.7cycloalkyl. In
another embodiment, R.sup.z in the group R.sup.3 is
C.sub.1-C.sub.6alkyl, and Fe in the group R.sup.4 is
C.sub.5-C.sub.6cycloalkyl. In another embodiment, R.sup.z in the
group R.sup.3 is C.sub.1-C.sub.6alkyl, and R.sup.z in the group
R.sup.4 is C.sub.6aryl. In another embodiment, R.sup.z in the group
R.sup.3 is C.sub.2-C.sub.5alkyl, and R.sup.z in the group R.sup.4
is a group selected from OC.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6alkyl, C.sub.3-C.sub.7cycloalkyl, or C.sub.6aryl. In
another embodiment, R.sup.z in the group R.sup.3 is
C.sub.2-C.sub.5alkyl, and R.sup.z in the group R.sup.4 is
C.sub.1-C.sub.6alkyl. In another embodiment, R.sup.z in each of
R.sup.3 and R.sup.4 is independently a C.sub.2-C.sub.5alkyl group.
In another embodiment, R.sup.z in the group R.sup.3 is
C.sub.2-C.sub.5alkyl, and R.sup.z in the group R.sup.4 is
C.sub.3-C.sub.7cycloalkyl. In another embodiment, R.sup.z in the
group R.sup.3 is C.sub.2-C.sub.5alkyl, and R.sup.z in the group
R.sup.4 is C.sub.5-C.sub.6cycloalkyl. In another embodiment,
R.sup.z in the group R.sup.3 is C.sub.2-C.sub.5alkyl, and R.sup.z
in the group R.sup.4 is C.sub.6aryl. In another embodiment, R.sup.z
in the group R.sup.3 is C.sub.3-C.sub.7cycloalkyl, and R.sup.z in
the group R.sup.4 is a group selected from OC.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6alkyl, C.sub.3-C.sub.7cycloalkyl, or C.sub.6aryl. In
another embodiment, R.sup.z in the group R.sup.3 is
C.sub.3-C.sub.7cycloalkyl, and R.sup.z in the group R.sup.4 is
C.sub.1-C.sub.6alkyl. In another embodiment, R.sup.z in the group
R.sup.3 is C.sub.3-C.sub.7cycloalkyl, and Fe in the group R.sup.4
is C.sub.2-C.sub.5alkyl. In another embodiment, R.sup.z in each of
R.sup.3 and R.sup.4 is independently a C.sub.3-C.sub.7cycloalkyl
group. In another embodiment, R.sup.z in the group R.sup.3 is
C.sub.3-C.sub.7cycloalkyl, and R.sup.z in the group R.sup.4 is
C.sub.5-C.sub.6cycloalkyl. In another embodiment, R.sup.z in the
group R.sup.3 is C.sub.3-C.sub.7cycloalkyl, and R.sup.z in the
group R.sup.4 is C.sub.6aryl. In another embodiment, R.sup.z in the
group R.sup.3 is C.sub.5-C.sub.6cycloalkyl, and R.sup.z in the
group R.sup.4 is a group selected from OC.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6alkyl, C.sub.3-C.sub.7cycloalkyl, or C.sub.6aryl. In
another embodiment, R.sup.z in the group R.sup.3 is
C.sub.5-C.sub.6cycloalkyl, and R.sup.z in the group R.sup.4 is
C.sub.1-C.sub.6alkyl. In another embodiment, R.sup.z in the group
R.sup.3 is C.sub.5-C.sub.6cycloalkyl, and Fe in the group R.sup.4
is C.sub.2-C.sub.5alkyl. In another embodiment, R.sup.z in the
group R.sup.3 is C.sub.5-C.sub.6cycloalkyl, and R.sup.z in the
group R.sup.4 is C.sub.3-C.sub.7cycloalkyl. In another embodiment,
R.sup.z in each of R.sup.3 and R.sup.4 is independently a
C.sub.5-C.sub.6cycloalkyl group. In another embodiment, R.sup.z in
the group R.sup.3 is C.sub.5-C.sub.6cycloalkyl, and R.sup.z in the
group R.sup.4 is C.sub.6aryl. In another embodiment, R.sup.z in the
group R.sup.3 is C.sub.6aryl, and R.sup.z in the group R.sup.4 is a
group selected from OC.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6alkyl,
C.sub.3-C.sub.7cycloalkyl, or C.sub.6aryl. In another embodiment,
R.sup.z in the group R.sup.3 is C.sub.6aryl, and R.sup.z in the
group R.sup.4 is C.sub.1-C.sub.6alkyl. In another embodiment,
R.sup.z in the group R.sup.3 is C.sub.6aryl, and R.sup.z in the
group R.sup.4 is C.sub.2-C.sub.5alkyl. In a further embodiment,
R.sup.z in the group R.sup.3 is C.sub.6aryl, and R.sup.z in the
group R.sup.4 is C.sub.3-C.sub.7cycloalkyl. In a further
embodiment, R.sup.z in the group R.sup.3 is C.sub.6aryl, and
R.sup.z in the group R.sup.4 is C.sub.5-C.sub.6cycloalkyl. In yet
another embodiment, R.sup.z in each of R.sup.3 and R.sup.4 is
independently a C.sub.6aryl group. In a further embodiment, the
compound of the invention is Compound B59, or a pharmaceutically
acceptable salt or solvate thereof.
[0126] The following structures are examples of sulfonate ester
prodrugs of the invention and are illustrative of the invention
only and they should not be construed as further limiting:
##STR00029##
or a pharmaceutically acceptable salt or solvate of any one of
Compounds D1 to D8.
[0127] In yet another aspect, the invention further relates to a
compound of Formula II, wherein at least one of R.sup.3 or R.sup.4
is a group of Formula F:
##STR00030##
wherein,
[0128] W--Y--Z is selected from C(O)OCH.sub.2, OC(O)CH.sub.2,
CH.sub.2C(O)O, and CH.sub.2OC(O);
[0129] R.sup.w, R.sup.x, and R.sup.y are each independently
selected from a hydrogen atom or a substituted or unsubstituted
C.sub.1-C.sub.3alkyl group, or R.sup.w and R.sup.z are taken
together with their adjacent carbon atoms to form a double bond;
and
[0130] k is an integer selected from 0, 1 and 2.
[0131] According to one aspect, the compound of the invention is a
compound of Formula II, and one of R.sup.3 or R.sup.4 is a group of
Formula F. In one embodiment of this aspect, R.sup.w is a methyl
group. In another embodiment, R.sup.w is a methyl group and each of
R.sup.x and R.sup.y are hydrogen atoms. In another embodiment,
R.sup.x and R.sup.y are each a methyl group and R.sup.w is a
hydrogen. In yet another embodiment, R.sup.w and R.sup.x are taken
together with their adjacent carbon atoms to form a double bond. In
yet another embodiment, R.sup.w and R.sup.x are taken together with
their adjacent carbon atoms to form a double bond, and R.sup.y is a
hydrogen.
[0132] According to another aspect, the compound of the invention
is a compound of Formula II, and R.sup.3 and R.sup.4 are each
independently a group of Formula F. In one embodiment of this
aspect, R.sup.w is a methyl group. In another embodiment, R.sup.w
is a methyl group and each of R.sup.x and R.sup.y are hydrogen
atoms. In another embodiment, R.sup.x and R.sup.y are each a methyl
group and R.sup.w is a hydrogen. In yet another embodiment, R.sup.w
and R.sup.x are taken together with their adjacent carbon atoms to
form a double bond. In yet another embodiment, R.sup.w and R.sup.x
are taken together with their adjacent carbon atoms to form a
double bond, and R.sup.y is a hydrogen.
[0133] The invention further relates to compounds of Formula II,
wherein said compound is any one or more of Compounds A71, A72,
A73, B76, B77, B78, B79, B80 and B81, or a pharmaceutically
acceptable salt or solvate thereof.
[0134] B. Oligomers and Gemini Dimers
[0135] In further aspects of the invention, the compounds of
Formula I may comprise two or more 1,3PDS molecules linked
together. Therefore, another aspect of the invention relates to
oligomers of 1,3PDS, i.e., a molecule comprising, or consisting
essentially of, or consisting of two or more molecules of 1,3PDS
linked together through cleavable linkage(s). Thus, the invention
relates to a compound of Formula III:
A-(L.sup.x-A).sub.p-L.sup.x-A (III)
wherein,
[0136] A is 1,3-propanedisulfonic acid moiety;
[0137] L.sup.x is a cleavable linkage for covalently and
dissociably coupling together two 1,3PDS moieties respectively;
and
[0138] p is 0 or an integer selected from 1, 2, 3, 4, or 5;
or a pharmaceutically acceptable salt, ester, or solvate
thereof.
[0139] Alternatively, the invention relates to a compound of
Formula III-A:
L.sup.y(A).sub.m (III-A)
wherein,
[0140] m is an integer from 2 to 5;
[0141] A is 1,3-propanedisulfonic acid moiety; and
[0142] L.sup.y is a multivalent carrier moiety for covalently and
dissociably coupling from two to five A moieties, at either
sulfonic acid end of A;
or a pharmaceutically acceptable salt, ester, or solvate
thereof.
[0143] The free sulfonic acid group at each end may or may not be
further esterified with a R.sup.3 or R.sup.4 group as described
herein. Those skilled in the art will be capable to select proper
linkers and linkage site and test the resulting product for
efficacy and for capability of cleavage under various chemical
and/or biological conditions.
[0144] The following structures are examples of prodrugs of the
invention containing more than one 1,3PDS moiety and are
illustrative of the invention only and they should not be construed
as further limiting.
##STR00031##
##STR00032##
or a pharmaceutically acceptable salt or solvate of any one of
Compounds G1 to G4.
[0145] C. Non-Ester Prodrugs
[0146] In one aspect, the invention relates to compounds of Formula
IV:
##STR00033##
wherein,
[0147] R.sup.18 is selected from OR.sup.3, NH.sub.2,
--NHC(O)R.sup.5, --NHC(NH)NHR.sup.5,
--NH(C.sub.5-C.sub.10heteroaryl), --NR.sup.20R.sup.21, R.sup.14,
and --NHR.sup.15;
[0148] R.sup.19 is selected from NH.sub.2, --NHC(O)R.sup.5,
--NHC(NH)NHR.sup.5, --NH(C.sub.5-C.sub.10heteroaryl),
--NR.sup.20R.sup.21, R.sup.14, and --NHR.sup.15;
[0149] R.sup.3, R.sup.5, R.sup.14, and R.sup.15 are as previously
defined; and
[0150] R.sup.20 and R.sup.21 are taken together with their adjacent
nitrogen atom to form a mono or bicyclic heteroaryl having from 5
to 10 ring members;
or a pharmaceutically acceptable salt or solvate thereof.
[0151] The invention relates to compounds of Formula IV, wherein
R.sup.18 is OH, or a pharmaceutically acceptable salt thereof. The
invention also relates to compounds of Formula IV, wherein R.sup.19
is --NHC(O)R.sup.5. The invention also relates to compounds of
Formula IV, wherein R.sup.19 is --NHC(NH)NHR.sup.5. The invention
also relates to compounds of Formula IV, wherein R.sup.19 is
--NH(C.sub.5-C.sub.10heteroaryl). For example, R.sup.19 is
--NH(C.sub.5-C.sub.10heteroaryl), wherein said
C.sub.5-C.sub.10heteroaryl is selected from thiazol-2-yl,
imidazol-2-yl, 1,3-oxazol-2-yl, 1,3-benzothiazol-2-yl,
1,3-benzoimidazol-2-yl, and 1,3-benzoxazol-2-yl. In another
example, R.sup.19 is --NH(C.sub.5-C.sub.10heteroaryl), wherein said
C.sub.5-C.sub.10heteroaryl is selected from thiazol-2-yl,
imidazol-2-yl, and 1,3-oxazol-2-yl. In a further example, R.sup.19
is --NH(thiazol-2-yl), and all other groups are as previously
defined.
[0152] The invention also relates to compounds of Formula IV,
wherein said R.sup.5 is selected from hydrogen and a substituted or
unsubstituted group selected from C.sub.1-C.sub.12alkyl,
C.sub.3-C.sub.15cycloalkyl, C.sub.3-C.sub.15heterocycloalkyl,
C.sub.6-C.sub.15aryl, and C.sub.5-C.sub.15heteroaryl. As an
example, R.sup.5 is selected from hydrogen and a substituted or
unsubstituted C.sub.1-C.sub.12alkyl. In another example, R.sup.5 is
hydrogen. In a further example, R.sup.5 is a substituted or
unsubstituted C.sub.1-C.sub.6alkyl, and all other groups are
previously defined.
[0153] The following structures are examples of prodrugs of the
invention containing non-sulfonate ester prodrug moiety and are
illustrative of the invention only and they should not be construed
as further limiting:
##STR00034## ##STR00035##
or a pharmaceutically acceptable salt or solvate of any one of
Compounds N1 to N18.
[0154] D. Precursor Prodrugs
[0155] In further aspects of the invention, the compounds of the
invention are precursors of 1,3PDS, i.e. Therefore, another aspect
of the invention relates to a molecule comprising, or consisting
essentially of, or consisting of . . . . Thus, the invention
relates to a compound of Formula V:
##STR00036##
wherein,
[0156] B and D are each independently a precursor of an SO.sub.3H
group;
or a pharmaceutically acceptable salt, ester, or solvate
thereof.
[0157] The invention further relates to compounds of Formula (V),
wherein B and D are each independently selected from SH and
SO.sub.2H.
[0158] The following structure is an example of a precursor prodrug
of the invention, is illustrative of the invention only and should
not be construed as further limiting:
##STR00037##
or a pharmaceutically acceptable salt or solvate of Compound
P1.
III. Synthesis of the Compounds of the Invention
[0159] In general, all compounds of the present invention may be
prepared by the methods illustrated in the Examples hereinafter
and/or other conventional methods, using readily available and/or
conventionally preparable starting materials, reagents and
conventional synthesis procedures. In these reactions, it is also
possible to make use of variants which are in themselves known, but
are not mentioned here. Certain novel and exemplary methods of
preparing the inventive compounds are described in the
Exemplification section. Such methods are within the scope of this
invention. Functional and structural equivalents of the compounds
described herein and which have the same general properties,
wherein one or more simple variations of substituents are made
which do not adversely affect the essential nature or the utility
of the compound are also included.
[0160] More particularly, the sulfonate ester prodrugs of the
present invention may be prepared by the methods illustrated in the
Examples section hereinafter.
[0161] The compounds of the present invention may be readily
prepared in accordance with the synthesis schemes and protocols
described herein, as illustrated in the specific procedures
provided. However, those skilled in the art will recognize that
other synthetic pathways and/or modified synthetic pathways for
preparing the compounds of this invention may be used, and that the
following is provided merely by way of example, and is not limiting
to the present invention. See, e.g., "Comprehensive Organic
Transformations" by R. Larock, VCH Publishers (1989), incorporated
herein by reference. It will be further recognized that various
protecting and deprotecting strategies will be employed that are
standard in the art (See, e.g., "Protective Groups in Organic
Synthesis" by Greene and Wuts (1991), incorporated herein by
reference). Those skilled in the relevant arts will recognize that
the selection of any particular protecting group (e.g., amine,
hydroxyl, thio, and carboxyl protecting groups) will depend on the
stability of the protected moiety with regards to the subsequent
reaction conditions and will understand the appropriate
selections.
[0162] Further illustrating the knowledge of those skilled in the
art is the following sampling of the extensive chemical literature:
"Chemistry of the Amino Acids" by J. P. Greenstein and M. Winitz,
John Wiley & Sons, Inc., New York (1961); "Advanced Organic
Chemistry: Reactions, Mechanisms, and Structure" by J. March, 4th
Edition, John Wiley & sons (1992); T. D. Ocain, et al., J. Med.
Chem., 31, 2193-99 (1988); E. M. Gordon, et al., J. Med. Chem., 31,
2199-10 (1988); "Practice of Peptide Synthesis" by M. Bodansky and
A. Bodanszky, Springer-Verlag, New York (1984); "Asymmetric
Synthesis: Construction of Chiral Molecules Using Amino Acids" by
G. M. Coppola and H. F. Schuster, John Wiley & Sons, Inc., New
York (1987); "The Chemical Synthesis of Peptides" by J. Jones,
Oxford University Press, New York (1991); and "Introduction of
Peptide Chemistry" by P. D. Bailey, John Wiley & Sons, Inc.,
New York (1992), each incorporated herein by reference.
[0163] The synthesis of compounds of the invention is preferably
carried out in a solvent. Suitable solvents are liquids at ambient
room temperature and pressure or remain in the liquid state under
the temperature and pressure conditions used in the reaction. The
choice of solvent is within the general skills of the skilled
artisan and will depend on the reaction conditions, such,
temperature, the nature of the reagents and starting material,
solubility and stability of the reagents and starting material, the
type of reaction, and the like. Depending on the circumstances,
solvents may be distilled or degassed. Solvents may be, for
example, aliphatic hydrocarbons (e.g., hexanes, heptanes, ligroin,
petroleum ether, cyclohexane, or methylcyclohexane) and halogenated
hydrocarbons (e.g., methylenechloride, chloroform,
carbontetrachloride, dichloroethane, chlorobenzene, or
dichlororbenzene); aromatic hydrocarbons (e.g., benzene, toluene,
tetrahydronaphthalene, ethylbenzene, or xylene); ethers (e.g.,
diglyme, methyl-tert-butyl ether, methyl-tert-amyl ether,
ethyl-tert-butyl ether, diethylether, diisopropylether,
tetrahydrofuran or methyltetrahydrofurans, dioxane,
dimethoxyethane, or diethyleneglycol dimethylether); amides (e.g.,
N,N-dimethylformamide, N,N-dimethylacetamide); nitriles (e.g.,
acetonitrile); ketones (e.g., acetone); esters (e.g., methyl
acetate or ethyl acetate); alcohols (e.g., methanol, ethanol,
isopropanol); water and mixtures thereof.
[0164] "Activated esters" and equivalent expressions may be
represented by the formula COX for carboxylate esters or SO.sub.2X
for sulfonate esters, where X is a leaving group, typical examples
of which include halogens (e.g. chloride or bromide),
N-hydroxysulfosuccinimidyl and N-hydroxysuccinimidyl groups;
aryloxy groups substituted with electron-withdrawing groups (e.g.,
p-nitro, pentafluoro, pentachloro, p-cyano, or p-trifluoromethyl);
and carboxylic acids activated by a carbodiimide or other
conventional coupling reagents to form an anhydride or mixed
anhydride, e.g., --OCOR.sup.a or --OCNR.sup.aNHR.sup.b, where
R.sup.a and R.sup.b are independently C.sub.1-C.sub.6 alkyl,
C.sub.5-C.sub.8 alkyl (e.g., cyclohexyl), C.sub.1-C.sub.6
perfluoroalkyl, or C.sub.1-C.sub.6 alkoxy groups. An activated
ester may be formed in situ or may be an isolable reagent. The
ester leaving group may be, for example, sulfosuccinimidyl esters,
pentafluorothiophenol esters, sulfotetrafluorophenol, substituted
or unsubstituted C.sub.1-C.sub.6 alkyl (such as methyl, ethyl,
propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl,
or hexyl), or substituted or unsubstituted C.sub.6-C.sub.14 aryl or
heterocyclic groups, such as 2-fluoroethyl, 2-chloroethyl,
2-bromoethyl, 2,2-dibromoethyl, 2,2,2-trichloroethyl,
3-fluoropropyl, 4-chlorobutyl, methoxymethyl,
1,1-dimethyl-1-methoxymethyl, ethoxymethyl, N-propoxymethyl,
isopropoxymethyl, N-butoxymethyl, tert-butoxymethyl, 1-ethoxyethyl,
1-methyl-1-methoxyethyl, 1-(isopropoxy)ethyl,
3-methoxypropyl-4-methoxybutyl, fluoromethoxymethyl,
2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl,
3-fluoropropoxymethyl, 4-chlorobutoxyethyl, di bromomethoxyethyl,
2-chloroethoxypropyl, fluoromethoxybutyl, 2-methoxyethoxymethyl,
ethoxymethoxyethyl, methoxyethoxypropyl, methoxyethoxybutyl,
benzyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl,
.alpha.-naphthylmethyl, .beta.-naphthylmethyl, diphenylmethyl,
triphenylmethyl, .alpha.-naphthyldiphenylmethyl, 9-anthrylmethyl,
4-methylbenzyl, 2,4,6-trimethylbenzyl, 3,4,5-trimethylbenzyl,
2-nitrobenzyl, 4-nitrobenzyl, 4-methoxybenzyl,
4-methoxyphenyldiphenylmethyl, 4-chlorobenzyl, 4-bromobenzyl,
4-cyanobenzyl, 4-cyanobenzyldiphenylmethyl, or
bis(2-nitrophenyl)methyl groups.
IV. Pharmaceutical Compositions
[0165] Preferably, the compounds of the invention are formulated
prior to administration into pharmaceutical compositions using
techniques and procedures well known in the art. Accordingly, in
another embodiment, the present invention relates to pharmaceutical
compositions (e.g. solid or semi-solid mixtures, solutions,
suspensions or emulsions) comprising effective amounts of one or
more compounds according to any of the Formulae herein and a
pharmaceutically acceptable vehicle, as well as methods of using
and manufacturing such pharmaceutical compositions.
[0166] The pharmaceutical compositions are formulated for suitable
administration (orally, parenterally, (IV, IM, depo-IM, SC, and
depo-SC), sublingually, intranasally (inhalation), intrathecally,
topically, or rectally). Suitable pharmaceutical vehicles include,
without limitation, any non-immunogenic pharmaceutical carrier or
diluent suitable for oral, parenteral, nasal, mucosal, transdermal,
topical, intrathecal, rectal, intravascular (IV), intraarterial
(IA), intramuscular (IM), and subcutaneous (SC) administration
routes, such as phosphate buffer saline (PBS). Also, the present
invention includes such compounds which have been lyophilized and
which may be reconstituted to form pharmaceutically acceptable
formulations for administration, as by intravenous, intramuscular,
or subcutaneous injection. Administration may also be intradermal
or transdermal.
[0167] Preferably, the pharmaceutical composition of the invention
is suitable for oral administration. The formulations may
conveniently be presented in unit dosage form and may be prepared
by any methods well known in the art of pharmacy. In general, the
formulations are prepared by uniformly and intimately bringing into
association a compound of the present invention with a
pharmaceutically acceptable vehicle (e.g. an inert diluent or an
assimilable edible, liquid or finely divided solid (or both),
carrier) and, optionally, one or more accessory ingredients and
then, if necessary, shaping the product. The amount of the
therapeutic agent in such therapeutically useful compositions is
such that a suitable dosage will be obtained.
[0168] Formulations of the invention suitable for oral
administration may be in the form of capsules (e.g. hard or soft
shell gelatin capsule), cachets, pills, tablets, lozenges, powders,
granules, pellets, dragees, e.g., coated (e.g., enteric coated) or
uncoated, or as a solution or a suspension in an aqueous or
non-aqueous liquid, or as an oil-in-water or water-in-oil liquid
emulsion, or as an elixir or syrup, or as pastilles (using an inert
base, such as gelatin and glycerin, or sucrose and acacia), and the
like, each containing a predetermined amount of a compound of the
present invention as an active ingredient. A compound of the
present invention may also be administered as a bolus, electuary or
paste, or incorporated directly into the subject's diet. Moreover,
the compounds can be orally formulated to (a) provide for instant
or rapid drug release (i.e., have no coating on them); (b) be
coated, e.g., to provide for sustained drug release over time; or
(c) be enterically coated for better gastrointestinal tolerability
or protection from degradation in the stomach.
[0169] In solid dosage forms of the invention for oral
administration the active ingredient is typically mixed with one or
more pharmaceutically acceptable carriers or non-active
pharmaceutical ingredients, such as sodium citrate or dicalcium
phosphate, or any of the following: fillers or extenders (e.g.
starches, lactose, sucrose, glucose, mannitol, or silicic acid);
binders (e.g. carboxymethylcellulose, alginates, gelatin, polyvinyl
pyrrolidone, sucrose or acacia); humectants (e.g. glycerol);
disintegrating agents (e.g. agar-agar, calcium carbonate, potato or
tapioca starch, alginic acid, certain silicates, and sodium
carbonate); solution retarding agents (e.g., as paraffin);
absorption accelerators (e.g. quaternary ammonium compounds);
wetting agents (e.g., cetyl alcohol and glycerol monostearate);
absorbents (e.g., kaolin and bentonite clay); lubricants (e.g.
talc, calcium stearate, magnesium stearate, solid polyethylene
glycols, sodium lauryl sulfate, and mixtures thereof); and coloring
agents. In the case of capsules, tablets and pills, the
pharmaceutical compositions may also comprise buffering agents.
Solid compositions of a similar type may also be employed as
fillers in soft and hard-filled gelatin capsules using such
excipients as lactose or milk sugars, as well as high molecular
weight polyethylene glycols and the like.
[0170] Peroral compositions typically also include liquid
solutions, emulsions, suspensions, and the like. The
pharmaceutically acceptable vehicles suitable for preparation of
such compositions are well known in the art. Typical components of
carriers for syrups, elixirs, emulsions and suspensions include
ethanol, glycerol, propylene glycol, polyethylene glycol, liquid
sucrose, sorbitol and water. For a suspension, typical suspending
agents include methyl cellulose, sodium carboxymethyl cellulose,
tragacanth, and sodium alginate; typical wetting agents include
lecithin and polysorbate 80; and typical preservatives include
methyl paraben and sodium benzoate. Peroral liquid compositions may
also contain one or more components such as sweeteners, flavoring
agents and colorants.
[0171] Pharmaceutical compositions suitable for injectable use
include sterile aqueous solutions (where water soluble) or
dispersions, and sterile powders for the extemporaneous preparation
of sterile injectable solutions or dispersion. In all cases, the
composition must be sterile and must be fluid to the extent that
easy syringability exists. It must be stable under the conditions
of manufacture and storage and must be preserved against the
contaminating action of microorganisms such as bacteria and fungi.
Sterile injectable solutions can be prepared by incorporating the
therapeutic agent in the required amount in an appropriate solvent
with one or a combination of ingredients enumerated above, as
required, followed by filtered sterilization. Generally,
dispersions are prepared by incorporating the therapeutic agent
into a sterile vehicle which contains a basic dispersion medium and
the required other ingredients from those enumerated above. In the
case of sterile powders for the preparation of sterile injectable
solutions, the methods of preparation are vacuum drying and
freeze-drying which yields a powder of the active ingredient (i.e.,
the therapeutic agent) plus any additional desired ingredient from
a previously sterile-filtered solution thereof. Solvent or
dispersion medium suitable for injectable use are, for example,
water, ethanol, polyols (for example, glycerol, propylene glycol,
and liquid polyethylene glycol, and the like), suitable mixtures
thereof, and vegetable oils. Proper fluidity is maintained, for
example, by the maintenance of the required particle size in the
case of dispersion and by the use of surfactants. Prevention of the
action of microorganisms can be achieved by various antibacterial
and antifungal agents, for example, parabens, chlorobutanol,
phenol, ascorbic acid, thimerosal, and the like. In many cases,
isotonic agents are included, for example, sugars, sodium chloride,
or polyalcohols such as mannitol and sorbitol, in the composition.
Prolonged absorption of the injectable compositions can be brought
about by including in the composition an agent which delays
absorption, for example, aluminum monostearate or gelatin.
[0172] Pharmaceutical formulations are also provided which are
suitable for administration as an aerosol, by inhalation. These
formulations comprise a solution or suspension of the desired
compound of any Formula herein or a plurality of solid particles of
such compound(s). As a liquid, the formulation will comprise, for
example, a water-soluble compound of the invention, or a salt
thereof, in a carrier which comprises water. A surfactant may be
present which lowers the surface tension of the formulation
sufficiently to result in the formation of droplets within the
desired size range when subjected to nebulization. On the other
hand, solid particles can be obtained by processing the solid form
of a compound, or a salt thereof, in any appropriate manner known
in the art, such as by micronization. The liquid droplets or solid
particles should have a particle size in the range of about 0.5 to
about 5 microns. The size of the solid particles or droplets will
be, for example, from about 1 to about 2 microns. The desired
formulation may be placed in a small chamber and nebulized.
Nebulization may be accomplished by compressed air or by ultrasonic
energy to form a plurality of liquid droplets or solid particles
comprising the agents or salts. In this respect, commercial
nebulizers are available to achieve this purpose.
[0173] The compositions of this invention can also be administered
topically to a subject, e.g., by the direct lying on or spreading
of the composition on the epidermal or epithelial tissue of the
subject, or transdermally via a "patch". Such compositions include,
for example, lotions, creams, solutions, gels and solids. These
topical compositions may comprise an effective amount, usually at
least about 0.1%, or even from about 1% to about 5%, of an agent of
the invention. Suitable carriers for topical administration
typically remain in place on the skin as a continuous film, and
resist being removed by perspiration or immersion in water.
Generally, the carrier is organic in nature and capable of having
dispersed or dissolved therein the therapeutic agent. The carrier
may include pharmaceutically acceptable emollients, emulsifiers,
thickening agents, solvents and the like.
[0174] Other compositions useful for attaining systemic delivery of
the subject agents include sublingual, buccal and nasal dosage
forms. Such compositions typically comprise one or more of soluble
filler substances such as sucrose, sorbitol and mannitol; and
binders such as acacia, microcrystalline cellulose, carboxymethyl
cellulose and hydroxypropyl methyl cellulose. Glidants, lubricants,
sweeteners, colorants, antioxidants and flavoring agents disclosed
above may also be included. The compound(s) of the invention may
also be administered parenterally, intraperitoneally,
intraspinally, or intracerebrally. For such compositions, the
compound(s) of the invention can be prepared in glycerol, liquid
polyethylene glycols, and mixtures thereof and in oils. Under
ordinary conditions of storage and use, these preparations may
contain a preservative to prevent the growth of microorganisms.
[0175] To administer the compound(s) of the invention by other than
parenteral administration, it may be useful to coat the compound(s)
with, or co-administer the compound(s) with a material to prevent
its inactivation. For example, the compound(s) of the invention may
be administered to a subject in an appropriate carrier, for
example, liposomes, or a diluent. Pharmaceutically acceptable
diluents include saline and aqueous buffer solutions. Liposomes
include water-in-oil-in-water CGF emulsions as well as conventional
liposomes.
[0176] Pharmaceutical compositions according to the invention may
also be coated by conventional methods, typically with pH or
time-dependent coatings, such that the compound(s) of the invention
is released in the vicinity of the desired location, or at various
times to extend the desired action. Such dosage forms typically
include, but are not limited to, one or more of cellulose acetate
phthalate, polyvinylacetate phthalate, hydroxypropyl methyl
cellulose phthalate, ethyl cellulose, waxes, and shellac.
[0177] Dosage forms provide the compound in a pharmaceutical
composition of the invention for in vivo administration to a
subject, e.g. a human patient. It is understood that appropriate
doses depend upon a number of factors within the knowledge of the
ordinarily skilled physician, veterinarian, or researcher (e.g. see
Wells et al. eds., Pharmacotherapy Handbook, 2.sup.nd Edition,
Appleton and Lange, Stamford, Conn. (2000); PDR Pharmacopoeia,
Tarascon Pocket Pharmacopoeia 2000, Deluxe Edition, Tarascon
Publishing, Loma Linda, Calif. (2000), incorporated herein by
reference). The dose(s) of the compound(s) of the invention will
vary, for example, depending upon a variety of factors including,
but not limited to: the activity, biological and pharmacokinetic
properties and/or side effects of the compound being used; the age,
body weight, general health, gender, and diet of the subject; the
time of administration, the route of administration, the rate of
excretion, and any drug combination, if applicable; the effect
which the practitioner desires the compound to have upon the
subject; and the properties of the compound being administered
(e.g. bioavailability, stability, potency, toxicity, etc). Such
appropriate doses may be determined using the assays described
herein or known in the art. When one or more of the compounds of
the invention is to be administered to humans, a physician may for
example, prescribe a relatively low dose at first, subsequently
increasing the dose until an appropriate response is obtained.
[0178] There are no particular limitations on the dose of each of
the compounds for use in the composition of the present invention.
Exemplary doses include milligram or microgram amounts of the
compound per kilogram of subject or sample weight (e.g., about 50
micrograms per kilogram to about 500 milligrams per kilogram, about
1 milligram per kilogram to about 100 milligrams per kilogram,
about 1 milligram per kilogram to about 50 milligram per kilogram,
about 1 milligram per kilogram to about 10 milligrams per kilogram,
or about 3 milligrams per kilogram to about 5 milligrams per
kilogram). Additional exemplary doses include single or multiple
doses of about 5 to about 1000 mg, about 25 to about 800 mg, about
25 to about 400 mg, about 50 to about 200 mg, or about 50, about
100, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about
400 mg, or about 500 mg, and, preferably, daily or twice daily, or
lower or higher amounts. Further exemplary doses include daily
doses in a human of about 50 mg to about 4000 mg, about 100 mg to
about 3500 mg, about 100 mg to about 2500 mg, about 100 mg to about
1200 mg, about 100 mg to about 800 mg, about 400 mg to about 2500
mg, about 400 mg to about 1200 mg, about 400 mg to about 800 mg,
about 800 mg to about 4000 mg, about 800 mg to about 3500 mg, about
800 mg to about 2500 mg, about 800 mg to about 1200 mg, about 1200
mg to about 4000 mg, about 1200 mg to about 3200 mg, about 1200 mg
to about 2500 mg, administered as a single daily dose or divided in
multiple doses throughout the day. Examples of dosages of 1,3PDS
(e.g. herein using molar equivalence or less of the prodrug) are
described in PCT published applications WO 2007/004072, WO
2007/125385 and WO 2008/078176, incorporated herein by reference in
their entirety for all purposes.
[0179] It is generally advantageous to formulate parenteral
compositions in dosage unit form for ease of administration and
uniformity of dosage. The term "unit dosage form" refers to a
physically discrete unit suitable as unitary dosages for human
subjects and other mammals, each unit containing a predetermined
quantity of active material calculated to produce the desired
therapeutic effect, in association with a suitable pharmaceutical
vehicle. The specification for the dosage unit forms of the
invention may vary and are dictated by and directly dependent on
(a) the unique characteristics of the therapeutic agent and the
particular therapeutic effect to be achieved, and (b) the
limitations inherent in the art of compounding such a therapeutic
agent for the prevention of treatment of the disease or
disorder.
[0180] Administration of the compounds and compositions of the
present invention to a subject to be treated can be carried out
using known procedures, at dosages and for periods of time
effective to achieved the desired purpose. Dosage regimens can be
adjusted to provide the optimum therapeutic response. For example,
several divided doses may be administered daily or the dose may be
proportionally reduced as indicated by the exigencies of the
therapeutic situation. Preferably, the compound(s) of the invention
is administered at a therapeutically effective dosage sufficient to
reduce the disease's or disorder's symptoms in a subject,
preferably a human subject.
[0181] The compound(s) of the invention may be packaged as part of
a kit or a pharmaceutical package, optionally including a container
(e.g. packaging, a box, a vial, etc). The kit may be commercially
used according to the methods described herein and may include
instructions for use in a method of the invention. Additional kit
components may include acids, bases, buffering agents, inorganic
salts, solvents, antioxidants, preservatives, or metal chelators.
The additional kit components are present as pure compositions, or
as aqueous or organic solutions that incorporate one or more
additional kit components. Any or all of the kit components
optionally further comprise buffers.
V. Methods of Uses of the Compounds
[0182] Another aspect of the invention pertains to a method for
treating a disease or disorder in a subject by administering an
effective amount of a prodrug of the present invention. The term
"subject" includes living organisms with a disease or disorder
treatable by 1,3PDS, or which are susceptible to such a disease or
disorder, e.g. amyloid A amyloidosis, renal disorders, diabetic
nephropathy, hyperglycemia, dyslipidemia, diabetes mellitus (e.g.
type 1 or type 2), diabetes with features of metabolic syndrome,
metabolic syndrome, any underlying or resulting disease or symptom
of any the foregoing, or any combination thereof. Examples of
subjects include humans, monkeys, cows, rabbits, sheep, goats,
pigs, dogs, cats, rats, mice, and transgenic species thereof. The
term "subject" preferably includes animals susceptible to states
characterized by amyloidosis and/or metabolic diseases, e.g.
mammals, e.g. primates, e.g. humans. The animal can also be an
animal model for a disorder, e.g., an AA amyloidosis mouse model,
or an obese or diabetic mouse or rat model.
[0183] In certain embodiments of the invention, the human subject
is in need of treatment by the methods of the invention, and is
selected for treatment based on this need. A subject in need of
treatment is art-recognized, and includes subjects that have been
identified as having any of the foregoing disease or disorder, has
a symptom of such a disease or disorder, or is at risk of such a
disease or disorder, and would be expected, based on diagnosis,
e.g., medical diagnosis, to benefit from treatment (e.g., curing,
healing, preventing, alleviating, relieving, altering, remedying,
ameliorating, improving, or affecting the disease or disorder, the
symptom of the disease or disorder, or the risk of the disease or
disorder).
[0184] For example, the human subject may be a human over 20 year
sold, over 30 years old, human over 40 years old, a human over 50
years old, a human over 60 years old, a human over 70 years old, a
human over 80 years old. The subject may be a female human,
including a postmenopausal female human, who may be on hormone
(estrogen) replacement therapy. The subject may also be a male
human. In another embodiment, the subject is under 40 years
old.
[0185] In one aspect, the subject has a disease that provokes a
sustained acute phase response. For example, such diseases include
chronic inflammatory disorders (e.g. long standing inflammation),
chronic local or systemic microbial infections, and malignant
neoplasms. For example, such a disease includes Rheumatoid
Arthritis or Familial Mediterranean Fever (a genetic disease).
[0186] In another aspect, the subject has amyloid A amyloidosis,
with or without renal impairment. For example, the subject has
amyloid A amyloidosis with renal, which may vary from mild,
moderate and severe impairement.
[0187] In another aspect, the subject's rate of creatinine
clearance is lower than about 80 mL/min, lower than about 30 mL/min
(severe), from about 30 to about 80 mL/min (moderate), or greater
than about 80 mL/min (mild to none).
[0188] In some aspects, the subject may have symptoms of a
metabolic disease or condition, such as diabetes (e.g. type II
diabetes), metabolic syndrome, obesity, etc. In another embodiment,
the subject may have symptoms of type II diabetes and be
overweight. For example, the subject has a body mass index (BMI) of
25 or more, a BMI between 25 and 30, or a BMI of 30 or more. The
Body Mass Index, or BMI is a measure of a person's weight taking
into account their height. It is given by the formula: BMI equals a
person's weight (mass) in kilograms divided by the square of the
person's height in metres. In some aspects, the subject is diabetic
and requires administration of exogenous insulin. In one aspect,
the subject is diabetic and does not require exogenous insulin, and
the treatment with the compound of the invention allows delaying
the requirement for treating the diabetic patient with insulin.
[0189] "Preventing" or "prevention" is intended to refer at least
the reduction of likelihood or the risk of (or susceptibility to)
acquiring a disease or disorder (i.e., causing at least one of the
clinical symptoms of the disease not to develop in a patient that
may be exposed to or predisposed to the disease but does not yet
experience or display symptoms of the disease). The term
"prevention" or "preventing" is also used to describe the
administration of a compound or composition of the invention to a
subject who is at risk of (or susceptible to) such a disease or
condition. Patients amenable to treatment for prevention of the
disease or condition include individuals at risk of the disease or
condition but not showing symptoms, as well as patients presently
showing symptoms. Predisposing factors identified or proposed in
the scientific literature include, among others, genetic factors,
environmental factors, chronic inflammation and other conditions
(such as ones predisposing to AA amyloidosis), sedentary lifestyle,
eating habits, and metabolic disorders predisposing a subject to a
disease or disorder as described herein. Prevention also includes
delaying onset of certain endpoint, for example, delaying the need
for dialysis in renally impaired patients, or the need for insulin
in diabetes patients.
[0190] "Treating" or "treatment" of any disease or disorder refers,
in some embodiments, to ameliorating at least one disease or
disorder (i.e., arresting or reducing the development of the
disease or at least one of the clinical symptoms thereof). In
certain embodiments "treating" or "treatment" refers to
ameliorating at least one physical parameter. In certain
embodiments, "treating" or "treatment" refers to inhibiting the
disease or disorder, either physically, (e.g., stabilization of a
discernible symptom), physiologically, (e.g., stabilization of a
physical parameter), or both. In certain embodiments, "treating" or
"treatment" refers to delaying the onset of the disease or
disorder. The term "treating" refers to any indicia of success in
the treatment or amelioration of an injury, pathology or condition,
including any objective or subjective parameter such as abatement;
remission; diminishing of symptoms or making the injury, pathology
or condition more tolerable to the subject; improving a subject's
physical or mental well-being, reducing symptoms experienced by the
patient; and, in some situations additionally improving at least
one parameter of a renal disorder (creatinine clearance,
proteinuria, etc) or metabolic disorder (e.g. glucose tolerance,
insulin secretion, reducing serum triglycerides levels, etc). The
treatment or amelioration of symptoms can be based on objective or
subjective parameters; including the results of a physical
examination or the subject's evaluation of symptoms, or of a test
known in the art (e.g. glucose level, etc). The treatment or
amelioration of symptoms also includes delaying the onset of
dialysis, i.e. the necessity for dialysis.
[0191] As used herein the term "therapeutically effective amount"
refers to the amount or dose of the compound, upon single or
multiple dose administration to the patient, which provides the
desired effect in the patient under diagnosis or treatment. An
effective amount can be readily determined by the attending
diagnostician, as one skilled in the art, by the use of known
techniques and by observing results obtained under analogous
circumstances. In determining the effective amount or dose of
compound administered, a number of factors are considered by the
attending diagnostician, including, but not limited to: the size,
age, and general health of the subject; the specific disease(s)
involved; the degree of or involvement or the severity of the
disease; the response of the individual subject; the particular
compound administered; the mode of administration; the
bioavailability characteristics of the preparation administered;
the dose regimen selected; the use of concomitant medication; and
other relevant circumstances.
[0192] Improvement in condition is present within the context of
the present invention if there is a measurable difference between
the performances of subjects treated using the methods of the
invention as compared to members of a placebo group, historical
control, or between subsequent tests given to the same subject.
[0193] It is to be understood that wherever values and ranges are
provided herein, e.g., in ages of subject populations, dosages, and
blood levels, all values and ranges encompassed by these values and
ranges, are meant to be encompassed within the scope of the present
invention. Moreover, all values in these values and ranges may also
be the upper or lower limits of a range.
[0194] In certain embodiments, the compounds and composition
according to the invention can be used in combination therapy with
at least one other therapeutic or a nutraceutical agent. The
compounds of the invention when administered in association with at
least one other agent(s), can act additively or, in certain
embodiments, synergistically.
[0195] The compounds of the invention can be administered prior,
subsequent to or concomitantly with the other agent. The
compositions of the present invention can be administered with the
other therapeutic agent as part of the same pharmaceutical
composition as, or in a different composition from, that containing
the compounds of the present invention. The at least one other
agent can be effective for treating the same or different disease,
disorder, or condition. Preferably, the other agent is suitable for
the treatment of symptoms of a metabolic disorder, e.g. diabetes,
diabetes with features of metabolic syndrome, metabolic syndrome,
and the like.
[0196] Methods of the present invention include administration of
one or more compounds or pharmaceutical compositions of the present
invention and one or more other therapeutic agents provided that
the combined administration does not inhibit the therapeutic
efficacy of the one or more compounds of the present invention
and/or does not produce adverse combination effects.
[0197] In some aspects, the combination therapy comprises
alternating between administering a composition of the present
invention and a composition comprising another therapeutic agent,
e.g., to minimize adverse side effects associated with a particular
drug. When a compound of the present invention is administered
concurrently with another therapeutic agent that potentially can
produce adverse side effects including, but not limited to,
toxicity, the therapeutic agent can advantageously be administered
at a dose that falls below the threshold at which the adverse side
effect is elicited. A pharmaceutical composition can also further
comprise substances to enhance, modulate and/or control release,
bioavailability, therapeutic efficacy, therapeutic potency,
stability, and the like.
[0198] The compounds or pharmaceutical compositions of the present
invention include, or can be administered to a patient together
with, another therapeutic drug that may be available
over-the-counter or by prescription. Therapeutic drugs as well as
nutraceuticals useful in a combination with a therapeutic compound
of the present invention are known to the skilled artisan.
Preferred therapeutic drugs to be used with the compounds or
pharmaceutical compositions of the present invention are
therapeutic drugs useful in the prevention or treatment of, but not
limited to, chronic inflammation, nephropathy, or diabetes and
other metabolism disorders, or any disease, disorder or symptom
associated with any of the conditions disclosed herein.
[0199] Preferred therapeutic drugs to be used with the 1,3PDS
prodrugs and dimers and oligomers of the present invention are
therapeutic drugs useful in the prevention or treatment of renal
disorders as well as diabetes and associated symptoms and
syndromes. PCT patent application WO 2008/078176 (incorporated
herein by reference) provide a long but non-exhaustive list of
"therapeutic drugs" that can be useful, in combination, according
to the invention.
VI. Standard Methods for Testing the Compounds of the Invention
[0200] The compounds according to the invention can be further
analyzed, tested or validated using a variety of in vitro assays,
or in vivo assays to confirm their safety and bioavailabity, their
capability to deliver 1,3PDS, etc. The following are illustrative
of the type of biological assays that can be conducted to assess
the instant compounds.
i) Determination of Enzymatic Cleavage of Prodrugs In Vitro
[0201] For orally administered prodrugs, it is generally desirable
that the prodrug remains mostly intact (i.e., uncleaved or not
converted to the parent drug) while in the gastrointestinal tract
and be cleaved (i.e., to release the parent drug) while in the
systemic circulation. A useful level of stability can at least in
part be determined by the mechanism and kinetics of absorption of
the prodrug by the gastrointestinal tract. A useful level of
lability can at least in part be determined by the pharmacokinetics
of the prodrug and parent drug in the systemic circulation. In
general, prodrugs that are more stable in a Caco-2 S9 and/or
pancreatin assay and are more labile in rat plasma, human plasma,
rat liver S9, and/or human liver S9 preparation can be useful as an
orally administered prodrug. The results of tests, for determining
the enzymatic cleavage of prodrugs in vitro can be used to select
prodrugs for in vivo testing.
ii) Bioavailability of Prodrugs In Vivo
[0202] Prodrugs that provide, following administered to a patient
or a subject, a certain level of bioavailability of the
corresponding parent drug can be useful as therapeutic agents.
Bioavailability of the compounds of the invention and of released
1,3PDS can be measured in vivo (humans and/or laboratory animals)
using methods well known in the art.
iii) Toxicity
[0203] A variety of different parameters can be monitored to assess
toxicity. Examples of such parameters include, but are not limited
to, cell proliferation, monitoring activation of cellular pathways
for toxicological responses by gene or protein expression analysis,
DNA fragmentation, changes in the composition of cellular
membranes, membrane permeability, activation of components of
death-receptors or downstream signaling pathways (e.g., caspases),
generic stress responses, NF-kappaB activation and responses to
mitogens. Related assays are used to assay for apoptosis (a
programmed process of cell death) and necrosis, including cGMP
formation and NO formation.
[0204] Toxicity and therapeutic efficacy of the compound(s) and
composition(s) of the invention can be determined by standard
pharmaceutical procedures in cell cultures or experimental animals,
e.g., for determining the LD50 (the dose lethal to 50% of the
population) and the ED50 (the dose therapeutically effective in 50%
of the population). The dose ratio between toxic and therapeutic
effects is the therapeutic index and can be expressed as the ratio
LD50/ED50, and usually a larger therapeutic index is more
efficacious. While agents that exhibit toxic side effects may be
used, care should be taken to design a delivery system that targets
such agents to the site of affected tissue in order to minimize
potential damage to unaffected cells and, thereby, reduce side
effects.
iv) Gastrointestinal Absorption
[0205] The compounds or drugs according to the invention can be
further analyzed, tested or validated for their ability to be
absorbed by the gut and/or intestine if so desired.
[0206] Intestinal permeability and transport of a drug candidate
may be estimated using a variety of in vitro, in situ, as well as
in vivo models (Balimane et al. (2000) J Pharmacol Toxicol Methods
44:385-401; Hidalgo I. (2001) Curr Top Med Chem 1:385-401,
Hillgreen K, Kato A and Borchardt R. (1995) 15:83-109, each
incorporated herein by reference).
[0207] For instance, parallel artificial membrane permeability
(PAMPA) assay and cell-based systems such as Caco-2 and
Mardin-Darby canine kidney (MDCK) cells are the most frequently
used in vitro models. The PAMPA model consists of a hydrophobic
filter material coated with a mixture of lecithin/phospholipids
dissolved in an inert organic solvent creating an artificial lipid
membrane barrier that mimics the intestinal epithelium. Caco-2
cells, a human colon adenocarcinoma, undergo spontaneous
enterocytic differentiation in culture and become polarized cells
with well-established tight junctions, resembling intestinal
epithelium in humans. Caco-2 cell model has been the most popular
and the most extensively characterized cell-based model in
examining the permeability of drugs in both the pharmaceutical
industries and academia. Alternatively, MDCK cells which also
develop tight junctions and form monolayers of polarized cells are
used.
[0208] An in situ study such as an intestinal perfusion could also
be performed to assess drug absorption. Isolated intestinal
segments comprise the absorptive cells and the underlying muscle
layers. As it is commonly used, this technique only allows sampling
from the mucosal side; drug disappearance is assumed to be equal to
drug absorption. Typically, a whole animal absorption study
(pharmacokinetic study) will be performed in parallel with the in
vitro and/or in situ studies to assess intestinal permeability. In
general, drug absorption in animals is believed to be a good
predictor of absorption in humans.
v) Gastrointestinal Toxicity
[0209] The compounds or drugs according to the invention can be
further analyzed, tested or validated for gastrointestinal (GI)
toxicity. Gastrointestinal toxicity of a compound in vivo can be
reliably established through the implementation of a standard
battery of general toxicological assessments. Generally, regulatory
test guidelines from the EU, OECD, ICH, FDA and JMOHW are used as
reference material for the preparation of study protocols for such
assessments. In North America, the toxicological assessments will
generally be carried out in compliance with the United States Food
and Drug Administration Title 21 Code of Federal Regulations Part
58, Good Laboratory Practice for Non-clinical studies issued on
Dec. 22, 1978, Federal Register plus subsequent amendments.
[0210] Within the context of such a non-clinical assessment of the
toxicity of a particular compound, GI toxicity may specifically be
assessed through the monitoring of body weight gain, the gross
examination of materials emitted by the test subject (specifically
vomitus and feces) and the monitoring of food/water consumption
(appetence). Furthermore, upon termination of a non-clinical
toxicological assessment, the retention and processing of GI tract
tissues from the test subject(s) to the slide stage, followed by
histopathological examination of said tissues by a trained
pathologist, is a useful tool, complementary to the aforementioned
"in-life" observations.
[0211] Those skilled in the art will recognize, or be able to
ascertain using no more than routine experimentation, numerous
equivalents to the specific procedures, embodiments, claims, and
examples described herein. Such equivalents are considered to be
within the scope of this invention and covered by the claims
appended hereto. The contents of all references, issued patents,
and published patent applications cited throughout this application
are hereby incorporated by reference. The invention is further
illustrated by the following examples, which should not be
construed as further limiting.
EXAMPLES
[0212] The Examples set forth herein below provide exemplary
syntheses of certain representative compounds of the invention.
[0213] Unless otherwise indicated, all numbers expressing
quantities of ingredients, reaction conditions, concentrations,
properties, stabilities, and so forth used in the specification and
claims are to be understood as being modified in all instances by
the term "about." At the very least, each numerical parameter
should at least be construed in light of the number of reported
significant digits and by applying ordinary rounding techniques.
Accordingly, unless indicated to the contrary, the numerical
parameters set forth in the present specification and attached
claims are approximations that may vary depending upon the
properties sought to be obtained. Notwithstanding that the
numerical ranges and parameters setting forth the broad scope of
the embodiments are approximations, the numerical values set forth
in the specific examples are reported as precisely as possible. Any
numerical value, however, inherently contain certain errors
resulting from variations in experiments, testing measurements,
statistical analyses and such.
[0214] The present invention also relates to novel compounds and
the synthesis thereof. The following detailed examples describe how
to prepare the various compounds and/or perform the various
processes of the invention and are to be construed as merely
illustrative, and not limitations of the preceding disclosure in
any way whatsoever. Those skilled in the art will promptly
recognize appropriate variations from the procedures both as to
reactants and as to reaction conditions and techniques. In some
cases, the compounds may be commercially available. Accordingly,
the following examples are presented to illustrate how some
sulfonate ester prodrugs according to the invention may be
prepared.
[0215] Commercial material is generally available from known
sources, for example, Sigma-Aldrich, Bachem, Lancaster, Alfa Aesar,
etc.
Example 1
General Synthetic Protocol for the Synthesis of Mono and
Disulfonate Esters
##STR00038##
[0216] a) 1,3-Propanedisulfonyl Dichloride:
[0217] 1,3-Propanedisulfonic acid disodium salt (1,3PDS(2Na)), 74
g, 0.29 mol) was well grounded and dried at 110.degree. C. for 15
h. PCl.sub.5 (72 g, 0.62 mol) was added and the two solids were
stirred until they melt. The reaction mixture was stirred for 2 h
then cooled to room temperature. The resulting material was added
with caution to ice (200 g), followed by addition of ethyl acetate
(200 mL). The mixture was stirred until a clear two phases was
obtained. The organic layer was separated, washed with hydrochloric
acid (1 M), and concentrated under reduced pressure to produce an
amorphous brownish solid. Recrystallization in ether allowed the
isolation of 1,3-propanedisulfonyl dichloride (62 g) as a white
solid: .sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. in ppm 2.78 (q,
J=7.0 Hz, 2H), 3.95 (t, J=7.0 Hz, 4H).
Alternate Protocol:
##STR00039##
[0219] Step 1:
[0220] To a solution of 1,3-propanedisulfonic acid disodium salt
(23.5 g, 94.7 mmol) in water (30 mL) was added a hot solution of
BaCl.sub.2.H.sub.2O in H.sub.2O (20 mL). A white precipitate was
formed. The suspension was heated at .about.80.degree. C. for 2 h
then cooled to room temperature and allowed to settle by standing.
The white solid was collected by filtration and dried under high
vacuum at 120.degree. C. for 15 h to afford barium
1,3-propanedisulfonate (20 g, 62%): .sup.1H NMR (CDCl.sub.3, 500
MHz) .delta. 2.04 (m, 2H), 2.92 (t, J=7.0 Hz, 4H).
[0221] Step 2:
[0222] The fine powder of barium 1,3-propanedisulfonate (15 g,
44.17 mmol) was mixed with phosphorus pentachloride (PCl.sub.5) and
heated at 110.degree. C. for 5 h. (the mixture melted completely
after 1-h heating). The reaction mixture was cooled to room
temperature, and then quenched with ice/water (150 mL) and ethyl
acetate. The organic layer was isolated, washed with water, dried
over sodium sulfate, and concentrated to dryness, affording
1,3-propanedisulfonyl dichloride (6 g): NMR (CDCl.sub.3, 500 MHz)
.delta. 2.78 (q, J=7.0 Hz, 2H), 3.95 (t, J=7.0 Hz, 4H).
b) 3-Phenoxysulfonyl-1-Propanesulfonyl Chloride:
[0223] To a cold (0.degree. C.) solution of 1,3-propanedisulfonyl
dichloride from Step (a) (4.8 g, 20 mmol) in dichloromethane (30
mL) was added dropwise a solution of phenol (1.88 g, 20 mmol) in
dichloromethane/pyridine (20 mL:5 mL). The reaction mixture was
stirred for 3 h while it was gradually warmed to room temperature.
Aqueous HCl (1M) was added to the reaction mixture. The organic
layer was separated, dried over magnesium sulfate, filtered and
concentrated. The residual material was purified by silica gel
chromatography using hexanes/ethyl acetate (70:30) as eluent to
isolate 3-phenoxysylfonyl-1-propanesulfonyl chloride (7.2 g):
.sup.1H NMR (500 MHz, CDCl.sub.3) .delta. in ppm 2.71 (quint, J=7.0
Hz, 2H), 3.52 (t, J=7.0 Hz, 2H), 3.95 (t, J=7.0 Hz, 2H), 7.26-7.45
(m, 5H).
c) 1,3-Propanedisulfonic Acid Monoesters:
##STR00040##
[0224] (R is R.sup.4 as previously described)
[0225] Step 1: Esterification:
[0226] To a cold (0.degree. C.) solution of
3-phenoxysylfonyl-1-propanesulfonyl chloride from Step (b) (5.97 g,
20 mmol, see (b)) in CH.sub.2Cl.sub.2 (30 mL) is added dropwise a
solution of the corresponding alcohol (22 mmol) in
CH.sub.2Cl.sub.2/pyridine (20 mL/5 mL). The reaction mixture is
stirred for 3-15 h while it is gradually warmed to room
temperature. Aqueous hydrochloric acid (1M) is added to the
reaction mixture. The organic layer is separated, dried over
magnesium sulfate and concentrated. The residual material is
purified by silica gel chromatography using hexanes/ethyl acetate
as eluent to isolate the corresponding intermediate
1,3-propanesulfonic acid alkyl phenyl ester.
[0227] Step 2: Deprotection:
[0228] To a solution of the intermediate 1,3-propanesulfonic acid
alkyl phenyl ester from Step 1 (2 mmol) in MeOH (50 mL) is added
acetic acid (5 mL) followed by addition of Pd(OH).sub.2 (200 mg) in
water (5 mL). The reaction mixture is stirred under hydrogen (1
atm., balloon) for 2-3 h (or until complete consumption of starting
material). The suspension is filtered, and the filtrate is
concentrated to dryness. To the residual material is added an
aqueous solution of sodium carbonate (1M, 2 mL); and the resulting
mixture is stirred for 30 min and then concentrated. The residue is
purified by silica gel chromatography using
dichloromethane/methanol (90:10 to 80:20) as eluent to give the
corresponding 1,3-propanedisulfonic acid monoester.
d) 1,3-Propanedisulfonic Acid Monoesters (Alternate Protocol):
##STR00041##
[0229] (R is R.sup.4 as previously described)
[0230] Compound C1 (Example 13) (5.0 mmol) and triethylamine (20.0
mmol) are added to a stirred solution of selected alcohol (5.25
mmol) in dichloromethane (15 mL). The resulting mixture is stirred
for 24 h at room temperature and the reaction mixture concentrated
in vacuo. The residue is diluted with water and passed through a
column of strongly acid cation exchange resin (Dowex.TM.
Marathon.TM. C, 30-40 mesh, 30 g). Elution with water permitted to
isolate the monosulfonic acid prior to silica gel chromatography.
The corresponding sodium salt can also be obtained after treatment
of the monosulfonic acid in methanol with aqueous 1N sodium
carbonate (10.0 mmol) for 15 min. at room temperature. The mixture
is then concentrated to dryness and subjected to silica gel
chromatography using a mixture of dichloromethane and methanol as
eluent to isolate the corresponding 1,3-propanedisulfonic acid
monoester. The final product can also be lyophilized as its final
solid form.
e) 1,3-Propanedisulfonic Acid Diesters:
##STR00042##
[0231] (R is R.sup.3 in one occurrence and R.sup.4 in another and
are as previously described)
[0232] To a cold (0.degree. C.) solution of 1,3-propanedisulfonyl
dichloride from Step (a) (4.8 g, 20 mmol) in dichloromethane (30
mL) is added dropwise a solution of a corresponding alcohol (44
mmol) in dichloromethane/pyridine (20 mL:5 mL). The reaction
mixture is stirred for 3-15 h while it is gradually warmed to room
temperature. Aqueous hydrochloric acid (1M) is added to the
reaction mixture. The organic layer is separated, dried over
magnesium sulfate and concentrated. The residual material is
purified by silica gel column using hexanes/ethyl acetate as eluent
to isolate the corresponding 1,3-propanedisulfonic acid
diester.
Example 2
Preparation of Compounds B1 and B2(Bis(Trifluoroacetate) Salt)
##STR00043##
[0234] Step 1:
[0235] To a stirred solution of commercial
3-bromo-2,2-dimethylpropanol (3.5 g, 21 mmol) in dimethylsulfoxide
(50 mL) was added well grounded potassium cyanide (3.8 g, 58 mmol).
The reaction mixture was stirred at 100.degree. C. for 15 h, then
cooled to room temperature and diluted with 1M hydrochloric acid.
The mixture was extracted with ethyl acetate and the extracts were
washed with 1M hydrochloric acid, dried over sodium sulfate and
evaporated to an oily residue. The residual material was purified
by column chromatography (silica gel, hexanes/ethyl acetate 70:30
then 50:50) to afford 3.2 g of 4-hydroxy-3,3-dimethylbutanenitrile.
.sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. (ppm) 1.01 (s, 6H), 2.00
(m, 1H), 2.31 (s, 2H), 3.36 (d, J=3.0 Hz, 2H); .sup.13C NMR
(CDCl.sub.3, 125 MHz) .delta. (ppm) 23.89, 27.10, 35.46, 70.0,
118.83.
[0236] Step 2:
[0237] Water-wet Raney-nickel (1 g) was added to a stirred solution
of 4-hydroxy-3,3-dimethylbutanenitrile from Step 1 (3.0 g, 26.51
mmol) in ethanol (100 mL). To this suspension was added ammonium
hydroxide (30% in water, 10 mL). The reaction mixture was stirred
under atmospheric pressure of hydrogen for 2 days, and then
filtered. The filtrate was concentrated; and the resulting residue
was dissolved in dichloromethane (60 mL) followed by addition of
di(tert-butyl)dicarbonate (6.3 g, 29 mmol). The reaction mixture
was stirred at room temperature for 2 h and then concentrated under
reduced pressure. The residual material was purified by silica gel
column chromatography (hexanes/ethyl actetate 80:20 then 70:30) to
isolate 4-t-butoxycarbonylamino-2,2-dimethyl-1-butanol (3.8 g,
66%). .sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. (ppm) 1.90 (s, 6H),
1.43 (s, 9H), 1.46 (m, 2H), 2.10 (bs, 1H), 3.13 (m, 2H), 3.35 (d,
J=6.0 Hz, 2H), 4.65 (bs, 1H).
[0238] Step 3:
[0239] To a stirred solution of
4-t-butoxycarbonylamino-2,2-dimethyl-1-butanol from Step 2 (0.43 g,
2 mmol) in pyridine (10 mL) was added 1,3-propanedisulfonyl
dichloride (Example 1 (a)) (812 mg, 4 mmol). The reaction mixture
was stirred at room temperature for 2 h, diluted with toluene, and
concentrated under reduced pressure. The residual material was
diluted with ethyl acetate. The resulting solution was washed with
water, dried over sodium sulfate and concentrated. The residual
material was purified by column chromatography (silica gel,
hexane/ethyl acetate 70:30 then 60:40), providing Compound B1 (1.1
g, 96% yield) as a white solid. .sup.1H NMR (CDCl.sub.3, 500 MHz)
.delta. (ppm) 1.00 (s, 12H), 1.44 (s, 18H), 1.52 (m, 4H), 2.43
(quint, J=7.2 Hz, 2H), 3.15 (m, 4H), 3.36 (t, J=7.0 Hz, 4H), 3.93
(s, 4H), 4.58 (bs, 2H); .sup.13C NMR (CDCl.sub.3, 125 MHz) .delta.
(ppm) 18.71, 24.10, 28.65, 33.97, 36.51, 38.61, 47.95, 77.70,
79.51, 156.08; ES-MS 601 (M-1).
[0240] Step 4:
[0241] Trifluoroacetic acid (1 mL) was added to a stirred solution
of Compound B1 from Step 3 (0.22 g, 0.36 mmol) in CH.sub.2Cl.sub.2
(6 mL). The reaction mixture was stirred at room temperature for 2
h then concentrated under reduced pressure to afford Compound B2
(bis(trifluoroacetate) salt) in quantitative yield as a colorless
waxy solid. .sup.1H NMR (D.sub.2O, 500 MHz) .delta. (ppm) 0.88 (s,
12H), 1.55 (m, 4H), 2.25 (quint, J=7.0 Hz, 2H), 2.91 (m, 4H), 3.47
(t, J=7.2 Hz, 4H), 3.95 (s, 4H); .sup.13C NMR (D.sub.2O, 125 MHz)
.delta. (ppm) 18.00, 22.65, 33.22, 35.29, 35.73, 47.17, 78.162;
ES-MS 403 (M+1).
Example 3
Preparation of Compounds A1(Potassium Salt) and A2
##STR00044##
[0243] Step 1:
[0244] To a stirred solution of
4-t-butoxycarbonylamino-2,2-dimethyl-1-butanol (Example 2, Step 2)
(0.43 g, 2 mmol) in pyridine/CH.sub.2Cl.sub.2 (10 mL:10 mL) was
added 1,3-propanedisulfonyl dichloride (Example 1 (a)) (407 mg, 2
mmol), followed by addition of 1M aqueous potassium carbonate (5
mL). The reaction mixture was vigorously stirred for 30 min then
concentrated under reduced pressure. The residual material was
purified by silica gel chromatography (dichloromethane/methanol
90:10 then 80:20) to isolate Compound A1(potassium salt) (0.42 g,
49% yield) as a white solid. .sup.1H NMR (D.sub.2O, 500 MHz)
.delta. (ppm) 0.86 (s, 6H), 1.29 (s, 9H), 1.38 (m, 2H), 2.14 (m,
2H), 2.93 (t, J=7.0 Hz, 2H), 2.98 (m, 2H), 3.43 (t, J=7.0 Hz, 2H),
3.92 (s, 2H); .sup.13C NMR (D.sub.2O, 125 MHz) .delta. (ppm) 19.10,
23.08, 27.91, 33.33, 36.13, 37.53, 47.84, 48.78, 78.98, 81.06,
158.28; ES-MS 402 (M-1-K).
[0245] Step 2:
[0246] Trifluoroacetic acid (1 mL) was added to a stirred solution
of Compound A1(K) from Step 1 (0.20 g, 0.47 mmol) in
dichloromethane (6 mL). The reaction mixture was stirred at room
temperature for 2 h then concentrated under reduced pressure. The
residual material was suspended in ethanol/diethyl ether; and the
resulting suspension was filtered. The solid material was washed
with ether then dried to obtain Compound A2 (0.12 g, 88% yield) as
a white solid. .sup.1H NMR (D.sub.2O, 500 MHz) .delta. (ppm) 0.88
(s, 6H), 1.57 (m, 2H), 2.14 (quint, J=7.0 Hz, 2H), 2.90-2.95 (m,
4H), 3.46 (t, J=7.0 Hz, 2H), 4.64 (s, 2H); .sup.13C NMR (D.sub.2O,
125 MHz) .delta. (ppm) 19.14, 22.72, 33.18, 35.35, 35.81, 47.84,
48.67, 78.24; ES-MS 302 (M-1).
Example 4
Preparation of Compounds B3, B4(Bis(Trifluoroacetate) Salt) and
B73
##STR00045##
[0248] Step 1 and Step 2:
[0249] Using an amended version of the procedure of Example 2
(Steps 3 and 4) used for the synthesis of Compounds B1 and
B2(bis(trifluoroacetate)salt), Compounds B3 (used as an
intermediate) and B4(bis(trifluoroacetate)salt) were prepared by
replacing 4-(t-butoxycarbonylamino-2,2-dimethyl-1-butanol with
commercial 3-(t-butoxycarbonylamino-2,2-dimethyl-1-propanol (Steps
1 and 2). Compound B4(bis(trifluoroacetate)salt) was obtained (0.59
g) as a colorless waxy solid. .sup.1H (D.sub.2O, 500 MHz) .delta.
in ppm 0.90 (s, 12H), 2.27 (quint, J=7.2 Hz, 2H), 2.88 (s, 4H),
3.48 (t, J=7.2 Hz, 4H), 4.07 (s, 4H); .sup.13C (D.sub.2O, 125 MHz)
.delta. (ppm) 17.90, 20.80, 33.92, 46.22, 47.32, 76.33, 116.00 (q,
J=293 Hz, CF.sub.3 of TFA), 163.00 (q, J=36 Hz, CO of TFA); ES-MS
373 (M-1-2TFA).
[0250] Step 3:
[0251] To a suspension of Compound B4(bis(trifluoroacetate)salt)
from Step 2 (0.671 g, 1.5 mmol) in dichloromethane (40 mL) was
added triethylamine (1.3 mL, 9.0 mmol) followed by commercial ethyl
chloroformate (0.86 mL, 9.0 mmol). The mixture was stirred for 2 h
at room temperature, diluted with 1H HCl and extracted three times
with ethyl acetate. The combined organic layers were washed with
water, dried over magnesium sulfate, filtered and filtrate
evaporated to give a residue. The crude product was purified by
silica gel chromatography using hexane/ethyl acetate (50:50) to
isolate Compound B73 (0.46 g, 59% yield) as a colorless oil.
.sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. in ppm 0.975 (s,
2.times.6H), 1.24 (t, J=7.3 Hz, 2.times.3H), 2.45 (quint, J=7.0 Hz,
2H), 3.12 (d, J=7.0 Hz, 2.times.2H), 3.39 (t, J=7.0 Hz,
2.times.2H), 3.97 (s, 2.times.2H), 4.10 (q, J=7.3 Hz, 2.times.2H),
4.96 (bt, 2.times.NH).
Example 5
Preparation of Compounds A3 (Potassium Salt) and A4
##STR00046##
[0253] Step 1:
[0254] Using an amended version of Step 1 of the procedure of
Example 3, used for the preparation of Compound A1(potassium salt),
Compound A3(potassium salt) was prepared from commercial
3-t-butoxycarbonylamino-2,2-dimethyl-1-propanol and
1,3-propanedisulfonyl dichloride (Example 1 (a)). Compound
A3(potassium salt) was obtained (0.19 g) as a white powder. .sup.1H
NMR (D.sub.2O, 500 MHz) .delta. ppm 0.82 (s, 6H), 1.29 (s, 9H),
2.13 (quint, J=7.2 Hz, 2H), 2.90 (s, 2H), 2.92 (t, J=7.2 Hz, 2H),
3.42 (t, J=7.2 Hz, 2H), 3.93 (s, 2H); .sup.13C NMR (D.sub.2O, 125
MHz) d 19.04, 21.22, 27.83, 35.73, 46.79, 47.84, 48.76, 76.87,
81.03, 158.50; ES-MS 426 (M-1).
[0255] Step 2:
[0256] Compound A4 was prepared from Compound A3(potassium salt)
from Step 2 using an amended version of Step 2 of the procedure of
Example 3, used for the preparation of Compound A2. Compound A4 was
obtained (0.16 g) as a white solid. .sup.1H NMR (D.sub.2O, 500 MHz)
.delta. ppm 0.97 (s, 6H), 2.13 (quint, J=7.2 Hz, 2H), 2.89 (s, 2H),
2.95 (t, J=7.2 Hz, 2H), 3.46 (t, J=7.0 Hz, 2H), 4.06 (s, 2H);
.sup.13C NMR (D.sub.2O, 125 MHz) .delta. 19.09, 20.88, 33.90,
46.32, 47.96, 48.66, 76.11; ES-MS 288 (M-1).
Example 6
Preparation of 1-Chloroethyl 2-Methylpropanoate
##STR00047##
[0258] To a cold (0.degree. C.) solution of isobutyryl chloride (10
mL, 98 mmol) in CH.sub.2Cl.sub.2 (250 mL) was added zinc chloride
(1.6 g, 9.8 mmol), followed by acetaldehyde (6.5 g, 147 mmol). The
reaction mixture was stirred for 4 h at room temperature then
concentrated. The crude material was diluted in diethyl ether and
water, and the phases obtained were separated. The organic layer
was washed with brine, dried over magnesium sulfate, filtered and
concentrated in vacuo. The residue was purified by silica gel
chromatography using diethyl ether/hexanes (1:10) as eluent to
provide 7.0 g of the title compound as a colorless liquid. .sup.1H
NMR (500 MHz, CDCl.sub.3) .delta. in ppm 1.17-1.20 (m, 6H), 1.79
(d, J 6.0 HHz, 3H), 2.51-2.61 (m, 1H), 6.54 (q, J=6.0 Hz, 1H),
Example 7
Preparation of Compounds A14, A51, A52(Sodium Salt), B14,
B51(Bis(Trifluoroacetate) Salt) and B52
a) Compound A51:
##STR00048##
[0260] Step 1:
[0261] To a mixture of commercial 3-amino-2,2-dimethyl-1-propanol
(1.33 g, 13 mmol) in tetrahydrofuran (40 mL) and 1 M aqueous
potassium carbonate (10 mL) was added a solution of
N-Boc-Phe-O-Succinimide (4.60 g, 13 mmol). The reaction mixture was
stirred vigorously at room temperature for 2 h. The two phases were
separated and the organic layer was concentrated to afford
3-(N-Boc-L-phenylalaninamido)-2,2-dimethylpropanol as a white solid
ready for use without further purification.
[0262] Step 2:
[0263] To a stirred solution of
3-(N-Boc-L-phenylalaninamido)-2,2-dimethylpropanol from Step 1 (2
mmol) in a mixture of pyridine/dichloromethane (5 mL:10 mL) was
added a solution of phenyl 3-phenoxysulfonyl-1-propanesulfonyl
chloride (Example 1 (b)) (2.2 mmol) in dichloromethane (5 mL). The
reaction mixture was stirred at room temperature for 15 h, then
concentrated and rediluted with ethyl acetate and aqueous
hydrochloric acid (1 N). The organic phase was isolated, washed
with aqueous hydrochloric acid (1N) and concentrated. The residual
material was purified by silica gel chromatography using
hexanes/ethyl acetate (70:30 to 50:50) as eluent to afford
3-phenoxysulfonyl-1-propanesulfonic acid
3-(N-Boc-L-phenylalaninamido)-2,2-dimethylpropyl ester.
[0264] Step 3:
[0265] To a solution of 3-phenoxysulfonyl-1-propanesulfonic acid
3-(N-Boc-L-phenylalaninamido)-2,2-dimethylpropyl ester from Step 2
(1.24 g, 2 mmol) in methanol (50 mL) was added acetic acid (5 mL)
followed by addition of Pd(OH).sub.2 (200 mg) in water (5 mL). The
reaction mixture was stirred under hydrogen atmosphere (balloon)
for 2-3 h (or until complete consumption of starting material). The
suspension was filtered, and the filtrate was concentrated to
dryness. The resulting crude material was dissolved in
dichloromethane (10 mL), followed by addition of trifluoroacetic
acid (5 ml). The reaction mixture was stirred for 2 h, concentrated
under reduce pressure, and purified by silica gel chromatography
using dichloromethane/methanol (90:10) as eluent to yield Compound
A51 (800 mg) as a white solid. .sup.1H NMR (D.sub.2O, 500 MHz)
.delta. in ppm 0.77 (s, 3H), 0.80 (s, 3H), 2.27 (quint, J=7.0 Hz,
2H), 2.95 (d, J=14.0 Hz, 1H), 3.06 (t, J=7.5 Hz, 2H), 3.15 &
3.25 (ABX, J=14.0 & 8.0 Hz, 2H), 3.24 (m, 1H), 3.53 (t, J=7.0
Hz, 2H), 3.97 (AB, J=9.0 Hz, 2H), 4.25 (dd, J=9.0 & 7.0 Hz,
1H), 7.31-7.44 (m, 5H), 8.05 (bt, CONH, not completely exchanged
with D.sub.2O).
b) Compound A52(Sodium Salt):
##STR00049##
[0267] To a stirred solution of
3-(N-Boc-L-phenylalaninamido)-2,2-dimethylpropanol (Example 7 (a),
Step 1) (2.0 g) in a mixture of pyridine (5 mL) and dichloromethane
(40 mL) was added 1,3-propanedisulfonyl dichloride (Example 1 (a))
(1.37 g). The reaction mixture was stirred at room temperature for
15 h and concentrated under reduced pressure. The residue was
purified by silica gel chromatography using hexanes/ethyl acetate
(70:30) as eluant to yield 1.5 g of the monoesterification product.
The product was dissolved in tetrahydrofuran (10 mL) to which was
added a 1M aqueous solution of sodium bicarbonate (10 mL) and
tetrahydrofuran (10 mL). The reaction mixture was stirred for 15 h
and concentrated under reduced pressure. The residual material was
purified by silica gel chromatography (dichloromethane/methanol
90:10) to isolate Compound A52(sodium salt) (0.63 g) as white
solid. .sup.1H NMR DMSO-d.sub.6 500 MHz) .delta. ppm 0.83 (s, 6H),
1.23 (s, minor rotamer, 1.3H) and 1.30 (s, major rotamer, 7.7H),
2.00 (quint, J=7.0 Hz, 2H), 2.55 (t, J=7.0 Hz, 2H), 2.76 (dd,
J=14.0 & 10.0 Hz, 1H), 2.90 (dd, J=14.0 & 5.0 Hz, 1H), 3.0
(t, J=7.0 Hz, 2H), 3.48 (t, J=7.5 Hz, 2H), 3.86 (s, 2H), 4.18 (m,
1H), 6.95 (d, J=8.5 Hz, 1H), 7.15-7.30 (m, 5H), 7.88 (t, J=6.5 Hz,
1H).
c) Compounds B51(Bis(Trifluoroacetate) Salt) and B52
##STR00050##
[0269] Step 1:
[0270] To a stirred solution of
3-(N-Boc-L-phenylalaninamido)-2,2-dimethylpropanol (Example 7 (a),
Step 1) (3.50 g) in a mixture of pyridine (10 mL) and
dichloromethane (50 mL) was added 1,3-propanedisulfonyl dichloride
(Example 1 (a)) (1.50 g). The reaction mixture was stirred at room
temperature for 15 h then concentrated under reduced pressure. The
residue was purified by silica gel chromatography using
hexanes/ethyl acetate (70:30) as eluant to afford 3.5 g of Compound
B52 which was used for the next step.
[0271] Step 2:
[0272] Compound B52 (3.5 g) from Step 1 was dissolved in
dichloromethane (10 mL) to which was added trifluoroacetic acid (5
mL). The reaction mixture was stirred for 2 h and concentrated
under reduced pressure to afford Compound B51(bis(trifluoroacetate)
salt) (0.5 g) as a white solid. .sup.1H NMR (CD.sub.3OD, 500 MHz)
.delta. ppm 0.85 (s, 2.times.3H), 0.90 (s, 2.times.3H), 2.35
(quint, J=7.0 Hz, 2H), 3.00 & 3.26 (AB, J=14.0 Hz, 2.times.2H),
3.10 & 3.20 (ABX, J=14.0 & 7.0 Hz, 2.times.2H), 3.46 (t,
J=7.3 Hz, 2.times.2H), 3.85 (AB, J=9.5 Hz, 2.times.2H), 4.11 (t,
J=7.5 Hz, 2.times.1H), 7.31-7.42 (m, 2.times.5H).
d) Compound A14:
##STR00051##
[0274] Step 1:
[0275] Commercial N-Cbz-L-valine-O-succinimide (5.44 g, 16 mmol)
was added to a solution of 4-amino-2,2-dimethyl-1-butanol (Example
2, Step 2 prior to the di(tert-butyl)dicarbonate step) (1.06 g, 6.9
mmol) and sodium bicarbonate (1.74 g, 20.7 mmol) in
water/tetrahydrofuran 1:1 (200 mL). After 18 h of stirring, the
solution was diluted with water (100 mL) and ethyl acetate (200
mL). The organic layer was separated and the aqueous layer was
extracted with ethyl acetate (100 mL). The combined organic layers
were washed with brine, filtered and concentrated to dryness. The
crude material was purified by silica gel chromatography
(hexanes/ethyl acetate 80:20 to 0:100 linear gradient) to afford
4-(N-CBz-L-valinamido)-2,2-dimethyl-1-butanol (2.14 g, 6.11 mmol,
88%) as a white solid.
[0276] Step 2:
[0277] Following the procedure shown in Example 1(c)-Step 1,
4-(N-CBz-L-valinamido)-2,2-dimethyl-1-butanol from Step 1 (1 g,
2.86 mmol) is reacted with 3-phenoxysulfonyl-1-propanesulfonyl
chloride (Example 1 (b)) (0.94 g, 3.2 mmol) in the presence of
pyridine (2.30 mL, 28.6 mmol). Following usual workup, the mixture
was purified by silica gel chromatography (hexanes/ethyl acetate
70:30 to 50:50) to afford 3-phenoxysulfonyl-1-propanesulfonic acid
4-(N-CBz-L-valinamido)-2,2-dimethyl-1-butyl ester (1.37 g, 78%) as
a pale yellow oil.
[0278] Step 3:
[0279] A solution of 3-phenoxysulfonyl-1-propanesulfonic acid
4-(N-CBz-L-valinamido)-2,2-dimethyl-1-butyl ester from Step 2 (1.37
g, 2.22 mmol) in methanol (100 mL) was degassed with nitrogen gas,
followed by addition of Pd/C (10% wet). The mixture was stirred for
24 h under 1 atmosphere of hydrogen. The reaction mixture was
filtered through a Celite.TM. pad. The filtrate was evaporated to
dryness. The residual material was purified by silica gel
chromatography (ethanol as eluent) to afford Compound A14 (800 mg,
89% yield) as a white solid. .sup.1H NMR (D.sub.2O, 500 MHz)
.delta. in ppm 1.00 (m, 12H), 1.59 (m, 2H), 1.13 (m, 1H), 2.27 (m,
2H), 3.06 (t, J=7.5 Hz, 2H), 3.26 (m, 1H), 3.34 (m, 1H), 3.57 (t,
J=7.5 Hz, 2H), 3.61 (d, J=6.0 Hz, 1H), 4.07 (s, 2H).
e) Compound B14:
##STR00052##
[0281] Step 1:
[0282] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)):
4-(N-CBz-L-valinamido)-2,2-dimethyl-1-butanol (2.14 g, 6.1 mmol)
(Example 7 (d), Step 1) was reacted with 1,3-propanedisulfonyl
dichloride (Example 1 (a)) (0.740 g, 3.1 mmol) in dichloromethane
(200 mL) in the presence of pyridine (2.5 mL, 30.6 mmol). Solvent
was evaporated, and the residual material was purified by silica
gel chromatography (hexanes/ethyl acetate 70:30 to 0:100 linear
gradient) to afford 1,3-propanedisulfonic acid
bis(4-(N-CBz-L-valinamido)-2,2-dimethyl-1-butyl) ester (1.73 g,
75%) as a pale yellow oil.
[0283] Step 2:
[0284] A solution of 1,3-propanedisulfonic acid
bis(4-(N-CBz-L-valinamido)-2,2-dimethyl-1-butyl) ester from Step 1
(0.70 g, 0.80 mmol) in EtOH (50 mL) was degassed with nitrogen gas,
followed by addition of Pd/C (10% wet). The mixture was stirred for
24 h under hydrogen gas atmosphere (1 atm.). The resulting solution
was filtered through a pad of Celite.TM. and the filtrate was
evaporated to dryness. The residual material was purified by
reverse phase chromatography (C18, water/methanol (0.01% ammonium
hydroxide) 100/0 to 80/20) to afford Compound B14 (0.41 g, 86%
yield) as a light yellow oil. .sup.1H NMR (DMSO, 500 MHz) .delta.
in ppm 0.77 (d, J=6.5 Hz, 6H), 0.85 (d, J=7.0 Hz, 6H), 0.93 (s,
12H), 1.41 (m, 4H), 1.83 (m, 2H), 2.11 (m, 2H), 2.88 (d, J=5.0 Hz,
2H), 3.10 (m, 4H), 3.51 (t, J=8.0 Hz, 4H), 3.92 (s, 4H), 7.81 (br
t, J=5.0 Hz, 2H).
Example 8
Preparation of Compounds A15(Sodium Salt) to A20(Sodium Salt) and
Compounds B15 to B20
TABLE-US-00001 ##STR00053## [0285] a b R' Compound (R) (S) i-Pr A15
(S) (R) i-Pr A16 (R) (S) OEt A17 (S) (R) OEt A18 (R) (S) Oi-Pr A19
(S) (R) Oi-Pr A20
a) Compound A20(Sodium Salt):
##STR00054##
[0287] Step 1:
[0288] To a solution of
(3S)-2,2-dimethyl-3-(phenylmethoxy)pent-4-en-1-ol (4.21 g; prepared
according to WO2009/033054, incorporated herein by reference) in
dichloromethane (40 mL) was added pyridine (7.8 mL), followed by a
slow addition of a solution of 3-phenoxysulfonyl-1-propanesulfonyl
chloride (Example 1 (b)) (6.87 g) in dichloromethane (15 mL). The
dark-colored solution obtained was stirred at room temperature for
18 h. The reaction mixture was diluted with 2N aqueous hydrochloric
acid (100 mL) and dichloromethane (100 mL). The aqueous layer was
extracted with dichloromethane (2.times.100 mL). The combined
organic layers were successively washed with 1N aqueous
hydrochloric acid (100 mL) and brine:water (1:1; 100 mL), dried
over magnesium sulfate and filtered. The solvent was evaporated to
give a dark oil residue, which was purified by silica gel
chromatography using ethyl acetate/hexane (20:80) as eluent to
obtain the O1-[(3S)-3-benzyloxy-2,2-dimethyl-pent-4-enyl] O3-phenyl
propane-1,3-disulfonate (7.05 g, 76% yield) as a white solid.
[0289] Step 2:
[0290] A solution of the ethenyl intermediate from Step 1 (3.98 g)
in dichloromethane (125 mL) was cooled to -78.degree. C. The
solution was purged with oxygen followed by a mixture of oxygen and
ozone at the same temperature until the solution turned slightly
blue. The reaction was followed by thin layer chromatography until
disappearance of the starting material. The solution was then
purged with oxygen and finally nitrogen to remove residual ozone.
Excess dimethylsulfide (3.0 mL) was added to the reaction mixture
at -78.degree. C. and stirred, over a period of 1 hour, with
gradual warming to room temperature. The solvents were removed
under reduced pressure using a rotary evaporator to give the
O1-[(3R)-3-benzyloxy-2,2-dimethyl-4-oxo-butyl] O3-phenyl
propane-1,3-disulfonate (4.62, 100% yield) as a colorless oil. The
residue was used for next step without further purification.
[0291] Step 3:
[0292] A solution of the aldehyde intermediate from Step 2 (4.62 g,
crude) in acetone (60 mL) was cooled to 0.degree. C. At this
temperature, a freshly prepared 2.0 M aqueous Jones-Reagent
solution (5.0 mL, 10 mmol)) was added slowly to the stirred
solution. The reaction mixture quickly turned brown and solid
formed. The reaction was stirred at 0.degree. C. for 1 hour. After
the starting material was completely consumed, excess isopropanol
(3.2 mL) was added at 0.degree. C. to consume excess oxidant and
the reaction mixture was stirred for an additional hour. The
reaction mixture was diluted with water (80 mL), acidified with 1N
aqueous hydrochloric acid (12 mL), transferred to an evaporator and
concentrated. The aqueous residue was diluted with ethyl acetate
and extracted three times with ethyl acetate. The combined organic
extracts were washed with brine, dried over magnesium sulfate,
filtered, and the solvents removed under reduced pressure. The
crude acid was purified by silica gel chromatography using a
mixture of hexane/ethyl acetate/acetic acid (70:30:3) as eluent to
afford the
(2R)-2-benzyloxy-3,3-dimethyl-4-(3-phenoxysulfonylpropylsulfonyloxy)
butanoic acid (3.0 g, 73% yield) as an oil which crystallized on
standing at +4.degree. C. to give a white solid.
[0293] Step 4:
[0294] The (R)-carboxylic acid from Step 3 (1.23 g) was dissolved
in anhydrous toluene (10 mL) and reacted with commercial
1-chloroethyl isopropylcarbonate (1.15 mL) in the presence of
silver carbonate (1.70 g, 6.15 mmol). The reaction mixture was
wrapped in aluminium foil and well stirred at 40.degree. C. for
over 18 h. The residual solid (silver salts) was filtered using a
short plug of Celite.TM. in a Buchner-funnel and the cake rinsed
with toluene. The solvent was removed under reduced pressure. The
crude material was further purified by silica gel chromatography
using ethyl acetate/hexane (20:80) as eluent to give
1-isopropoxycarbonyloxyethyl(2R)-2-benzyloxy-3,3-dimethyl-4-(3-phenoxysul-
fonylpropyl sulfon yloxy)butanoate (0.72 g, 47% yield) as an
oil.
[0295] Step 5:
[0296] The (R)-ester from Step 4 (722 mg) was dissolved in a
mixture of methanol (24 mL) and water (3 mL). To this mixture was
added 20% palladium hydroxide (0.16 g) and the mixture was
subjected to hydrogen (one atmosphere, balloon). The mixture was
stirred at room temperature for 18 hours. The mixture is filtered
through a pad of Celite.TM. and the cake rinsed with methanol. The
filtrate was treated with one equivalent of 1.0N NaOH, stirred at
room temperature for 5 minutes, and concentrated under reduced
pressure to give the crude product. The crude material was purified
by silica gel chromatography using a mixture of
dichloromethane/methanol (4:1) as eluent to afford Compound
A20(sodium salt) (0.51 g, 91% yield) as a white solid. .sup.1H NMR
(500 MHz, DMSO) .delta. in ppm 0.89 (d, J=5.1 Hz, 3H) & 0.95
(d, J=5.1 Hz, 3H), 1.22-1.24 (m, 6H), 1.46 (d, J=5.4 Hz, 3H),
1.96-2.01 (m, 2H), 2.54 (t, J=7.1 Hz, 2H), 3.41-3.52 (m, 2H),
3.87-3.93 (m, 2H), 4.06-4.09 (m, 1H), 4.76-4.82 (m, 1H), 5.84 (d,
J=5.6 Hz, 0.5H, OH) & 5.90 (d, J=5.6 Hz, 0.5H, OH), 6.67-6.72
(m, 1H).
b) Compound A18(Sodium Salt):
##STR00055##
[0298] Compound A18(sodium salt) is prepared using the same
methodology as described for Compound A20(sodium salt) (Example 8
(a)) by replacing 1-chloroethyl isopropylcarbonate in Step 4 with
commercially available 1-chloroethyl ethylcarbonate. Compound
A18(sodium salt) was obtained (0.43 g) as a white solid. .sup.1H
NMR (500 MHz, DMSO) .delta. in ppm 0.89 (d, J=6.1 Hz, 3H) &
0.94 (d, J=6.1 Hz, 3H), 1.20-1.23 (m, 3H), 1.47 (dd, J=5.6 Hz, 3H),
1.95-2.01 (m, 2H), 2.54 (t, J=7.1 Hz, 2H), 3.41-3.51 (m, 2H),
3.87-3.93 (m, 2H), 4.06-4.08 (m, 1H), 4.13-4.18 (m, 2H), 5.87 (d,
J=5.6 Hz, 0.5H, OH) & 5.90 (d, J=5.6 Hz, 0.5H, OH), 6.67-6.72
(m, 1H).
c) Compound A16(Sodium Salt):
##STR00056##
[0300] Compound A16(sodium salt) was prepared using the same
methodology as described for Compound A20(sodium salt) (Example 8
(a)) by replacing 1-chloroethyl 2-isopropylcarbonate in Step 4 with
1-chloroethyl 2-methylpropanoate (Example 6). Compound A16(sodium
salt) was obtained (0.35 g) as a white solid. .sup.1H NMR (500 MHz,
DMSO) .delta. in ppm 0.88 (d, J=7.3 Hz, 3H), 0.94 (d, J=2.2 Hz,
3H), 1.07-1.09 (m, 6H), 1.44-1.45 (m, 3H), 1.95-2.01 (m, 2H),
2.50-2.57 (m, 1H+2H, partly underneat DMSO-d6), 3.42-3.52 (m, 2H),
3.87-3.93 (m, 2H), 4.06-4.09 (m, 1H), 5.82 (d, J=5.6 Hz, 0.5H, 0.5
OH) & 5.87 (J=5.6 Hz, 0.5H, 0.5 OH), 6.78-6.82 (m, 1H).
d) Compound A15(Sodium Salt):
##STR00057##
[0302] Compound A15(sodium salt) was prepared using the same
methodology as described for Compound A16(sodium salt) by replacing
in Step 1 starting material
(3S)-2,2-dimethyl-3-(phenylmethoxy)pent-4-en-1-ol with
(3R)-2,2-dimethyl-3-(phenylmethoxy)pent-4-en-1-ol, which was
prepared similarly from the corresponding (S)-pantolactone.
e) Compound A17(Sodium Salt):
##STR00058##
[0304] Compound A17(sodium salt) was prepared using the same
methodology as described for the sodium salt of Compound A15(sodium
salt) by replacing 1-chloroethyl 2-methylpropanoate in Step 4 with
commercially available 1-chloroethyl ethylcarbonate.
f) Compound A19(Sodium Salt):
##STR00059##
[0306] Compound A19(sodium salt) was prepared using the same
methodology as described for Compound A15(sodium salt) by replacing
1-chloroethyl 2-methylpropanoate in Step 4 with commercial
1-chloroethyl isopropylcarbonate.
g) Compounds B15 to B20:
[0307] Compound B15 to B20 are prepared following an amended
version of Example 8(a) to (f) used for the preparation of
Compounds A15(sodium salt) to A20(sodium salt), replacing
3-phenoxysulfonyl-1-propanesulfonyl chloride (Example 1(b)) in Step
1 with 1,3-propanedisulfonyl dichloride (Example 1(a)) and
adjusting the molar ratio of alcohol/disulfonyl dichloride
derivative to (2:1).
Example 9
Preparation of Compounds A26(Sodium Salt) and A53(Sodium Salt)
a) Compound A26(Sodium Salt):
##STR00060##
[0309] Step 1:
[0310] To a stirred 0.degree. C. solution of
(2R)-2-benzyloxy-3,3-dimethyl-4-(3-phenoxysulfonylpropylsulfonyloxy)butan-
oic acid (Example 8(a), Step 3) (0.8 g) in dichloromethane (10 mL),
was added oxalyl chloride (0.28 mL) followed by a drop of
N,N-dimethylformamide. The reaction mixture was stirred for 1 hour
and concentrated in vacuo. The resulting residue was dissolved in
dichloromethane (10 mL), to which was added ethanol (2 mL). The
reaction mixture was stirred overnight at room temperature. The
volatiles were removed, and the residual material was purified by
silica gel chromatography (hexanes/ethyl acetate 70:30) to afford
ethyl(2R)-2-benzyloxy-3,3-dimethyl-4-(3-phenoxysulfonylpropylsulfonyloxyl-
)butanoate (0.70 g).
[0311] Step 2:
[0312] To a stirred solution of the ethyl ester from Step 1 (0.7 g)
in methanol (10 mL) was added acetic acid (2 mL) followed by
Pd(OH).sub.2 (0.2 g) in water (2 mL). The reaction mixture was
stirred under hydrogen (balloon) for 2-3 hours (or until complete
consumption of starting material). The suspension was filtered, and
the filtrate was concentrated to dryness. A 1M aqueous sodium
bicarbonate solution (2.6 ml) was added and the resulting mixture
was stirred for 30 min, and then concentrated. The residual
material was purified by silica gel chromatography using
dichloromethane/ethanol (80:20) as eluent to yield the Compound
A26(sodium salt) (0.4 g) as a white solid. .sup.1H NMR (D.sub.2O,
500 MHz) .delta. in ppm 1.05 (s, 6H), 1.31 (t, J=7.0 Hz, 3H), 2.28
(quint, J=7.0 Hz, 2H), 3.07 (t, J=7.0 Hz, 2H), 3.57 (t, J=7.0 Hz,
2H), 4.15 & 4.21 (AB, J=9.3 Hz, 2H), 4.17 (s, 1H), 4.27 (m,
1H).
b) Compound A53(Sodium Salt):
##STR00061##
[0314] Compound 53(sodium salt) was produced using the same
procedure as described for the synthesis of Compound A26(sodium
salt) (Example 9 (a)) by replacing ethanol in Step 1 with
isopropanol to give Compound 53 (sodium salt) (0.35 g) as a white
solid. .sup.1H NMR (D.sub.2O, 500 MHz) .delta. in ppm 1.05 (s, 3H),
1.06 (s, 3H), 1.31 (d, J=7.0 Hz, 3H), 1.32 (d, J=7.0 Hz, 3H), 2.29
(quint, J=7.0 Hz, 2H), 3.08 (t, J=7.0 Hz, 2H), 3.59 (t, J=7.0 Hz,
2H), 4.14 (s, 1H), 4.16 & 4.23 (AB, J=9.5 Hz, 2H), 5.11 (hept,
J=7.0 Hz, 1H).
Example 10
Preparation of Compounds A13 and B13
a) Compound A13:
##STR00062##
[0316] Step 1:
[0317] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(c), Step 1),
1-(4-hydroxy-2,2-dimethyl-1-butylaminocarbonyloxy)-1-ethyl
2-methylpropanoate (US published application 2005/0222431,
incorporated herein by reference) (1.0 g, 3.6 mmol) was reacted
with 3-phenoxysulfonyl-1-propanesulfonyl chloride (Example 1(b))
(1.20 g, 4.0 mmol) in the presence of pyridine (2.93 mL, 36.4
mmol). The crude mixture obtained was purified by silica gel
chromatography (hexanes/ethyl acetate 70:30 to 50:50) to afford
1-[[3,3-dimethyl-4-(3-phenoxysulfonylpropylsulfonyloxyl)butyl]carbamoylox-
y]ethyl 2-methylpropanoate (1.65 g, 85% yield) as a pale yellow
oil.
[0318] Step 2:
[0319] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(c), Step 2), starting
material from Step 1 of Example 10(a) (1.65 g, 3.09 mmol) in
methanol (100 mL) was degassed with nitrogen before addition of
palladium on charcoal (10% wet). The mixture was stirred for 24 h
under hydrogen gas (1 atm.). The mixture was filtered through
Celite.TM. and the filtrate was concentrated under reduced
pressure. The residual material was purified by silica gel
chromatography (dichloromethane/methanol 100:0 to 60:40) to afford
Compound A13 (1.16 g, 82% yield) as a white solid. .sup.1H NMR
(DMSO, 500 MHz) .delta. in ppm 0.91 (s, 6H), 1.05 (d, J=2.0 Hz,
3H), 1.07 (d, J=2.5 Hz, 3H), 1.037 (d, J=5 Hz, 3H), 1.41 (t,
J=8.0H, 2H), 1.99 (m, 2H), 2.50 (m, 1H), 2.55 (t, J=7.5 Hz, 2H),
3.00 (m, 2H), 3.48 (dd, J=7.5, 9.5 Hz, 2H), 3.86 (s, 2H), 6.65 (q,
J=5.5 Hz, 1H), 7.44 (t, J=5.5 Hz, 1H).
b) Compound B13:
##STR00063##
[0321] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e):
1-(4-hydroxy-2,2-dimethyl-1-butylaminocarbonyloxy)-1-ethyl
2-methylpropanoate (US published application 2005/0222431) (2.60 g,
9.45 mmol) was reacted with 1,3-propanedisulfonyl dichloride
(Example 1(a)) (1.14 g, 4.73 mmol) in dichloromethane (200 mL) in
the presence of pyridine (7.6 mL, 94.5 mmol). After evaporation,
the crude product was purified by silica gel chromatography
(hexanes/ethyl acetate 80/20 to 50/50) to afford Compound B13 (2.31
g, 68% yield) as a pale yellow oil. .sup.1H NMR (CDCl.sub.3, 500
MHz) .delta. in ppm 1.00 (s, 12H), 1.16 (d, J=7.0 Hz, 12H), 1.45
(d, J=5.5 Hz, 6H), 1.55 (t, J=8.0 Hz, 4H), 2.43 (m, 2H), 2.53 (m,
2H), 3.17-3.25 (m, 4H), 3.36 (m, 4H), 3.94 (s, 4H), 4.86 (br d,
J=4.5 Hz, 2H), 6.76 (q, J=5.5 Hz, 2H).
Example 11
Preparation of Compounds A29(Sodium Salt), A30(Sodium Salt), B29
and B30
a) Compound A29(Sodium Salt):
##STR00064##
[0323] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(d)), commercial ethyl
3-hydroxy-2,2-dimethylpropanoate was reacted with Compound C1
(Example 13). Compound A29(sodium salt) was obtained (4.3 g) as a
white solid. .sup.1H NMR (D.sub.2O, 500 MHz) .delta. in ppm 4.37
(s, 2H), 4.21 (q, J=7.1 Hz, 2H), 3.57 (t, J=7.6 Hz, 2H), 3.06 (t,
J=7.6 Hz, 2H), 2.26 (quintet, J=7.6 Hz, 2H), 1.28 (t, overlap with
a singlet at 1.275, J=7.1 Hz, 3H), 1.275 (s, 6H).
b) Compound A30(Sodium Salt):
##STR00065##
[0325] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(d)), commercial benzyl
3-hydroxy-2,2-dimethylpropanoate was reacted with Compound C1
(Example 13). Compound A30(sodium salt) was obtained (0.91 g) as
white solid. .sup.1H NMR (D.sub.2O, 500 MHz) .delta. in ppm 1.28
(s, 6H), 2.12-2.18 (m, 2H), 2.96 (t, J=7.6 Hz, 2H), 3.40 (t, J=7.3
Hz, 2H), 4.35 (s, 2H), 5.23 (s, 2H), 7.42-7.46 (m, 5H).
c) Compound B29:
##STR00066##
[0327] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), commercial ethyl
3-hydroxy-2,2-dimethylpropanoate was reacted with
1,3-propanedisulfonyl dichloride (Example 1 (a)). Compound B29 was
obtained (16.0 g) as a white solid. .sup.1H NMR (CDCl.sub.3, 500
MHz) .delta. in ppm 4.23 (s, 4H), 4.17 (q, J=7.1 Hz, 4H), 3.35 (t,
J=7.3 Hz, 4H), 2.37 (m, 2H), 1.273 (t, overlap with a singlet at
1.266, 6H) 1.266 (s, 12H).
d) Compound B30:
##STR00067##
[0329] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), commercial benzyl
3-hydroxy-2,2-dimethylpropanoate was reacted with
1,3-propanedisulfonyl dichloride (Example 1 (a)). Compound B30 was
obtained (9.0 g, 78% yield) as a white solid. .sup.1H NMR
(CDCl.sub.3, 500 MHz) .delta. in ppm 1.29 (s, 12H), 2.21 (quint,
J=7.0 Hz, 2H), 3.17 (t, J=7.0 Hz, 4H), 4.22 (s, 4H), 5.15 (s, 4H),
7.33-7.38 (m, 10H); MS positive mode: 602 (M+NH.sub.4.sup.+); MS
negative mode: 643 (M+AcO.sup.-).
Example 12
Preparation of Compounds A32(Sodium Salt) and B32
##STR00068##
[0331] Step 1:
[0332] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), commercial methyl
salicylate was reacted with 1,3-propanedisulfonyl dichloride
(Example 1 (a)). Compound B32 was obtained (1.8 g, 74% yield) as an
oil. .sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. in ppm 2.75 (quint,
J=7.0 Hz, 2H), 2.73 (t, J=7.0 Hz, 4H), 3.91 (s, 6H), 7.26-7.45 (m,
4H), 7.58 (t, J=8.0 Hz, 2H), 7.98 (d, J=7.8 Hz, 2H).
[0333] Step 2:
[0334] To a solution of Compound B32 from Step 1 (1.89 g, 4 mmol)
in methanol (100 mL) was added acetic acid (10 mL) followed by
Pd(OH).sub.2 (0.3 g) in water (2 mL). The reaction mixture was
stirred under hydrogen (1 atm., balloon) for 3 h. The suspension
was filtered, and the filtrate was concentrated to dryness. The
residual material was dissolved in methanol (10 mL), followed by
addition of 1M aqueous sodium carbonate (4 mL). The mixture was
stirred for 1 h, concentrated and purified by silica gel
chromatography using dichloromethane/methanol (90:10 to 80:20) as
eluent to give Compound A32(sodium salt) (0.85 g, 59% yield) as a
white solid. .sup.1H NMR (D.sub.2O, 500 MHz) .delta. in ppm 2.41
(quint, J=7.0 Hz, 2H), 3.10 (t, J=7.0 Hz, 2H), 3.75 (t, J=7.0 Hz,
2H), 3.94 (s, 3H), 7.45-7.55 (m, 4H), 7.72 (t, J=8.0 Hz, 2H), 7.96
(d, J=7.8 Hz, 2H).
Example 13
Preparation of Compound C1
##STR00069##
[0336] A stirred solution of 1,3-propanedisulfonic acid (30 g) in
phosphorus(V) oxychloride (P(O)Cl.sub.3, 100 ml) was heated at
100.degree. C. for 1 h. The reaction mixture was allowed to cool to
room temperature and chloroform (300 mL) was added. The resulting
solid was filtered and washed with chloroform (2.times.100 mL). The
solid was then added to 1.4 L of a stirring ice/water mixture. The
solid was then filtered, washed with water (2.times.200 mL) and
dried under high vacuum to afford Compound C1 (23.3 g, 85% yield)
as a white solid. .sup.1H NMR (D.sub.2O, 500 MHz) .delta. in ppm
2.13 (m, 2H), 3.01 (t, J=7.5 Hz, 4H).
Example 14
Preparation of Compounds A23(Sodium Salt) and B23
a) Starting Material:
##STR00070##
[0338] Step 1:
[0339] A solution of commercial 2,2-dimethylbutyrolactone (5 mL) in
tetrahydrofuran (20 mL) was added dropwise to a cooled (-78.degree.
C.) solution of 1M lithium aluminum hydride in diethylether (44
mL). After 1 h at -78.degree. C., the mixture was warmed to room
temperature and stirred for 15 hours. The reaction was then cooled
to 0.degree. C., and ethyl acetate (10 mL) was added followed by
careful addition of water (10 mL). The mixture was stirred at room
temperature for 1 h. The resulting solution was filtered over a pad
of Celite.TM. and the solid was washed several times with ethyl
acetate. After evaporation, the product was purified by silica gel
chromatography (hexanes/ethyl acetate 70:30 to 0:100) to afford the
desired 2,2-dimethylbutane-1,4-diol (3.18 g, 61% yield) as a
colorless oil.
[0340] Step 2:
[0341] Benzoyl chloride (3.13 mL) was added to a cooled
(-78.degree. C.) solution of 2,2-dimethylbutane-1,4-diol from Step
1 (3.18 g), triethylamine (7.5 mL) and 4-(dimethylamino)pyridine
(0.05 g) in dichloromethane (100 mL). The mixture was then slowly
warmed up to room temperature and stirred overnight. The reaction
mixture was concentrated in vacuo and the compound was purified by
silica gel chromatography (hexanes/ethyl acetate 95:5 to 60:40) to
afford 3,3-dimethyl-4-hydroxy-1-butyl benzoate (2.6 g, 44% yield)
as a colorless oil.
b) Compound B23:
##STR00071##
[0343] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)),
3,3-dimethyl-4-hydroxy-1-butyl benzoate (Example 14 (a), Step 2)
was reacted with 1,3-propanedisulfonyl dichloride (Example 1 (a)).
Compound B23 was obtained (0.65 g, 54% yield) as a white solid.
.sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. in ppm 1.08 (s, 12H);
1.83 (t, J=7.0 Hz, 4H); 2.43 (m, 2H); 3.34 (t, J=7.0 Hz, 4H); 4.02
(s, 4H); 4.40 (t, J=7.0 Hz, 4H); 7.44 (t, J=8.0 Hz, 4H); 7.56 (t,
J=7.0 Hz, 2H); 8.02 (dd, J=8.0, 1 Hz, 4H).
c) Compound A23(Sodium Salt):
##STR00072##
[0345] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(d)),
3,3-dimethyl-4-hydroxy-1-butyl benzoate (Example 14 (a), Step 2)
was reacted with Compound C1 (Example 13). Compound A23(sodium
salt) was obtained (16.8 g) as a white solid. .sup.1H NMR (DMSO,
500 MHz) .delta. in ppm 1.01 (s, 6H); 1.75 (t, J=7.0 Hz, 2H); 2.01
(m, 2H); 2.57 (t, J=7.5 Hz, 2H); 3.49 (t, J=7.5 Hz, 2H); 3.97 (s,
2H); 4.36 (t, J=7.0 Hz, 2H); 7.53 (t, J=8.0 Hz, 2H); 7.65 (t, J=7.5
Hz, 1H); 7.97 (d, J=7.0 Hz, 2H).
Example 15
Preparation of Compounds A6(Sodium Salt) and B6
##STR00073##
[0347] To a stirred solution of neopentyl alcohol (1.75 g) in a
mixture of pyridine (10 mL) and dichloromethane (50 mL) was added
1,3-propanedisulfonyl dichloride (Example 1 (a)) (4.82 g). The
reaction mixture was stirred at room temperature for 15 hours and
concentrated in vacuo. A 1M aqueous solution of sodium bicarbonate
(20 mL) was added and the reaction mixture was stirred for 1 h and
concentrated under reduced pressure. The residual material was
purified by silica gel chromatography using
dichloromethane/methanol as an eluant with first, a 98:2 ratio to
yield Compound B6, and second, with a 80:20 ratio to yield Compound
A6(sodium salt) (0.5 g) as a white solid. .sup.1H NMR (D.sub.2O,
500 MHz) .delta. in ppm 0.98 (s, 9H), 2.28 (quint, J=7.5 Hz, 2H),
3.08 (t, J=7.5 Hz, 2H), 3.55 (t, J=7.5 Hz, 2H), 4.02 (s, 2H).
Compound B6 (0.47 g) as a white solid, .sup.1H NMR (CDCl.sub.3, 500
MHz) .delta. in ppm 3.90 (s, 4H), 3.34 (t, J=7.0 Hz, 4H), 2.43 (q,
J=7.0 Hz, 2H), 0.99 (s, 18H).
Example 16
Preparation of Compound A56(Sodium Salt)
##STR00074##
[0349] Step 1:
[0350] To a 0.degree. C. solution of commercial (S)-camphanic acid
(1.98 g) in methanol (50 mL), was added freshly prepared solution
of diazomethane in diethyl ether until the yellow coloration
persisted. The solvent was removed to obtain the desired ester in
quantitative yield. The ester was dissolved in THF (100 mL) to
which was added slowly at 0.degree. C., 20 mL of a 1M solution of
lithium aluminium hydride in tetrahydrofuran. The reaction mixture
was stirred at room temperature for 8 h, then quenched with aqueous
hydrochloric acid (1 M) and diluted with ethyl acetate. The organic
layer was isolated, dried over magnesium sulfate and concentrated
under vacuum. The residual material was purified by silica gel
chromatography (hexanes/ethyl acetate 50:50) to isolate the desired
4-(hydroxymethyl)-1,7,7-trimethyl-3-oxabicyclo[2.2.1]heptan-2-one-
.
[0351] Step 2:
[0352] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(d)), the alcohol from Step
1 was reacted with Compound C1 (Example 13). Compound A56(sodium
salt) was obtained (0.4 g) as a white powder. .sup.1H NMR
(D.sub.2O, 500 MHz) .delta. in ppm 0.91 (s, 3H), 0.95 (s, 3H), 0.99
(s, 3H), 1.60-1.70 (m, 2H), 1.95-2.00 (m, 3H), 2.20 (m, 2H), 2.30
(quint, J=7.0 Hz, 2H), 2.45 (m, 1H), 4.70 (AB, J=16.5 Hz, 2H).
Example 17
Preparation of Compounds A58, A60, A61 and G4
a) Compound A58:
##STR00075##
[0354] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(d)), methyl
3-hydroxy-2,2-dimethyl-propanoate (WO 2007/053346, incorporated
herein by reference) was reacted with Compound C1 (Example 13).
Compound A58 was obtained (1.2 g, 48% yield) as a white solid.
.sup.1H NMR (D.sub.2O, 500 MHz) .delta. in ppm 1.26 (s, 6H), 2.40
(m, 2H), 3.05 (t, J=7.5 Hz, 2H), 3.55 (t, J=7.5H, 2H), 3.74 (s,
3H), 4.35 (s, 2H).
b) Compound A60(Sodium Salt):
##STR00076##
[0356] To a solution of Compound A30(sodium salt) (0.54 g, 1.3
mmol; Example 11(b)) in a 3:1 water/ethanol solution (30 mL) was
added a suspension of 10% Pd/C (0.12 g) in ethanol (2 mL). The
resulting solution was stirred for 30 min under hydrogen atmosphere
(balloon) and filtered over a pad of Celite.TM.. The cake was
washed with methanol (15 mL) and the filtrate was evaporated to
dryness to afford Compound A60(sodium salt) (0.41 g, 96% yield) as
a white solid. .sup.1H NMR (DMSO, 500 MHz) .delta. in ppm: 1.15 (s,
6H), 1.94-2.00 (m, 2H), 2.52-2.55 (t, 2H, partly masked by
DMSO-d6), 3.47 (t, J=7.8 Hz, 2H), 4.14 (s, 2H), 12.65 (bs, 0.75H,
CO2H).
c) Compound A61:
##STR00077##
[0358] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(d)), ethyl
2-(tert-butoxycarbonylamino)-3-hydroxy-2-methyl-propanoate (Yu S.
et al. (2005), Angewandte Chemie, International Edition, 44(1),
135-138, incorporated herein by reference) was reacted with
Compound C1 (Example 13). The resulting mixture was treated with
trifluoroacetic acid in dichloromethane to afford Compound A61 (4.2
g, 52% yield) as a white solid. .sup.1HNMR (D.sub.2O, 500 MHz)
.delta. in ppm 1.31 (t, J=7.1 Hz, 3H), 1.64 (s, 3H), 2.25 (quint,
J=7.0 Hz, 2H), 3.05 (t, J=7.0 Hz, 2H), 3.62 (t, J=7.0 Hz, 2H), 4.36
(q, J=7.1 Hz, 2H), 4.52 & 4.84 (AB, J=11.3 Hz, 2H).
d) Compound G4:
##STR00078##
[0360] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(d)), commercial
2,2-bis(hydroxymethyl)propanedioate were reacted with Compound C1
(Example 13). Compound G4 was obtained (0.41 g, 31% yield) as white
solid. .sup.1H NMR (D.sub.2O, 500 MHz) .delta. in ppm 1.30 (t,
J=7.0 Hz, 6H), 2.26 (quint, J=7.5 Hz, 4H), 3.06 (t, J=7.5 Hz, 4H),
3.62 (t, J=7.5 Hz, 4H), 4.34 (q, J=7.0 Hz, 4H), 4.86 (s, 4H).
Example 18
Preparation of Compounds B58 to B69
a) Compound B58:
##STR00079##
[0362] To a solution of Compound B30 (0.96 g, 1.64 mmol, Example 11
(d)) in ethanol (20 mL) was added a suspension of 10% Pd/C (0.17 g)
in ethanol (2 mL). The resulting solution was stirred 2 h under
hydrogen atmosphere (balloon) before being filtered over a pad of
Celite.TM.. The cake was washed with ethanol (15 mL) and the
filtrate was evaporated to dryness and afforded Compound B58 (0.65
g, 98% yield) as a white solid. .sup.1H NMR (DMSO, 500 MHz) .delta.
in ppm 1.16 (s, 12H), 2.05-2.12 (m, 2H), 3.50 (t, J=7.6 Hz, 4H),
4.18 (s, 4H), 12.70 (bs, 1.5H, 2.times.CO2H).
b) Compound B59:
##STR00080##
[0364] To a solution of Compound B29 (1.06 g, 3.19 mmol; Example 11
(c)) and silver carbonate (0.86 g, 3.19 mmol) in acetonitrile (25
mL) was added chloromethylbenzoate (2.73 mL, 16.0 mmol). The
mixture was stirred for 4 h at 60.degree. C. and filtered over a
pad of Celite.TM.. The cake was washed with acetonitrile
(2.times.20 ml). The filtrate was concentrated in vacuo and the
residue was purified by silica gel chromatography (hexanes/ethyl
acetate 90:10 to 50:50). Compound B59 (1.30 g, 97% yield) was
obtained as a colorless oil. .sup.1H NMR (CDCl.sub.3, 500 MHz)
.delta. in ppm 1.24 (s, 6H), 1.26 (t, J=7.0 Hz, 3H), 2.39 (quint,
J=7.5 Hz, 2H), 3.30 (t, J=7.0 Hz, 2H), 3.44 (t, J=7.5 Hz, 2H), 4.15
(q, J=7.5 Hz, 2H), 4.19 (s, 2H), 6.07 (s, 2H), 7.50 (t, J=7.5 Hz,
2H), 7.65 (t, J=7.5 Hz, 1H), 8.09 (d, J=7.0 Hz, 2H).
c) Compound B60:
##STR00081##
[0366] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), isopropyl
3-hydroxy-2,2-dimethyl-propanoate (WO 2007/053346) was reacted with
1,3-propanedisulfonyl dichloride (Example 1 (a)). Compound B60
(0.47 g, 70% yield) was obtained as a colorless oil. .sup.1H NMR
(CDCl.sub.3, 500 MHz) .delta. in ppm 1.24 (d, J=6.4 Hz, 12H), 1.25
(s, 6H), 2.38 (quint, J=7.0 Hz, 2H), 3.35 (t, J=7.0 Hz, 4H), 4.22
(s, 4H), 5.01 (hept, J=6.4 Hz, 2H).
d) Compound B61:
##STR00082##
[0368] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), methyl
3-hydroxy-2,2-dimethyl-propanoate (WO 2007/053346) was reacted with
1,3-propanedisulfonyl dichloride (Example 1 (a)) to afford Compound
B61 (5.3 g, 85% yield) as a white solid. .sup.1H NMR (CDCl.sub.3,
500 MHz) .delta. in ppm 4.23 (s, 4H), 3.73 (s, 6H), 3.35 (t, J=7.1
Hz, 4H), 2.37 (m, 2H), 1.27 (s, 12H).
e) Compound B62:
##STR00083##
[0370] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), butyl
3-hydroxy-2,2-dimethyl-propanoate (WO 2007/053346) was reacted with
1,3-propanedisulfonyl dichloride (Example 1 (a)). Compound B62 was
obtained (4.5 g, 40% yield) as a white solid. .sup.1H NMR
(CDCl.sub.3, 500 MHz) .delta. in ppm 4.22 (s, 4H), 4.12 (t, J=6.5
Hz, 4H), 3.35 (t, J=7.0 Hz, 4H), 2.38 (m, 2H), 1.63 (m, 4H), 1.39
(m, 4H), 1.28 (s, 12H), 0.94 (t, J=7.3 Hz, 6H).
f) Compound B63:
##STR00084##
[0372] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), hexyl
3-hydroxy-2,2-dimethyl-propanoate (WO 2007/053346) was reacted with
1,3-propanedisulfonyl dichloride (Example 1 (a)). Compound B63 was
obtained (2.0 g, 36% yield) as a colorless oil. .sup.1H NMR
(CDCl.sub.3, 500 MHz) .delta. in ppm 0.89 (t, J=7.0 Hz,
2.times.3H), 1.27 (s, 2.times.6H), 1.30-1.35 (m, 2.times.6H), 1.57
(quint, J=7.5 Hz, 2.times.2H), 2.37 (quint, J=7.0 Hz, 2H), 3.35 (t,
J=7.1 Hz, 2.times.2H), 4.12 (t, J=7.0 Hz, 2.times.2H), 4.22 (s,
2.times.2H).
g) Compound B64:
##STR00085##
[0374] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), propyl
3-hydroxy-2,2-dimethyl-propanoate (WO 2007/053346) was reacted with
1,3-propanedisulfonyl dichloride (Example 1 (a)). Compound B64 was
obtained (7.0 g, 71% yield) as a white solid. .sup.1H NMR
(CDCl.sub.3, 500 MHz) .delta. in ppm: 4.23 (s, 4H), 4.08 (t, J=6.6
Hz, 4H), 3.35 (t, J=7.2 Hz, 4H), 2.38 (m, 2H), 1.67 (m, 4H), 1.27
(s, 12H), 0.9 (t, J=7.4 Hz, 6H).
h) Compound B65:
##STR00086##
[0376] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), cyclobutyl
3-hydroxy-2,2-dimethyl-propanoate (WO 2007/053346) was reacted with
1,3-propanedisulfonyl dichloride (Example 1 (a)). Compound B65 was
obtained (0.61 g, 44% yield) as a colorless oil. .sup.1H NMR
(CDCl.sub.3, 500 MHz) .delta. in ppm 1.26 (s, 2.times.6H),
1.59-1.69 & 1.79-1.85 (m, 2.times.(1H & 1H), 2.02-2.10 (m,
2.times.2H), 2.32-2.40 (m, 2H+(2.times.2H)), 3.34 (t, J=7.1 Hz,
2.times.2H), 4.21 (s, 2.times.2H), 4.98 (q, J=7.6 Hz,
2.times.1H).
i) Compound B66:
##STR00087##
[0378] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), isobutyl
3-hydroxy-2,2-dimethyl-propanoate (WO 2007/053346) was reacted with
1,3-propanedisulfonyl dichloride (Example 1 (a)). Compound B66 was
obtained (3.9 g, 32% yield) as a light yellow oil. .sup.1H NMR
(CDCl.sub.3, 500 MHz) .delta. in ppm 4.23 (s, 4H), 3.90 (d, J=6.6
Hz, 4H), 3.34 (t, J=7.8 Hz, 4H), 2.37 (m, 2H), 1.95 (m, 2H), 1.28
(s, 12H), 0.94 (d, J=6.8 Hz, 12H).
j) Compound B67(Bis(Hydrochloride) Salt):
##STR00088##
[0380] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), ethyl
2-(tert-butoxycarbonylamino)-3-hydroxy-2-methyl-propanoate (Yu S.
et al. (2005), Angewandte Chemie, International Edition, 44(1),
135-138) was reacted with 1,3-propanedisulfonyl dichloride (Example
1 (a)). The resulting mixture was treated with trifluoroacetic acid
in dichloromethane and with 1N aqueous hydrochloric acid to afford
compound B67(bis(hydrochloride) salt) (0.75 g, 49% yield) as a
white solid. .sup.1H NMR (D.sub.2O, 500 MHz) .delta. in ppm 1.31
(t, J=7.3 Hz, 2.times.3 H), 1.63 (s, 2.times.3 H), 2.35 (quint,
J=7.0 Hz, 2H), 3.63 (t, J=7.3 Hz, 2.times.2 H), 4.35 (q, J=7.3 Hz,
2.times.2 H), 4.53 & 4.83 (AB, J=11.3 Hz, 2.times.2 H).
k) Compound B68:
##STR00089##
[0382] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), ethyl
3-hydroxy-2,2-dimethyl-butanoate (Boyd, V. L. et al. (1987), J.
Med. Chem., 30(2), 366-374, incorporated herein by reference) was
reacted with 1,3-propanedisulfonyl dichloride (Example 1(a)).
Compound B68 was obtained (0.65 g, 54% yield) as a colorless oil.
.sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. in ppm 1.17 (s, 6H); 1.25
(s, 6H); 1.28 (t, J=7.0, 6H); 1.40 (d, J=6.5 Hz, 6H); 2.35 (m, 2H);
3.30 (t, J=7.0 Hz, 4H); 4.16 (m, 4H); 5.10 (q, J=6.5 Hz, 2H).
l) Compound B69:
##STR00090##
[0384] Step 1:
[0385] To a suspension of paraformaldehyde (0.87 g, 26.4 mmol) and
potassium carbonate (7.3 g, 52.8 mmol) in ethanol (100 mL) was
added diethylmalonate (3 mL, 17.6 mmol). The reaction mixture was
stirred at room temperature for 24 h, filtered over a pad of
Celite.TM., and the cake obtained was washed with ethanol (2*20
mL). The filtrate was concentrated in vacuo and the residue was
purified by silica gel chromatography (hexanes/ethyl acetate 90:10
to 70:30) to afford diethyl
2-(hydroxymethyl)-2-methyl-propanedioate (2.8 g, 78% yield) as a
colorless oil.
[0386] Step 2:
[0387] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(a)), the alcohol from Step 1
was reacted with 1,3-propanedisulfonyl dichloride (Example 1 (a)).
Compound B69 was obtained (2.64 g, 67% yield) as a colorless oil.
.sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. in ppm 1.28 (t, J=7.5 Hz,
12H); 1.55 (s, 6H); 2.36 (m, 2H); 3.35 (t, J=7.0 Hz, 4H); 4.23 (q,
J=7.5 Hz, 8H); 4.54 (s, 4H)
Example 19
Preparation of Compounds A62(Sodium Salt) and A63(Sodium Salt)
a) Compound A62(Sodium Salt):
##STR00091##
[0389] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(d)), diethyl ester
(2-hydroxy-1,1-dimethylethyl)-phosphonic acid, (Cann P. F. et al.
(1972), J. Chem. Soc., Perkin Transactions 2, (3), 304-311,
incorporated herein by reference) was reacted with Compound C1
(Example 13). Compound A62(sodium salt) was obtained (0.7 g, 84%
yield) as a colorless paste. .sup.1H NMR (D.sub.2O, 500 MHz)
.delta. in ppm 1.23 (s, 3H), 1.28 (s, 3H), 1.35 (t, J=7.0 Hz, 6H),
2.30 (quint, J=7.2 Hz, 2H), 3.07 (t, J=7.0 Hz, 2H), 3.58 (t, J=7.5
Hz, 2H), 4.2 (m, 4H), 4.28 (s, 1H), 4.32 (s, 1H).
b) Compound A63(Sodium Salt):
##STR00092##
[0391] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(d)),
2-methyl-2-nitro-1-propanol (Janzen, E. G. et al. (1978), J. Org.
Chem (1978), 43(10), 1900-1903, incorporated herein by reference)
was reacted with Compound C1 (Example 13). Compound A63(sodium
salt) was obtained (0.5 g, 15% yield) as a white powder. .sup.1H
NMR (D.sub.2O, 500 MHz) .delta. in ppm 1.68 (s, 6H), 2.26 (quint,
J=7.0 Hz, 2H), 3.05 (t, J=7.0 Hz, 2H), 3.59 (t, 7.0 Hz, 2H), 4.79
(s, 2H).
Example 20
Preparation of Compounds B56 and B70 to B72
a) Compound B56:
##STR00093##
[0393] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), the alcohol from Step 1
of Example 16 was reacted with 1,3-propanedisulfonyl dichloride
(Example 1 (a)). Compound B56 was obtained (0.32 g, 10% yield) as a
colorless paste. .sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. in ppm
0.97 (s, 2.times.3H), 0.98 (s, 2.times.3H), 1.11 (s, 2.times.3H),
1.67-1.73 (m, 2.times.1H), 1.83-1.89 (m, 2.times.1H), 2.00 (m,
2.times.1H), 2.08 (m, 1H), 2.47 (quint, J=7.0 Hz, 2H), 3.44 (m,
2.times.2H), 2.48 (AB, J=11.7 Hz, 2.times.2H).
b) Compound B70:
##STR00094##
[0395] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), the diethyl ester of
(2-hydroxy-1,1-dimethylethyl)-phosphonic acid (Cann P. F. et al.
(1972), J. Chem. Soc., Perkin Transactions 2, (3), 304-311) was
reacted with 1,3-propanedisulfonyl dichloride (Example 1 (a)).
Compound B70 was obtained (0.70 g, 24% yield) as a yellow oil.
.sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. in ppm 1.24 (s,
2.times.3H), 1.27 (s, 2.times.3H), 1.34 (t, J=7.2 Hz, 2.times.6H),
2.44 (quint, J=7.2 Hz, 2H), 3.39 (t, J=7.0 Hz, 2.times.2H), 4.16
(m, 2.times.4H), 4.22 (s, 2.times.1H), 4.25 (s, 2.times.1H).
c) Compound B71:
##STR00095##
[0397] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), commercial
3-hydroxy-2,2-dimethyl-propanenitrile was reacted with
1,3-propanedisulfonyl dichloride (Example 1 (a)). Compound B71 was
obtained (4.10 g, 66% yield) as a white solid. .sup.1H NMR
(CDCl.sub.3, 500 MHz) .delta. in ppm 1.45 (s, 2.times.6H), 2.53
(quint, J=7.0 Hz, 2H), 3.47 (t, J=7.0 Hz, 2.times.2H), 4.15 (s,
2.times.2H).
d) Compound B72:
##STR00096##
[0399] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)),
2-methyl-2-nitro-1-propanol (Janzen et al. (1978), J. Org. Chem.
(1978), 43(10), 1900-1903) was reacted with 1,3-propanedisulfonyl
dichloride (Example 1 (a)). Compound B72 was obtained (5.0 g, 62%
yield) as a white solid. .sup.1H NMR (CDCl.sub.3, 500 MHz) .delta.
in ppm 1.68 (s, 2.times.6H), 2.36 (quint, J=7.0 Hz, 2H), 3.36 (t,
J=7.0 Hz, 2.times.2H), 4.52 (s, 2.times.2H).
Example 21
Preparation of Compound A64
##STR00097##
[0401] Step 1:
[0402] A solution of commercial 3-amino-2,2-dimethyl-1-propanol
(1.7 g, 16.5 mmol), N-[(1,1-dimethylethoxy)carbonyl]-D-Valine,
2,5-dioxo-1-pyrrolidinyl ester (Giuntini F. et al., J. Med. Chem.
(2009), 52(13), 4026-4037, incorporated herein by reference) (4.7
g, 15.0 mmol) and 1M aqueous potassium carbonate (10 mL, 10.0 mmol)
in acetonitrile (30 mL) was stirred at room temperature for 2 h.
The mixture was concentrated to about one third of its volume,
diluted with 1M hydrochloric acid and extracted three times with
ethyl acetate. The combined organic layers were washed with water,
dried over magnesium sulfate, filtered and the filtrate evaporated
to a residue. The crude product was purified by silica gel
chromatography using hexane/ethyl acetate (50:50) to isolate 4 g
(88% yield) of tert-butyl
N-[(1S)-1-[(3-hydroxy-2,2-dimethyl-propyl)carbamoyl]-2-methyl-propyl]carb-
amate.
[0403] Step 2:
[0404] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(d)), the alcohol from Step
1 (1.7 g, 5.62 mmol) was reacted with Compound C1 (Example 13)
(1.15 g, 6.18 mmol) to give 2.6 g (89% yield) of the intermediate
sodium
3-[3-[[(2S)-2-(tert-butoxycarbonylamino)-3-methyl-butanoyl]amino]-2,2-dim-
ethyl-propoxy]sulfonylpropane-1-sulfonate.
[0405] Step 3:
[0406] The intermediate from Step 2 (2.6 g, 5.0 mmol) was stirred
for 3 h at room temperature in a mixture of trifluoroacetic acid (6
mL) and dichloromethane (10 mL). The mixture was evaporated to
dryness to afford Compound A64 (2.3 g, 90% yield) as a white solid.
.sup.1H NMR (D.sub.2O, 500 MHz) .delta. in ppm 0.99 (s, 6H), 1.02
(d, J=7.0 Hz, 3H), 1.05 (d, J=7.0 Hz, 3H), 2.22 (m, 1H), 2.28
(quint, J=7.0 Hz, 2H), 3.06 (t, J=7.0 Hz, 2H), 3.16 & 3.32 (AB,
J=14.0 Hz, 2H), 3.56 (t, J=7.3 Hz, 2H), 3.82 (d, J=5.9 Hz, 1H),
4.06 (s, 2H), 8.34 (bt, CONH not completely exchanged with
D2O).
Example 22
Preparation of Compounds A65(Sodium Salt) to A68(Sodium Salt)
a) Compound A65(Sodium Salt):
##STR00098##
[0408] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(d)), commercial
1-benzoate-2,2-dimethyl-1,3-propanediol was reacted with Compound
C1 (Example 13). Compound A65(sodium salt) was obtained (2.3 g, 59%
yield) as white solid. .sup.1H NMR (D.sub.2O, 500 MHz) .delta. in
ppm 0.99 (s, 6H), 1.02 (d, J=7.0 Hz, 3H), 1.05 (d, J=7.0 Hz, 3H),
2.22 (m, 1H), 2.28 (quint, J=7.0 Hz, 2H), 3.06 (t, J=7.0 Hz, 2H),
3.16 & 3.32 (AB, J=14.0 Hz, 2H), 3.56 (t, J=7.3 Hz, 2H), 3.82
(d, J=5.9 Hz, 1H), 4.06 (s, 2H), 8.34 (bt, CONH not completely
exchanged with D2O).
b) Compound A66(Sodium Salt):
##STR00099##
[0410] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(d)), phosphoric acid,
diethyl 3-hydroxy-2,2-dimethylpropyl ester (Ogilvie et al., J. Am.
Chem. Soc. (1977), 99(4), 1277-1278, incorporated herein by
reference) was reacted with Compound C1 (Example 13). Compound
A66(sodium salt) was obtained (1.2 g, 27% yield) as a colorless
waxy solid. .sup.1H NMR (D.sub.2O, 500 MHz) .delta. in ppm 1.03 (s,
6H), 1.33 (t, J=7.0 Hz, 6H), 2.28 (quint, J=7.0 Hz, 2H), 3.07 (t,
J=7.0 Hz, 2H), 3.59 (t, J=7.0 Hz, 2H), 3.92 (d, J=4.6 Hz, 2H), 4.16
(s, 2H), 4.20 (m, 4H).
c) Compounds A67(Sodium Salt) and A68(Sodium Salt):
##STR00100##
[0412] Step 1:
[0413] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(d)), commercial
2,2,5-trimethyl-1,3-dioxane-5-methanol (1.0 g, 6.24 mmol) was
reacted with Compound C1 (Example 13) (1.2 g, 6.44 mmol). Compound
A67(sodium salt) was obtained (0.7 g, 30% yield) as a white solid.
.sup.1H NMR (D.sub.2O, 500 MHz) .delta. in ppm 0.93 (s, 3H), 1.42
(s, 3H), 1.50 (s, 3H), 2.30 (quint, J=7.2 Hz, 2H), 3.07 (t, J=7.3
Hz, 2H), 3.59 (t, J=7.6 Hz, 2H), 3.78 (AB, J=12.5 Hz, 4H), 4.39 (s,
2H).
[0414] Step 2:
[0415] Compound A67(sodium salt) from Step 1 (0.70 g, 2.0 mmol) was
dissolved in water (3 mL) and diluted with acetic acid (7 mL). The
mixture was stirred for 10 h and the solvents were removed by
evaporation to give Compound A68(sodium salt) (0.5 g, 80% yield) as
a white solid. .sup.1H NMR (D.sub.2O, 500 MHz) .delta. in ppm 0.95
(s, 3H), 2.30 (quint, J=7.2 Hz, 2H), 3.07 (t, J=7.3 Hz, 2H), 3.50
(AB, J=12.5 Hz, 4H), 3.57 (t, J=7.6 Hz, 2H), 4.22 (s, 2H).
Example 23
Preparation of Compound B74
##STR00101##
[0417] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), commercial
1-benzoate-2,2-dimethyl-1,3-propanediol was reacted with
1,3-propanedisulfonyl dichloride (Example 1 (a)). Compound B74 was
obtained (0.71 g, 65% yield) as a colorless oil. .sup.1H NMR
(CDCl.sub.3, 500 MHz) .delta. in ppm 1.12 (s, 2.times.6H), 2.40
(quint, J=7.2 Hz, 2H), 3.32 (quint, J=7.0 Hz, 2.times.2H), 4.13 (s,
2.times.2H), 4.17 (s, 2.times.2H), 7.46 (t, J=7.8 Hz, 2.times.2H),
7.58 (t, J=7.0 Hz, 2.times.1H), 8.05 (d, J=8.5 Hz, 2.times.2H).
Example 24
Preparation of Compounds A69 and B75
a) Compound A69:
##STR00102##
[0419] Step 1:
[0420] To a solution of 3,3-dimethylglutaric anhydride (3 g, 21.1
mmol) in ethanol (30 mL) was added a 21% w/w solution of sodium
ethoxide in ethanol (5.0 mL, 23.2 mmol). After 20 h of stirring,
the solution was evaporated and the resulting solid was suspended
in diethyl ether (50 mL). The mixture was filtered and the solid
was washed with diethyl ether (2.times.20 mL). The solid was dried
under high vacuum to afford 5-ethoxy-2,2-dimethyl-5-oxo-pentanoic
acid sodium salt (2.92 g, 66% yield) as a light yellow solid.
[0421] Step 2:
[0422] To a solution of acid from Step 1 (2.92 g, 13.9 mmol) in a
mixture of THF/DMF (5:1, 60 mL) was added isopropylchloroformate
(211 mL, 20.9 mmol). After 20 h of stirring at room temperature,
the solution was cooled to 0.degree. C. and NaBH.sub.4 (1.06 g,
27.9 mmol) followed methanol (5 mL) was added to the solution.
After 30 min of stirring, a saturated aqueous solution of ammonium
chloride was added (20 mL) and followed by ethyl acetate (20 mL).
The layers were separated and the aqueous layer was extracted with
ethyl acetate (2.times.30 mL). The combined organic layers were
washed with brine, dried with magnesium sulfate, filtered and the
filtrate was concentrated in vacuo. The residue was purified by
silica gel chromatography (hexanes/ethyl acetate 95:5 to 60:40).
After evaporation at low temperature, ethyl
5-hydroxy-4,4-dimethyl-pentanoate (1.82 g, 75% yield) was obtained
as a volatile colorless oil.
[0423] Step 3:
[0424] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(d)), the alcohol from Step
2 was reacted with Compound C1 (Example 13). Compound A69 was
obtained (1.1 g, 56% yield) as a white solid. .sup.1H NMR
(D.sub.2O, 500 MHz) .delta. in ppm 0.97 (s, 6H), 1.25 (t, J=7.0 Hz,
3H), 1.67 (t, J=8.5 Hz, 2H), 2.28 (m, 2H), 2.41 (t, J=8.0 Hz, 2H),
3.07 (t, J=7.0 Hz, 2H), 3.57 (t, J=7.5 Hz, 2H), 4.06 (s, 2H), 4.14
(q, J=7.0 Hz, 2H)
b) Compound B75:
##STR00103##
[0426] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), the alcohol from Step 2
of Example 24 (a) was reacted with 1,3-propanedisulfonyl dichloride
(Example 1 (a)). Compound B75 was obtained (7.3 g, 57% yield) as a
colorless oil. .sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. in ppm
0.98 (s, 2.times.6 H), 1.26 (t, J=7.1 Hz, 2.times.3 H), 1.67 (t,
J=7.0 Hz, 2.times.2 H), 2.30 (t, J=7.0 Hz, 2.times.2 H), 2.43
(quint, J=7.0 Hz, 2H), 3.36 (t, J=7.10 Hz, 2.times.2 H), 3.93 (s,
2.times.2 H), 4.14 (q, J=7.10 Hz, 2.times.2 H).
Example 25
Preparation of Compound A70(Sodium Salt)
##STR00104##
[0428] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(d)),
diethyl(4-hydroxy-3,3-dimethyl-butyl)phosphate (WO2006/014282,
incorporated herein by reference) was reacted with Compound C1
(Example 13). Compound A70(sodium salt) was obtained (0.45 g, 26%
yield) as a colorless paste. .sup.1H NMR (D.sub.2O, 500 MHz)
.delta. in ppm 1.03 (s, 6H), 1.33 (t, J=7.0 Hz, 6H), 2.28 (quint,
J=7.0 Hz, 2H), 3.07 (t, J=7.0 Hz, 2H), 3.56 (t, J=7.0 Hz, 2H), 4.09
(s, 2H), 4.15-4.25 (m, 6H).
Example 26
Preparation of Compounds A71(Sodium Salt) to A73(Sodium Salt)
a) Compound A71(Sodium Salt):
##STR00105##
[0430] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(d)),
dihydro-3-(hydroxymethyl)-3-methyl 2(3H)-furanone (US 2009/099253,
incorporated herein by reference) was reacted with Compound C1
(Example 13). Compound A71(sodium salt) was obtained (0.42 g, 26%
yield) as a white powder. .sup.1H NMR (D.sub.2O, 500 MHz) .delta.
in ppm 1.32 (s, 3H), 2.22-2.32 (m, 3H), 2.54 (m, 1H), 3.06 (t,
J=7.3 Hz, 2H), 3.60 (dt, J=7.2 and 3.7 Hz, 2H), 4.37 & 4.46
(AB, J=10.0 Hz, 2H), 4.47 (t, J=6.0 Hz, 2H).
b) Compound A72(Sodium Salt):
##STR00106##
[0432] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(d)),
dihydro-5-(hydroxymethyl)-5-methyl-2(3H)-furanone (US 2009/099253)
was reacted with Compound C1 (Example 13). Compound A72(sodium
salt) was obtained (0.85 g, 14% yield) as a white powder. .sup.1H
NMR (D.sub.2O, 500 MHz) .delta. in ppm 1.50 (s, 3H), 2.20 (m, 1H),
2.28 (quint, J=7.3 Hz, 2H), 2.38 (m, 1H), 2.77 (t, J=7.0 Hz, 2H),
3.07 (t, J=7.0 Hz, 2H), 3.60 (t, J=7.1 Hz, 2H), 4.42 (AB, J=11.3
Hz, 2H).
c) Compound A73(Sodium Salt):
##STR00107##
[0434] Following the general procedure for the synthesis of
monoprotected sulfonic acids (Example 1(d)), commercial
(3R)-dihydro-3-hydroxy-4,4-dimethyl-2(3H)-furanone was reacted with
Compound C1 (Example 13). Compound A73(sodium salt) was obtained
(0.47 g, 28% yield) as a waxy solid. .sup.1H NMR (D.sub.2O, 500
MHz) .delta. in ppm 1.11 (s, 3H), 1.25 (s, 3H), 2.31-2.37 (m, 2H),
3.07 (t, J=7.6 Hz, 2H), 3.70 (t, J=7.6 Hz, 2H), 4.19-4.24 (m, 2H),
5.41 (s, 1H).
Example 27
Preparation of Compounds B76 to B81
a) Compound B76:
##STR00108##
[0436] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)),
dihydro-3-(hydroxymethyl)-3-methyl-2(3H)-furanone (US 2009/099253)
was reacted with 1,3-propanedisulfonyl dichloride (Example 1 (a)).
Compound B76 was obtained (11.7 g, 79% yield) as a white solid.
.sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. in ppm 1.31 (s, 6H), 2.08
(ddd, J=13.2, 7.6 and 4.0 Hz, 2H), 2.30-2.40 (m, 2H), 2.60 (dt,
J=13.2 and 8.5 Hz, 2H), 3.36 (t, J=7.1 Hz, 4H), 4.22 and 4.33 (AB,
J=10.0 Hz, 4H), 4.30 (t, J=8.5 Hz, 2H), 4.40 (m, 2H).
b) Compound B77:
##STR00109##
[0438] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), commercial
(3R)-dihydro-3-hydroxy-4,4-dimethyl-2(3H)-furanone was reacted with
1,3-propanedisulfonyl dichloride (Example 1 (a)). Compound B77 was
obtained (9.3 g, 70% yield) as a white solid. .sup.1H NMR
(D.sub.2O, 500 MHz) .delta. in ppm 5.01 (s, 2H), 4.11 (d, J=9.0 Hz,
2H), 4.05 (d, J=9.0 Hz, 2H), 3.58-3.72 (10-peaks, 4H), 2.62 (pent,
2H), 1.29 (s, 6H), 1.18 (s, 6H).
c) Compound B78:
##STR00110##
[0440] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)),
dihydro-5-(hydroxymethyl)-5-methyl-2(3H)-furanone (US 2009/099253)
was reacted with 1,3-propanedisulfonyl dichloride (Example 1 (a)).
Compound B78 was obtained (1.1 g, 57% yield) as a colorless oil.
.sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. in ppm 1.48 (s,
2.times.3H), 2.03-2.10 (m, 2H), 2.32-2.44 (m, 2.times.2H),
2.61-2.75 (m, 2.times.2H), 3.40 (m, 2.times.2H), 4.26 (m,
2.times.2H).
d) Compound B79:
##STR00111##
[0442] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), commercial
dihydro-3-hydroxy-4,4-dimethyl-2(3H)-furanone was reacted with
1,3-propanedisulfonyl dichloride (Example 1 (a)). Compound B79 was
obtained (1.34 g, 63% yield) as a white solid. .sup.1H NMR
(CDCl.sub.3, 500 MHz) .delta. in ppm 1.18 (s, OH) & 1.29 (s,
6H), 2.57-2.69 (m, 2H), 3.59-3.72 (m, 4H), 4.05 (d, J=9 Hz, 2H)
& 4.11 (d, J=9 Hz, 2H), 5.00 (s, 1H) & 5.02 (s, 1H).
e) Compound B80:
##STR00112##
[0444] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), commercial
(3S)-dihydro-3-hydroxy-4,4-dimethyl-2(3H)-furanone was reacted with
1,3-propanedisulfonyl dichloride (Example 1(a)). Compound B80 was
obtained (1.70 g, 80% yield) as a white solid. .sup.1H NMR
(CDCl.sub.3, 500 MHz) .delta. in ppm 1.18 (s, 6H) & 1.29 (s,
6H), 2.60-2.65 (m, 2H), 3.59-3.64 (m, 2H) & 3.66-3.72 (m, 2H),
4.05 (d, J=9 Hz, 2H) & 4.11 (d, J=9 Hz, 2H), 5.00 (s, 2H).
f) Compound B81:
##STR00113##
[0446] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), commercial tetronic acid
was reacted with 1,3-propanedisulfonyl dichloride (Example 1 (a)).
Compound B81 was obtained (0.85 g, 56% yield) as a white solid.
.sup.1H NMR (DMSO, 500 MHz) & in ppm 2.34 (m, 2H), 3.99 (t,
J=7.5 Hz, 4H), 5.00 (s, 4H), 6.05 (t, J=1.5 Hz, 2H).
Example 28
Preparation of Compound P1(Disodium Salt)
##STR00114##
[0448] Step 1:
[0449] To a solution of 1,3-propanthiol (1 mL, 10 mmol) and
acrylonitrile (2 mL, 30 mmol) was added Triton B (0.1 mL). The
mixture was then warmed up to rt and stirred at this temperature
for 20 h. The mixture was concentrated in vacuo and the residue was
purified by silica gel chromatography (hexanes/ethyl acetate 80:20
to 0:100) to afford
3-[3-(2-cyanoethylsulfanyl)propylsulfanyl]propanenitrile (2.14 g,
100% yield) as a colorless oil.
[0450] Step 2:
[0451] To a solution of disulfide from Step 1 (0.5 g, 2.34 mmol) in
water (10 mL) was added a 32% solution of peracetic acid in acetic
acid (3.3 mL, 14.0 mmol). After 4 h at room temperature, the formed
solid was filtered and washed with water (2.times.10 mL) and
ethanol (2.times.10 mL). The cake was dried under high vacuum to
afford 3-[3-(2-cyanoethylsulfonyl) propylsulfonyl]-propanenitrile
(0.62 g, 95% yield) as a white solid.
[0452] Step 3:
[0453] To a suspension of disulfone from Step 2 (0.62 g, 2.23 mmol)
in methanol (15 mL) was added a 0.5M solution of sodium methoxide
in methanol (8.9 mL, 4.58 mmol). After 24 h of stirring, the
homogenous solution was concentrated in vacuo and the resulting
solid was suspended in ethanol (20 mL) and the suspension was
stirred 1 h at room temperature. The suspension was filtered and
the cake washed with ethanol (2.times.10 mL) and diethyl ether
(2.times.10 mL). Water (2 mL) was added to the solid and the
mixture passed through a C8 pad eluting with water. The fractions
containing Compound P1(disodium salt) were collected and
lyophilized, affording Compound P1(disodium salt) (0.41 g, 85%
yield) as a white solid. .sup.1H NMR (D.sub.2O, 500 MHz) .delta. in
ppm 1.84 (quint, J=8.0 Hz, 2H), 2.44 (t, J=8.0 Hz, 4H).
Example 29
Preparation of Compounds B11 and B12
a) Compound B11:
##STR00115##
[0455] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), commercial pyridin-2-ol
was reacted with 1,3-propanedisulfonyl dichloride (Example 1 (a)).
Compound B11 was obtained (0.59 g, 82% yield) as a colorless oil.
.sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. in ppm: 2/9 (q, J=7.5 Hz,
2H), 3.98 (t, J=7.5 Hz, 4H), 7.15 (c, J=8.0 Hz, 2H), 7.30 (dd,
J=5.0, 7.5 Hz, 2H), 7.84 (td, J=8.0, 2.0 Hz, 2H), 8.34 (dd, J=2.0,
5.0 Hz, 2H).
b) Compound B12:
##STR00116##
[0457] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(a)), pyridin-3-ol was reacted
with 1,3-propanedisulfonyl dichloride (Example 1 (a)). Compound B12
was obtained (0.61 g, 67% yield) as a colorless oil. .sup.1H NMR
(DMSO, 500 MHz) .delta. in ppm 8.64 (d, J=2.7 Hz, 2H), 8.62 (dd,
J=1.2, 4.6 Hz, 2H), 7.87 (ddd, J=1.2, 2.8, 8.5 Hz, 2H), 7.58 (dd,
J=4.6, 8.5 Hz, 2H), 3.85 (t, J=7.5 Hz, 4H), 2.49-2.40 (m, 2H).
Example 30
Preparation of Compounds B82 to B87
a) Compound B82:
##STR00117##
[0459] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), ethyl
2-hydroxy-3,3-dimethyl-butanoate (Wang et al. (2006), Synlett
2006(8), 1169-1172, incorporated herein by reference) was reacted
with 1,3-propanedisulfonyl dichloride (Example 1 (a)). Compound B82
was obtained (2.0 g, 82% yield) as a colorless oil. .sup.1H NMR
(CDCl.sub.3, 500 MHz) .delta. in ppm 1.06 (s, 2.times.9H), 1.32 (t,
J=7.0 Hz, 2.times.3H), 2.53 (quint, J=7.0 Hz, 2H), 3.44 (t, J=7.0
Hz, 2.times.2H), 4.27 (m, 2.times.2H), 4.66 (s, 2.times.1H).
b) Compound B83:
##STR00118##
[0461] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), ethyl
2-hydroxy-3-methyl-butanoate (Anand et al. (1994), Syn. Comm.,
24(19), 2743-2747, incorporated herein by reference) was reacted
with 1,3-propanedisulfonyl dichloride (Example 1 (a)). Compound B83
was obtained (0.85 g, 73% yield) as a colorless oil. .sup.1H NMR
(CDCl.sub.3, 500 MHz) .delta. in ppm 0.97 (d, J=6.8 Hz,
2.times.3H), 1.08 (d, J=7.0 Hz, 2.times.3H), 1.30 (t, J=7.0 Hz,
2.times.3H), 2.33 (m, 2H), 2.57 (m, 2.times.1H), 3.49 (m,
2.times.2H), 4.27 (q, J=7.0 Hz, 2.times.2H), 4.88 (d, J=4.0 Hz,
2.times.1H).
c) Compound B84:
##STR00119##
[0463] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)),
2-hydroxy-3,3-dimethyl-butanenitrile was reacted with
1,3-propanedisulfonyl dichloride (Example 1 (a)). Compound B84 was
obtained (4.4 g, 56% yield) as a white solid. .sup.1H NMR
(CDCl.sub.3, 500 MHz) .delta. in ppm 1.15 (s, 2.times.9H), 2.55
(quint, J=7.0 Hz, 2H), 3.52 (t, J=7.0 Hz, 2.times.2H), 4.86 (s,
2.times.1H).
d) Compound B85:
##STR00120##
[0465] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)),
ethyl(2S)-2-hydroxy-3-methyl-butanoate (WO2008/087560, incorporated
herein by reference) was reacted with 1,3-propanedisulfonyl
dichloride (Example 1 (a)). Compound B85 was obtained (8.2 g, 71%
yield) as a white solid. .sup.1H NMR (CDCl.sub.3, 500 MHz) .delta.
in ppm: 0.97 (d, J=6.8 Hz, 2.times.3H) & 1.08 (d, J=6.8 Hz,
2.times.3H), 1.31 (t, J=7.1 Hz, 2.times.3H), 2.30-2.36 (m, 2H),
2.54-2.60 (m, 2.times.1H), 3.46-3.52 (m, 2.times.2H), 4.23-4.30 (m,
2.times.2H), 4.89 (d, J=3.9 Hz, 2.times.1H).
e) Compound B86:
##STR00121##
[0467] Compound B77 (8.6 g; Example 27 (b)) was dissolved in 2M
ammonia in ethanol (150 mL). The solution was stirred at room
temperature for 48 h. The solvent was removed under vacuum and the
residual material was washed with hexanes (2.times.100 mL) to give
the crude product (5 g) which was recrystallized from methanol.
After overnight standing at room temperature, the solid was
filtered and washed with cold methanol to afford Compound B86 (2.4
g, 25% yield) as a white solid. .sup.1H NMR (DMSO, 500 MHz) .delta.
in ppm 0.89 (s, 6H), 0.91 (s, 6H), 2.21 (m, 2H), 3.20 (m, 2H), 3.26
(m, 2H), 3.47 (t, J=7.5 Hz, 4H), 4.69 (s, 2H), 4.83 (t, J=4.5 Hz,
2H), 7.43 (brs, 2H), 7.58 (brs, 2H).
f) Compound B87:
##STR00122##
[0469] Following the general procedure for the synthesis of
diprotected sulfonic acids (Example 1(e)), ethyl
2-hydroxy-2-methyl-propanoate was reacted with
1,3-propanedisulfonyl dichloride (Example 1(a)). Compound B87 was
obtained (0.85 g, 53% yield) as a colorless oil. .sup.1H NMR
(CDCl.sub.3, 500 MHz) .delta. in ppm 1.32 (t, J=7.0 Hz,
2.times.3H), 1.73 (s, 2.times.6H), 2.50 (quint, J=7.0 Hz, 2H), 3.46
(t, J=7.0 Hz, 2.times.2H), 4.27 (q, J=7.0 Hz, 2.times.2H).
Example 31
General Synthetic Protocol for the Synthesis of Oxomethyl
Disulfonate Esters
a) 1,3-Propanedisulfonic Acid Disilver Salt:
##STR00123##
[0471] To a solution of 1,3PDS (109 g, 534 mmol) in H.sub.2O (500
mL) was added silver carbonate (162 g, 587 mmol) in portion over 30
min. After 30 min at room temperature, the solution was filtered
over a pad of Celite.TM. and the cake was washed once with water
(100 mL). After evaporation of the solution on the rotavap, the
solid was suspended in ethanol (500 mL) and the resulting mixture
was stirred for 30 min at room temperature and filtered. The cake
was washed twice with ethanol (2.times.150 mL) and dried under
vacuum at 40.degree. C. to afford 1,3-propanedisulfonic acid
disilver salt (1,3PDS(2Ag)) (198 g, 89% yield) as a white
solid.
b) 1,3-Propanedisulfonic Acid Oxomethyl Diesters:
##STR00124##
[0473] To a suspension of 1,3-propanedisulfonic acid disilver salt
from Step (a) in acetonitrile is added the selected
chloromethylacetate (5 eq). The mixture is heated for 24 h at
60.degree. C. before being cooled down to room temperature and
filtered over a pad of Celite.TM.. The cake is then washed with
acetonitrile and the filtrate is evaporated on the rotavap. The
residue is purified by silica gel chromatography to afford the
corresponding 1,3-propanedisulfonic acid oxomethyl diester.
Example 32
Preparation of Compounds D1 to D8
a) Compound D1:
##STR00125##
[0475] Following the general procedure for the synthesis of
oxomethyl disulfonate esters (Example 31 (b)), commercial
chloromethylpivaloate was reacted with 1,3-propanedisulfonic acid
disilver salt (Example 31 (a)). Compound D1 was obtained (18.3 g,
81% yield) as a white solid. .sup.1H NMR (CDCl.sub.3, 500 MHz)
.delta. in ppm 1.25 (s, 18H), 2.42 (quint, 7.0 Hz, 2H), 3.41 (t,
J=7.0 Hz, 4H), 5.81 (s, 4H).
b) Compound D2:
##STR00126##
[0477] Following the general procedure for the synthesis of
oxomethyl disulfonate esters (Example 31 (b)), commercial
chloromethylbenzoate was reacted with 1,3-propanedisulfonic acid
disilver salt (Example 31 (a)). Compound D2 was obtained (0.40 g,
71% yield) as a white solid. .sup.1H NMR (CDCl.sub.3, 500 MHz)
.delta. in ppm 2.40 (quint, 7.0 Hz, 2H), 3.40 (t, J=7.0 Hz, 4H),
6.02 (s, 4H), 7.49 (dt, J=8.0, 1.5 Hz, 4H), 7.64 (tt, J=9.0, 1.5
Hz, 2H), 8.08 (td, 8.5, 1.5 Hz, 4H).
c) Compound D3:
##STR00127##
[0479] Following the general procedure for the synthesis of
oxomethyl disulfonate esters (Example 31 (b)),
chloromethylbutanoate (Baudy et al. (2009), J. Med. Chem. 52(3),
771-778, incorporated herein by reference) was reacted with
1,3-propanedisulfonic acid disilver salt (Example 31 (a)). Compound
D3 was obtained (10.8 g, 76% yield) as colorless oil. .sup.1H NMR
(CDCl.sub.3, 500 MHz) .delta. in ppm 0.98 (t, J=7.5 Hz, 6H), 1.70
(m, 4H), 2.42 (m, 6H), 3.41 (t, J=7.0 Hz, 4H), 5.81 (s, 4H).
d) Compound D4:
##STR00128##
[0481] Following the general procedure for the synthesis of
oxomethyl disulfonate esters (Example 31 (b)), commercial
chloromethylisopropylcarbonate was reacted with
1,3-propanedisulfonic acid disilver salt (Example 31 (a)). Compound
D4 was obtained (0.98 g, 95% yield) as a colorless oil. .sup.1H NMR
(CDCl.sub.3, 500 MHz) .delta. in ppm 1.35 (d, J=6.5 Hz, 12H), 2.43
(quint, J=7.0 Hz, 2H), 3.43 (t, J=7.0 Hz, 4H), 4.97 (m, 2H), 5.81
(s, 4H).
e) Compound D5:
##STR00129##
[0483] Following the general procedure for the synthesis of
oxomethyl disulfonate esters (Example 31 (b)),
chloromethylcyclohexanecarboxylate (Baudy et al. (2009), J. Med.
Chem. 52(3), 771-778) was reacted with 1,3-propanedisulfonic acid
disilver salt (Example 31 (a)). Compound D5 was obtained (25.0 g,
72% yield) as a white solid. .sup.1H NMR (CDCl.sub.3, 500 MHz)
.delta. in ppm 1.23-1.35 (m, 6H), 1.46 (m, 4H), 1.66 (m, 2H), 1.77
(m, 4H), 1.94 (m, 4H), 2.41 (m, 4H), 3.40 (t, J=7.5 Hz, 4H), 5.81
(s, 4H).
f) Compound D6:
##STR00130##
[0485] Following the general procedure for the synthesis of
oxomethyl disulfonate esters (Example 31 (b)),
chloromethyl2,2-dimethylbutenoate (Baudy at al. (2009), J. Med.
Chem. 52(3), 771-778) was reacted with 1,3-propanedisulfonic acid
disilver salt (Example 31 (a)). Compound D6 was obtained (2.0 g,
66% yield) as a colorless oil. .sup.1H NMR (CDCl.sub.3, 500 MHz)
.delta. in ppm 0.86 (t, J=7.5 Hz, 6H); 1.21 (s, 12H); 1.61 (q,
J=7.5 Hz, 4H); 2.42 (quint, J=7.0 Hz, 2H); 3.41 (t, J=7.0 Hz, 4H);
5.81 (s, 4H).
g) Compound D7:
##STR00131##
[0487] Following the general procedure for the synthesis of
oxomethyl disulfonate esters (Example 31 (b)),
chloromethylpropanoate (Baudy et al. (2009), J. Med. Chem. 52(3),
771-778) was reacted with 1,3-propanedisulfonic acid disilver salt
(Example 31 (a)). Compound D7 was obtained (13.2 g, 66% yield) as a
white solid. .sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. in ppm 1.91
(t, J=7.5 Hz, 6H); 2.42 (quint, J=7.0 Hz, 2H); 2.47 (q, J=7.5 Hz,
4H); 3.41 (t, J=7.0 Hz, 4H); 5.82 (s, 4H).
h) Compound D8:
##STR00132##
[0489] Following the general procedure for the synthesis of
oxomethyl disulfonate esters (Example 31 (b)),
chloromethylpentanoate (Baudy et al. (2009), J. Med. Chem. 52(3),
771-778) was reacted with 1,3-propanedisulfonic acid disilver salt
(Example 31 (a)). Compound D8 was obtained (1.8 g, 57% yield) as a
white solid. .sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. in ppm 0.93
(t, J=7.5 Hz, 6H); 1.37 (m, 4H); 1.65 (quint, J=7.0 Hz, 4H);
2.39-2.45 (m, 6H); 3.41 (t, J=7.0 Hz, 4H); 5.81 (s, 4H).
Example 33
Preparation of Compound C2
##STR00133##
[0491] To a refluxing suspension of 1,3-propanedisulfonic acid
disilver salt (Example 31 (a)) (60 g, 140 mmol) in acetonitrile (1
L) was added a solution of diiodomethane (17 mL, 210 mmol) in
acetonitrile (20 mL) over 15 h (syringe pump). After the addition
was completed, the mixture was refluxed for an additional 24 h,
cooled down to room temperature and filtered over a pad of
Celite.TM.. The cake was washed with acetonitrile (2*100 mL) and
the filtrate was concentrated in vacuo to about 150 mL. To this
solution, 40 g of silica gel was added and the mixture was
evaporated to dryness. The residue was loaded on a silica gel
column and eluted with hexanes/ethyl acetate 80:20 to 50:50 to
afford Compound C2 (22.6 g, 73% yield) as a white solid. .sup.1H
NMR (CDCl.sub.3, 500 MHz) .delta. in ppm 2.54 (m, 2H), 3.60 (t,
J=6.0 Hz, 4H), 5.80 (s, 2H).
Example 34
Preparation of Compound C3
##STR00134##
[0493] To a solution of commercial diethyl
2,2-bis(hydroxymethyl)propanedioate (0.91 g, 4.15 mmol) and
pyridine (1.7 mL, 20.7 mmol) in dichloromethane (200 mL) was added
1,3-propanedisulfonyl dichloride (Example 1 (a)) (1 g, 4.15 mmol).
The solution was refluxed for 3 days and concentrated in vacuo. The
residue was purified by silica gel chromatography (hexanes/ethyl
acetate 90:010 to 50:50) to afford Compound C3 (0.32 g, 20% yield)
as a white solid. .sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. in ppm
1.31 (t, J=7.0 Hz, 6H), 2.46 (m, 2H), 3.45 (m, 4H), 4.30 (q, J=7.0
Hz, 4H), 4.66 (s, 4H).
Example 35
General Synthetic Protocol for the Synthesis of Disulfonamides
##STR00135##
[0495] 1,3-Propanedisulfonyl dichloride (Example 1(a)) (20 mmol) is
added to a stirred solution of selected amine (40 mmol)) in a
mixture of pyridine (10 mL) and dichloromethane (50 mL). The
reaction mixture is stirred at room temperature for 15 h and then
concentrated in vacuo. The residual material is purified by silica
gel chromatography using a mixture of dichloromethane/methanol as
eluant to yield the corresponding disulfonamide.
Example 36
Preparation of Compounds N12 and N14
a) Compound N12:
##STR00136##
[0497] Following the general procedure for the synthesis of
disulfonamides (Example 35), commercial 3,5-dimethylpyrazole was
reacted with 1,3-propanedisulfonyl dichloride (Example 1 (a)).
Compound N12 was obtained (0.73 g, 68% yield) as a white solid.
.sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. ppm 5.98 (s, 2H), 3.54
(t, J=7.0 Hz, 4H), 2.47 (s, 6H), 2.25 (s, 6H), 2.15 (q, J=7.0 Hz,
2H).
b) Compound N14:
##STR00137##
[0499] Following the general procedure for the synthesis of
disulfonamides (Example 35), commercial imidazole was reacted with
1,3-propanedisulfonyl dichloride (Example 1 (a)). Compound N14 was
obtained (0.45 g, 53% yield) as a beige solid. .sup.1H NMR (DMSO,
500 MHz) .delta. ppm 8.18 (s, 2H), 7.64 (s, 2H), 7.16 (s, 2H), 3.83
(t, J=7.5 Hz, 4H), 1.78 (q, J=7.5 Hz, 2H).
Example 37
Preparation of Compounds N15 and N16
##STR00138##
[0501] Step 1:
[0502] Following the general procedure for the synthesis of
disulfonamides (Example 35), commercial ethyl ester L-phenylalanine
hydrochloride (1.8 g, 8.0 mmol) was reacted with
1,3-propanedisulfonyl dichloride (Example 1 (a)) (0.964 g, 4.0
mmol). Compound N15 was obtained (0.6 g, 28% yield) as an oil.
.sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. in ppm 1.25 (t, J=7.0 Hz,
6H), 2.04 (m, 2H), 2.73 (m, 2H), 2.91 (m, 2H), 3.04 & 3.14
(ABX, J=14.0 & 5.7 Hz, 4H), 4.18 (m, 4H), 4.34 (m, 2H), 5.07
(d, J=9.3 Hz, 2H), 7.17-7.32 (m, 10H).
[0503] Step 2:
[0504] To a solution of Compound N15 from Step 1 (0.60 g, 1.1 mmol)
in ethanol (10 mL) was added 6N aqueous hydrochloric acid (20 mL)
and the mixture was stirred under reflux for 4 h. The mixture was
cooled, evaporated to dryness and diluted in a 95:5 mixture of
dichloromethane/methanol for purification by silica gel
chromatography. Elution with a mixture of ethyl acetate/acetic acid
(97:3) permitted to isolate Compound N16 (0.31 g, 57% yield) as a
white solid. .sup.1H NMR (DMSO, 500 MHz) .delta. in ppm 1.64
(quint, J=7.0 Hz, 2H), 2.47 (m, 2H), 2.60 (m, 2H), 2.78 (dd, J=13.5
& 9.5 Hz, 2H), 3.05 (dd, 13.5 & 5.5 Hz, 2H), 3.98 (m, 2H),
7.20-7.32 (m, 10H), 7.80 (d, J=9.0 Hz, 2H), 13.00 (bs, 2H).
Example 38
Preparation of Compounds N17 and N18(Bis(Trifluoroacetate)Salt)
##STR00139##
[0506] Step 1:
[0507] To a stirred solution of 1,3-propanedisulfonyl dichloride
(Example 1 (a)) (1.5 g, 6.2 mmol) in tetrahydrofuran (30 mL) was
added 28% ammonium hydroxide (6 mL). The reaction was exothermic
and was stirred for an additional hour at room temperature. The
mixture was concentrated under vacuum, dissolved in a minimum
amount of water/methanol, mixed with silica gel and evaporated to
dryness. The silica gel support was applied on top of column for
silica gel chromatography using as eluent a mixture of
dichloromethane/methanol (70:30) to afford Compound N17 (0.30 g,
24% yield) as a white powder. .sup.1H NMR (D.sub.2O, 500 MHz)
.delta. in ppm 2.19 (quint, J=7.0 Hz, 2H), 3.28 (t, J=7.0 Hz,
4H).
[0508] Step 2:
[0509] To a solution of Compound N17 from Step 1 (0.303 g, 1.5
mmol) in DMF (20 mL) were added commercial
N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanine,
2,5-dioxo-1-pyrrolidinyl ester (1.2 g, 3.3 mmol) and DBU (0.49 mL,
3.3 mmol). The mixture was stirred for 15 h, diluted with ethyl
acetate and 1N HCl, and extracted three times with ethyl acetate.
The combined organic layers were washed with water, dried over
magnesium sulfate, filtered and filtrate concentrated in vacuo. The
residue was purified by silica gel chromatography using
hexanes/ethyl acetate (50:50) to isolate the desired tert-butyl
N-[1-benzyl-2-[3-[[2-(tert-butoxycarbonylamino)-3-phenyl-propanoyl]sulfam-
oyl]propylsulfonylamino]-2-oxo-ethyl]carbamate (0.9 g, 87%
yield).
[0510] Step 3:
[0511] To a solution of intermediate from Step 2 (0.90 g, 1.3 mmol)
in dichloromethane (10 mL) was added trifluoroacetic acid (5 mL).
The mixture was stirred at room temperature for 5 h and
concentrated to dryness. Trituration using an ether/hexanes mixture
allowed to isolate Compound N18(bis(trifluoroacetate)salt) (0.68,
72% yield) as a white solid. .sup.1H NMR (D.sub.2O, 500 MHz)
.delta. in ppm 2.01 (quint, J=7.0 Hz, 2H), 3.06 & 3.15 (ABX,
J=14.0 & 7.0 Hz, 4H), 3.29-3.42 (m, 4H), 4.07 (t, J=7.0 Hz,
2H), 7.15-7.30 (m, 10H).
Example 39
In Vitro Stability of the Compounds of the Invention
a) Water and Simulated Gastric Fluid Stability
[0512] The objective of this test was to determine the stability of
the prodrugs in simulated gastric fluid (SGF) and water at
37.degree. C. up to 2 hours and in water at room temperature up to
24 hours. The stability was performed as indicated in Table 1.
TABLE-US-00002 TABLE 1 Temperatures and Sampling Summary
Time-Points dH.sub.2O at room (hours) SGF at 37.degree. C.
dH.sub.2O at 37.degree. C. temperature 0 Yes No Yes 1 Yes Yes No 2
Yes Yes No 24 No No Yes
[0513] Simulated gastric fluid and water samples were incubated in
a shaking water bath at 37.degree. C. for up to 2 hours. The
compound (prodrug) was added at Time-point 0. At each selected time
point (refer to table), sample aliquots were withdrawn and analyzed
to determine the concentration of 1,3-propanedisulfonic acid
(1,3PDS). The concentrations of 1,3PDS were calculated based on
their respective peak area. The % appearance of 1,3PDS was
determined by the amounts of compound determined at each time point
compared to nominal concentration (100%) of 1,3PDS generated by
100% of the prodrug (equivalent concentration).
i) Simulated Gastric Fluid Preparation:
[0514] Amounts of 0.2 g of sodium chloride and 0.32 g of pepsin
were weighted and transferred into a 100-mL volumetric flask.
Approximately 50 mL of deionized water was added and the mixture
well mixed. A volume of 700 .mu.L of hydrochloric acid was added,
and the volume completed to 100 mL with deionized water. The
resulting mixture was transferred in a polypropylene bottle and pH
measured (pH=1.5).
ii) Sample Preparation:
[0515] A fresh stock solution at approximately 2 mg/mL of the
compound was prepared. One stability solution at 200 .mu.g/mL in
the SGF was prepared (sample referred to as Tube A). A stability
solution at 200 .mu.g/mL in deionized water was prepared (sample
referred to as Tube B). Immediately after preparation, each 200
.mu.g/mL solution was diluted in triplicates to 20 .mu.g/mL in
deionized water and analyzed using LC-MS/MS method (Time-point 0).
Thereafter, the incubation of tubes A and B was continued in the
shaking water bath at 37.degree. C. for 1 and 2 hours while one
aliquot of tube B was kept at room temperature for 24 hours. At
each specific time point of incubation, 3 aliquots (triplicate) of
50 .mu.L were removed, diluted in 450 .mu.L of water and analyzed
using LC-MS/MS method. In parallel, 3 reference samples of 1,3PDS
at 100, 10 and 1 .mu.g/mL were prepared, diluted in triplicate in
water and injected at the beginning and at the end of the batch.
These samples were considered as reference samples.
iii) Evaluation:
[0516] The concentrations of 1,3PDS were calculated based on
response of the reference samples and their respective peak area
response. The % appearance of 1,3PDS was determined by the amounts
of compound determined at each time point compared to expected
nominal concentration (100%) of 1,3PDS generated by 100% of the
prodrug (equivalent concentration). The results of water stability
are presented in Table 2 and simulated gastric fluid are presented
in Table 3.
TABLE-US-00003 TABLE 2 Water Stability Results Conversion to 1,3PDS
(%) ID No 0 h 1 h 2 h 24 h A6(Na) 0.4 1.0 1.6 1.4 A13 0.0 0.0 0.0
0.0 A14 0.2 0.4 1.4 -- A18(Na) 12.8 23.0 28.4 15.8 A26(Na) 3.1 5.9
8.6 10.0 A32(Na) 0.0 0.1 0.1 0.0 A51 13 14 18 -- A52(K) 7.0 14.6
18.8 21.3 B13 0.3 0.4 0.4 -- B14 0.0 0.0 0.0 -- B23 0.0 0.0 0.0 0.0
B30 0.0 0.0 0.0 0.0 C1 50.3 57.3 63.1 61.2
TABLE-US-00004 TABLE 3 Simulated Gastric Fluid Stability Results
Conversion to 1,3PDS (%) ID No 0 h 1 h 2 h A6(Na) 0.3 1.0 1.6 A13
0.0 0.0 0.0 A14 0.2 0.3 0.4 A18(Na) 2.2 3.8 4.8 A26(Na) 2.7 5.8 8.4
A32(Na) 0.0 0.0 0.0 A51 11 11 13 A52(K) 6.2 13.1 15.9 B13 0.1 0.2
0.2 B14 0.0 0.0 0.0 B23 0.0 0.0 0.0 B30 0.0 0.0 0.0 C1 51.2 59.8
65.9
b) Whole Blood Stability:
[0517] The objective of this test was to determine the stability of
the prodrugs in fresh human whole blood at different time-points
(0, 0.5, 1, 4, 24 hours). Blood samples were incubated in a shaking
water bath at 37.degree. C. for up to 24 hours. The compound
(prodrug) was added at Time-point 0, and sample aliquots were
withdrawn and analyzed at each time point to determine the
concentration of 1,3PDS. If possible, the loss of compound was
determined by the amounts of compound determined at each time point
compared to the amount determined at Time-point 0. To eliminate the
conversion due to the matrix, a special Time-point 0 was prepared
in pre-extracted blood sample.
i) Sample Preparation:
[0518] Approximately 2.5 mL of whole blood was incubated in a
gently shaking water bath at 37.degree. C. for 15 minutes. Two (2)
mL of the pre-incubated whole blood were aliquoted in an eppendorf
tube. A 100 .mu.L aliquot of blood was removed and 100 .mu.L of the
compound Stock Solution was added. The solution was mixed by
inversion. This sample was referred to as Tube A. The final
concentration of the compound in tube A was approximately at 100
.mu.g/mL. Immediately after mixing, 100 .mu.L of Tube A was
aliquotted into 3 different eppendorf tubes. These samples were
extracted as described in the "Extraction Procedure" Section. These
samples were referred to Time-point 0. Thereafter, the incubation
of Tube A was continued in the shaking water bath at 37.degree. C.
for 0.5, 1, 4 and 24 hours. At each specific time point of
incubation, aliquots (triplicate) of 100 .mu.L were removed and
extracted as described in the "Extraction Procedure" Section. To
avoid potential further degradation of compound and/or possible
degradation products, the aliquot extracts were kept on ice until
analysis. After extraction, samples were analyzed using LC-MS/MS
method.
ii) Extraction Procedure:
[0519] A volume of 300 .mu.L of cold-ice acetonitrile was added to
a 1.5 mL eppendorf tube and kept on ice until utilization. 100
.mu.L of the sample to be extracted was added and the mix was
vortexed (acetonitrile and blood). The sample was centrifuged at
16250.times.g (13200 rpm on IEC centrifuge with eppendorf rotor)
for 5 minutes. A volume of 250 .mu.L of the supernatant was
transferred to another tube and evaporated to dryness under a
nitrogen stream. The residue was reconstituted with the mobile
phase. This sample was then analyzed according to 1,3PDS specific
methods.
iii) Evaluation:
[0520] The concentrations of 1,3PDS were calculated based on the
nominal concentration of the calibration standards and their
respective peak area ratio. A linear regression using a weight of
1/x.sup.2 is used to derive the concentration of 1,3PDS. The %
appearance of 1,3PDS was determined by the amounts of compound
determined at each time point compared to nominal concentration
(100%) of 1,3PDS generated by 100% of the prodrug (equivalent
concentration). The results obtained are summarized in Table 4
below.
TABLE-US-00005 TABLE 4 Human Whole Blood Stability Results
Conversion to 1,3PDS (% by molar ratio) ID No 0 h 0.5 h 1 h 4 h 24
h A6(Na) 0.5 0.7 0.8 1.2 4.7 A13 12.8 44.0 47.8 61.7 62.3 A14 1.6
2.5 3.0 5.8 23.3 A18(Na) 9.5 16.4 18.3 39.8 71.9 A26(Na) 11.1 12.2
14.5 14.5 31.6 A32(Na) 0.1 0.1 0.2 0.4 2.0 A51 23.7 21.8 26.5 34.4
63.6 A52(K) 21.7 24.4 29.0 32.8 55.6 B13 5.5 106.1 91.1 67.0 73.2
B14 0.1 5.0 17.0 44.9 55.1 B23 1.2 103.4 98.5 59.0 66.5 B30 BLLQ
0.1 0.2 2.0 15.0 C1 AULQ AULQ AULQ AULQ AULQ BLLQ: Below lower
limit of quantitation AULQ: Above upper limit of quantitation
[0521] In summary, the stability results showed that the compounds
act as prodrugs and liberate 1,3PDS either in gastric fluid or in
whole blood. In fact most of them were found to be cleaved in whole
blood to a greater extent than in gastric fluid or water, even some
released 1,3PDS only in whole blood while being relatively stable
in water and simulated gastric fluids.
Example 40
Preparation of Dosing Formulation
a) Dosing Vehicle for Formulation:
[0522] Double processed tissue culture water (Sigma, W3500) was
used for all the formulation prepared in water. The vehicle 0.5%
Methocel.TM. (Methocel.TM. K4M, Dow Chemical, #002891) in water
(double processed tissue culture water) used for preparation of all
Methocel.TM. formulations was prepared according to literature
procedures. The 2% benzyl alcohol in corn oil was prepared by
adding benzyl alcohol to corn oil according to proportions, which
was used for the preparation of oil formulation of prodrugs.
b) Dosing Formulation Concentration:
[0523] For 1,3PDS(2Na), the concentration in the dosing formulation
was standardized to such a level that the dose would be 100 mg/kg
(or 0.4 mmol/kg) for in vivo protocol specified dosing volume in a
particular animal species. For a prodrug, the weight of sample in
the dosing formulation varied based on molecular weight in such a
way that equimolar dose (0.4 mmol/kg) for all the prodrugs would be
administered when given same volume of dosing formulation to the
animals. The dosing volume used for was 10 mL/kg for rats and
monkeys, and 5 mL/kg for ferrets; or the concentration of dosing
formulation was 0.04 mmol/mL for rats and monkeys, and 0.08
mmole/mL for ferrets. The vehicles used can either be water, 0.5%
Methocel.TM. in water or 2% benzyl alcohol in corn oil. The dosing
solution can either be a solution, a suspension or an emulsion. For
different levels of doses, the amounts of the compounds used in the
dosing formulation preparation were adjusted accordingly.
c) Dosing Formulation Preparation:
[0524] For compounds soluble in the selected vehicle, the
appropriate amount was added to a stirring solution of vehicle. The
mixture was prepared 30 min prior dosing.
[0525] For compound insoluble in the selected vehicle, suspension
(for solid) or emulsion (for oil) was prepared using a planetary
micro mill (Pulverisette 7, Fritsch). The vehicles used are either
0.5% Methocel.TM. in water or 2% benzyl alcohol in corn oil. The
appropriate amount of compound was added, in portion, to the
selected vehicle and the mixture was processed using the planetary
micro mill for 10 min at 800 rpm. The obtained suspension or
emulsion was kept under stirring using a stirring bar until dosing.
The mixture could be prepared 30 min to 18 h prior dosing.
Example 41
In Vivo Protocols
a) PK Study in Rats
[0526] One group of four male Sprague-Dawley rats of age 7-9 weeks
(body weight of 200-300 g) were fasted for 15 to 17 h before being
dosed through oral gavage administration with the dosing
solution/suspension prepared from test compounds according to
Example 40 at a dose specified in Table 5 in a concentration
adjusted to a dosing volume of 10 ml/kg-body weight. Food was
supplied two hours post dose. Blood samples (200 .mu.L blood) were
collected into Sarstedt micro tubes (EDTA K.sub.3E/0.5 mL) from the
jugular vein of each animal (4 animals/group) at pre-dose and at
the following time-points of post-dose: 15 min., 30 min., 1 h, 2 h,
4 h, 6 h, 8 h, 12 h, and 24 h. The collected blood samples were
kept on ice and then centrifuged at 4.degree. C. at a minimum speed
of 3000 rpm (1620G) for 10 min to prepare the plasma samples. The
plasma samples were stored at -80.degree. C. until analysis. An
aliquot of dosing formulation was also taken prior to the dosing
and stored at -20.degree. C. for analysis.
TABLE-US-00006 TABLE 5 1,3PDS AUC Results in Rats after Oral
Administration of Prodrugs Dose.sup.3 1,3PDS AUC.sub.0-Tlast ID
No.sup.1 Vehicle.sup.2 (mg/kg) (ng h/mL).sup.7 1,3PDS(2Na) 1 100
40374 1,3PDS(2Na) 2 100 32104 A4 2 116 14855 A6(Na) 1 119 650 A13 1
185 25817 A14 1 161 25972 A16(Na) 2 188 30000 A18(Na) 1 189 26146
A20(Na) 1 195 19225 A23(Na) 2 163 19387 A26(Na) 1 154 5456 A29(Na)
1 142 3088 A30(Na) 1 167 14040 A32(Na) 1 144 1097 A51 1 175 29713
A51 2 175 23270 A52(K) 1 230 18109 A53(Na) 1 159 5778 A58 1 127
4734 A60(Na) 2 131 45530 A61 2 133 49388 A62(Na) 2 167 741 A63(Na)
2 131 2013 A64 2 155 13501 A65(Na) 2 167 595 A66(Na) 2 179 BLLQ
A68(Na) 2 131 BLLQ A69 1 144 23423 A69 2 144 9567 A70(Na) 2 185
98.0 A71(Na) 2 135 2022 A72(Na) 2 135 2602 A73(Na) 2 135 5582 B11 2
143 5682 B13 3 288 11770 B14 3 240 15084 B23 2 245 6033 B29 2 .sup.
92.sup.4 20670 B29 2 184 37717, 47664 B29 2 .sup. 461.sup.5 65070
B29 2 .sup. 921.sup.6 98321 B29 3 184 45585 B30 3 234 36903
B51(2TFA) 1 359 10756 B58 2 .sup. 81.sup.4 31865 B58 2 162 52982,
53724 B58 2 .sup. 809.sup.6 188592 B59 2 187 5060 B60 2 195 24258
B61 2 173 33340, 43365 B62 2 207 10566 B63 2 229 4028 B64 2 195
20687 B65 2 205 14372 B66 2 207 10802 B67(2HCl) 2 214 44526, 46223
B68 2 195 14178 B70 2 235 128 B71 2 147 BLLQ B72 2 163 BLLQ B73 2
207 1472 B74 2 234 753 B75 2 207 31039, 29201 B76 2 .sup. 86.sup.4
22150 B76 2 171 36025, 36606 B76 2 .sup. 857.sup.6 131932 B77 2
.sup. 86.sup.4 19175 B77 2 171 57973, 38230 B77 2 .sup. 429.sup.5
30726 B78 2 171 36767 B80 2 171 44258 B81 2 147 9572 B82 2 195
13535 B83 2 184 499297 B83 2 184 522308 B84 2 158 2953 B85 2 184
222417 B87 2 173 37909 C1 1 74 41103 C1 2 74 34219 C1 3 74 45637 C2
2 .sup. 43.sup.4 29800 C2 2 86 66542, 58313 C2 2 .sup. 216.sup.5
142985 C3 2 155 10049 D1 2 173 46036, 44860 D1 2 .sup. 865.sup.6
249360 D1 3 173 54987 D2 2 189 38053 D3 2 .sup. 81.sup.4 26199 D3 2
162 51842, 61390 D3 2 .sup. 809.sup.6 223842 D4 2 175 47144 D5 2
194 57353 D6 2 184 37036 D7 2 151 59543, 57502 D7 2 .sup. 753.sup.6
270641 D8 2 173 51253 G4 1 119 1457 P1(2Na) 2 86 BLLQ .sup.1A
compound can be tested as the parent or a salt form. When the
compound is in a salt form, the specific salt form is indicated in
the bracket following the code number: Na, sodium salt; 2Na,
disodium salt; K potassium salt; 2HCl, dichloride salt; 2TFA,
bis(trifluoroacetate) salt. .sup.2Dosing vehicle used: 1, water; 2,
0.5% Methocel .TM. in water; 3, 2% benzyl alcohol in corn oil
.sup.3Dose of 1,3PDS prodrugs is molar equivalent to 100 mg/kg
1,3PDS(2Na) except when specified otherwise .sup.4Dose is equimolar
to 50 mg/kg 1,3PDS(2Na) .sup.5Dose is equimolar to 250 mg/kg of
1,3PDS(2Na) .sup.6Dose is equimolar to 500 mg/kg of 1,3PDS(2Na)
.sup.7Two values indicate results from two independent experiments.
BLLQ = below low limit of quantification.
b) PK Study in Monkeys
[0527] One group of four non-naive cynomolgus monkeys (2 males and
2 females) received a single dose of a compound by oral gavage
administration with at least a 7-day washout period between each
experiment. The dosing formulation was prepared according to
Example 40. A representative dosing formulation (5 mL) was taken
prior dosing for analysis. The dosing formulation was administed
using a gavage tube attached to a plastic syringe. The dosing
volume was 10 mL/kg for all animals; and the actual dosing volume
was calculated and adjusted according the most recent body weight
of each animal. The animals were housed individually in stainless
steel monkey cages at a conventional animal facility, maintained
under 12-h light/dark cycle at 24.+-.3.degree. C. and 50.+-.20%
relative humidity. All animals had access to 5 cookies (Harlan 25%
Protein Primate Diet #2055) in the morning (at about 07:45) and 5
cookies in the afternoon (at about 16:30) except on the morning of
dosing where the morning cookies were given at least 4 hours after
the dose. Maximum allowable concentrations of contaminants in the
diet (e.g. heavy metals, alfatoxin, organophosphate, chlorinated
hydrocarbons and PCB's) were controlled and routinely analyzed by
the manufacturer. Reverse osmosis water was available ad libitum at
all times. In addition, all animals had access to a daily
enrichment diet (e.g. Prima treats, ice with fruits, popcorn,
fruits, vegetables, peanuts, pasta, fruit crunchies or fruity
gems). However, no treats were given to any animals within 4 hours
of dosing. The animals were acclimated to the gavage procedure for
3 days during the 7-day pretreatment period. Thereafter, the
animals were acclimated to the oral gavage procedure only if they
are more than 7 days between administrations of 2 compounds. Prior
to the first dosing, four (4) animals (2 males and 2 females) were
assigned to the study. Any animal with unacceptable pretreatment
data (i.e. clinical signs, body weight) would not be included in
the study. All animals were subjected to a detailed physical
examination once during the 7-day pretreatment period and weekly
thereafter. Cage-side clinical signs (ill, health, behavioral
changes, etc.) were recorded once daily during the treatment
period. Body weights were recorded for all animals once during the
7-day pretreatment period and weekly thereafter. All animals were
restrained using a sling apparatus from the completion of the oral
gavage until a maximum of 1 hour post-dose to facilitate blood
collection. All animals were then returned to their respective
housing cage for the remaining blood collection period.
[0528] Blood samples (approximately 1.0 mL each) were collected via
the femoral vein from each animal at the following time-points:
Pre-dose, 15, 30 min., 1, 2, 4, 6, 8, 12 and 24 h post-dose. Any
deviations in blood sampling times were documented in the report.
For each time-point, blood samples were collected and split into
two tubes containing K.sub.3-EDTA. One series of tubes (for plasma
samples) were kept on wet ice pending centrifugation (maximum 30
minutes). Samples were centrifuged under refrigeration (4.degree.
C.) at a minimum speed of 3000 rpm for 10 minutes. Plasma were
harvested into polypropylene tubes, immediately placed on dry ice
and stored frozen (at approximately -80.degree. C.) until shipment.
The second series of tubes (whole blood) were immediately placed on
dry ice and stored frozen until shipment and analysis.
TABLE-US-00007 TABLE 6 PK Parameters for 1,3PDS after Oral
Administration of Prodrugs to Monkeys.sup.1 Dose.sup.3 C.sub.max
T.sub.max AUC.sub.0-Tlast ID No.sup.2 (mg/kg) (ng/mL) (h) (ng h/mL)
1,3PDS(2Na) 100 1933 1.0 19573 A23(Na) 172 7818 4.0 51197 A51 175
10308 2.0 26480 B75 207 9180 1.5 37280 B76 171 21846 2.0 98971 B77
171 7440 2.0 57079 D5 194 3933 4.0 26369 .sup.1Pharmacokinetic
parameter values are mean except for Tmax for which the median is
presented .sup.2See the footnote 1 under Table 5. .sup.3Dose of
prodrugs is molar equivalent to 100 mg/kg 1,3PDS.
c) In Vivo Study in Ferrets
[0529] One group of three male non-naive ferrets (domestic strain,
>16 weeks, >1.2 Kg) were starved for approximately 1.5 h
prior to administration of a dosing formulation. Food was given 2
hours post dose. All animals were dosed with the dosing formulation
of a compound by oral gavage administration at dose level of 0.4
mmole/kg either in 0.5% Methocel.TM. or in water. The dosing volume
was adjusted to 5 mL/kg. Clinical signs were recorded throughout
the study period. Blood samples (200 .mu.l of blood) were
collected, from the jugular vein from each animal (3 animals/group)
at time-point of 15 min, 30 min, 1, 2, 4, 6, 8 and 12 h post dose,
into Sarstedt micro tubes (EDTA K.sub.3E/0.5 ml), kept on ice until
centrifugation at 4.degree. C. at a minimum speed of 3000 rpm
(1620G) for 10 min, to prepare plasma samples. Plasma samples were
stored frozen at -80.degree. C. pending transfer to analysis. An
aliquot of dosing solution (0.5 mL) was taken prior to dosing and
stored frozen at -20.degree. C. pending transfer to analysis.
Animals used for multiple studies after a wash out of a minimum
twelve day period.
[0530] Prodrugs evaluated in ferrets were Compounds A23(Na), A51,
A61, B29, B58, B75, B76, B77, B82, B83, C2, D1, D3, D5, and D7.
Compounds A23(Na), A51, A61, B29, B76, B77, B82, and B83 were all
safe prodrugs and showed no clinical signs at standard dose (0.04
mmol/kg) after oral administration. After administration of
Compound B75, 2 out of 3 animals showed abdomen scratching but
recovered after 1 h. Administration of B58 caused animal vomiting.
Compound C2 showed severe toxicity and all the three animals became
sick and had to be killed 4 days after compound administration.
Administration of Compounds D1, D3, D5, and D7 caused different
side effects, ranging from green face (D1) to abdominal contracting
and/or vomiting (D3, D5, and D7).
d) Rat Urine Collection Experiment
[0531] Animals (one group of four), dose, and the compound
administration were the same as described in Example 41 (a). Food
was given 2 h post dose. Following prodrug administration, animals
were housed individually in metabolic cage; and urine samples were
collected from each animal, one pre-dose and one during the period
of the first 24 h post-dose. Urine sample was collected in
pre-weighed polypropylene tube over dry-ice, and then stored at
-80.degree. C. immediately following collection pending transfer to
analysis. An aliquot of dosing solution (0.5 mL) was taken prior to
dosing and stored frozen at -20.degree. C. pending transfer to
analysis.
TABLE-US-00008 TABLE 7 1,3PDS Urinary Excretion after Oral
Administration of Prodrugs ID No.sup.1 Dose (mg/kg).sup.2 F.sub.e
(% dose).sup.3 1,3PDS(2Na) 100 54.2, 49.1 A23(Na) 163 44.9 A29(Na)
142 7.8 B29 183 69.0 B58 162 87.5 B61 173 72.1 B68 195 32.7 B76 171
22.4, 23.4 B77 171 7.4, 6.7 B83 184 45.5 C2 86 80.4 D1 173 71.1 D3
162 79.8 D7 151 85.2 .sup.1See footnote 1 under Table 5. .sup.2All
the compounds were administrated orally at 0.4 mmole/kg (equivalent
to 100 mg/kg dose of 1,3PDS(2Na)). All the compounds were dosed in
0.5% Methocel .TM.. .sup.3F.sub.e is calculated from the molar
amount of 1,3PDS excreted in urine divided by the molar amount of
prodrug administrated, expressed in percentage. Two values indicate
two independent experiments.
Example 42
Plasma and Urine Sample Analysis
a) Plasma Sample Analysis
[0532] 1,3PDS was extracted from an aliquot of rat, mouse, ferret
or monkey plasma using protein precipitation and then injected into
a liquid chromatograph equipped with a tandem mass spectrometry
detector. Quantification was done by peak area ratio method. A
weighted (1/x.sup.2) linear regression was performed to back
calculate the concentration of the analyte. On the day of analysis,
1 standard curve, a minimum of 2 replicates of each QC level and
the appropriate study plasma samples were analyzed using the
following step: [0533] Vortex the samples. [0534] Aliquot 25 .mu.L
of each sample into separate 1.5-mL polypropylene tubes. [0535] Add
100 .mu.L of ISWS in appropriate samples. [0536] Add 150 .mu.L of
chilled acetonitrile and vortex for a few seconds. [0537]
Centrifuge at 13200 rpm at room temperature for 5 minutes. [0538]
Transfer the supernatant into a 96-well polypropylene collection
plate and evaporate to dryness (approximately 20 minutes). [0539]
Reconstitute the residue with 400 .mu.L of dH.sub.2O and vortex the
plate. [0540] Centrifuge the plate at 2000 rpm for 2 minutes at
room temperature. [0541] Inject samples onto the LC-MS/MS.
b) Urine Sample Analysis
[0542] 1,3PDS was extracted from an aliquot of urine sample using
sample dilution. The diluted sample was then injected into a liquid
chromatograph equipped with a tandem mass spectrometry detector.
Quantitation was done by peak area ratio method. A weighted
(1/x.sup.2) Quadratic regression was performed to back calculate
the concentration of the analyte. On the day of analysis, 1
standard curve, a minimum of 2 replicates of each QC level and the
appropriate study plasma samples were analyzed using the following
step: [0543] Vortex the samples. [0544] Aliquot 25 .mu.L of each
sample into separate 50-mL polypropylene tubes. [0545] Add 100
.mu.L of ISWS in appropriate samples. [0546] Add 50 mL of water and
vortex adequately. [0547] Transfer 400 .mu.L of the solution into a
96-well polypropylene collection plate. [0548] Centrifuge the plate
at 2000 rpm for 2 minutes at room temperature. [0549] Inject
samples onto the LC-MS/MS.
Example 43
PK Data Analysis
[0550] For the various pharmacokinetic studies conducted in rats,
ferrets and monkeys, plasma (and blood) concentration-time data for
the prodrug and 1,3PDS were analyzed by non-compartmental analysis
(NCA) using the software program WinNonlin.RTM. Professional
Version 5.2.1. In order to conduct the NCA, at least 3 measurable
concentrations had to be available in a concentration-time profile.
The following pharmacokinetic parameters were determined for plasma
(or blood) data: C.sub.max, T.sub.max, AUC.sub.0-Tlast,,,
AUC.sub.0-.infin., .lamda..sub.z, and T.sub.1/2. Since the prodrugs
and 1,3PDS were administered at equimolar doses, the effect of the
prodrugs on the bioavailability of 1,3PDS was assessed by comparing
the C.sub.max and AUC of 1,3PDS after administering a prodrug with
that after administering 1,3PDS.
Example 44
Bacterial Mutation Tests (Ames Test)
[0551] Bacterial mutation tests were performed at Charles River
Laboratories to evaluate the mutagenic potential of various
prodrugs. Salmonella typhimurium strains (TA1535, TA1537, TA98,
TA100) and Escherichia coli strain WP2 uvrA were treated with
prodrugs at concentrations ranging from 1.58 to 5000 .mu.g/plate in
the presence and absence of a supplemented liver fraction (S9 mix)
using the pre-incubation version of the bacterial mutation test.
All concentrations of each compound were evaluated in triplicate.
Bacteria were incubated with standard positive control agents, and
the response of the various bacterial strains to these agents
confirmed the sensitivity of the test system and the activity of
the S9 mix.
TABLE-US-00009 TABLE 8 Results of Bacterial Mutation Tests Result
ID No.sup.1 Vehicle In presence of S9 In absence of S9 A23(Na) DMSO
Negative Negative A29(Na) Water Positive Negative A51 Water
Negative Negative A61 Water Positive Positive B29 DMSO Positive
Negative B58 DMSO Positive Positive B68 DMSO Negative Negative B75
DMSO Negative Negative B76 DMSO Negative Negative B77 DMSO Negative
Negative B78 DMSO Negative Negative B83 DMSO Negative Negative
.sup.1See footnote 1 below Table 5.
[0552] It is understood that the examples and embodiments described
herein are for illustrative purposes only and that various
modifications or changes in light thereof will be suggested to
persons skilled in the art and are to be included within the spirit
and purview of this application and scope of the appended claims.
Any publication, document, patent, patent application or
publication referred to herein should be construed as incorporated
by reference each in their entirety for all purposes.
* * * * *